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The socioeconomic demand for biomaterials has never been greater. 
Formulation at the organic/inorganic interface of materials has enabled the 
conception of several novel biomaterial systems for bone repair and bone 
fusion applications, which are presented across four research chapters 
(Chapters 2-5).  
In Chapter 2, a poly(ether ether ketone) (PEEK) and calcium sulphate 
(CS) composite is formulated. The inclusion of the polymer slowed CS 
degradation and augmented the mechanical properties of the material 
significantly. Chapter 3 examines the formation mechanism of tubular calcium 
phosphate structures from a gel/solution interface. The tube composition and 
microstructure was analogous with intricate features of bone. In Chapter 4, a 
model bone defect was augmented with particles that could generate calcium 
phosphate tubes in the presence of biological tissue. 3D computed 
tomography reconstructions revealed extensive bone-like mineral deposition 
throughout the cavity. Chapter 5 explores the chemical coupling of 
hydroxyapatite particles within a PEEK matrix, a composite that may be used 
for fabricating spinal fusion devices. Physical properties of chemically linked 
composites were improved by a reduction in additive debonding and inhibition 
of micro crack formation. This allowed more effective load transfer between 
phases.  
Together, the research presented herein puts forward a novel 
collection of biomaterials that may be applied to the treatment of bone 




I wish to extend a massive thank you to my supervisor, Prof. Liam 
Grover, whose supervision throughout my EngD has been invaluable. I’m so 
grateful to have had the opportunity to work and develop as a scientist under 
your guidance. I also want to thank Dr. Richard Greenwood for giving me the 
chance to undertake the EngD project. It has been a blast!  
I extend my thanks to TWI Ltd for allowing me to gain industry 
experience during my project. Thank you to my industrial supervisors over the 
course of my project, including Dr. Judith Juhasz, Prof. Medhi Tavakoli, and 
Dr. Roger Wise.  
I want to thank all the past and current members of TRIAL lab, as well 
as the many researchers I have been lucky enough to collaborate with over 
the last five years. Special thanks must go to Dr. Richard Williams for his 
eclectic mix of expertise and banter. Not forgetting the countless work 
sessions in Costa!   
I offer my wholehearted thanks to my family, especially my parents and 
sister for supporting me throughout my EngD. I couldn’t have done this 
without you. Most importantly, I have to thank the love of my life, Holly, for her 
support. You have made me laugh every day we have been together and 
throughout my write-up. I know you love your books but I have a feeling my 






































TABLE OF CONTENTS 
 
Chapter 1. Introduction 1 
1.0 EXECUTIVE SUMMARY 1 
1.1 RESEARCH MOTIVATION 2 
1.1.1 Increasing and ageing population  2 
1.1.2 Occurrence  
    1.1.2.1 Bone fractures 




1.1.3 Prevention shortcomings 
   1.1.3.1 Bone fractures 




1.1.4 Socioeconomic demand 
   1.1.4.1 Bone fractures 




1.2 BONE  7 
1.2.1 Overview of bone  7 
1.2.2 Bone properties and function 8 
1.3 BONE COMPOSITION  9 
1.3.1 Organic components 9 
1.3.2 Inorganic components 10 
1.4 BONE ORGANISATION 11 
1.4.1 Organisation of collagen 11 
1.4.2 Organisation of apatite 12 
vi 
1.4.3 Cortical bone  13 
1.4.4 Trabecular bone  14 
1.5 BONE CELLS  15 
1.5.1 Osteoblasts 16 
1.5.2 Osteocytes 17 
1.5.3 Osteoclasts 17 
1.6 BONE REMODELLING  18 
1.6.1 Activation  18 
1.6.2 Resorption 19 
1.6.3 Reversal 20 
1.6.4 Formation 20 
1.7 BONE REPAIR 22 
1.7.1 Inflammation 22 
1.7.2 Repair 23 
1.7.3 Remodeling 24 
1.8 BONE RELATED BIOMATERIALS APPLICATIONS  24 
1.8.1 Bone graft 25 
1.8.2 Bone fusion 26 
1.9 BIOMATERIALS FOR BONE REPAIR 28 
1.9.1 Tissue derived biomaterials  28 
   1.9.1.1 Autograft 28 
   1.9.1.2 Allograft 29 
   1.9.1.3 Xenograft  31 
1.9.2 Ceramic biomaterials 31 
vii 
   1.9.2.1 Bioglass 32 
   1.9.2.2 Calcium phosphates 32 
   1.9.2.3 Calcium sulphate 34 
   1.9.2.4 Calcium silicate 37 
   1.9.2.5 Pre-sets 37 
   1.9.2.6 Cements  38 
1.9.3 Polymeric biomaterials  40 
   1.9.3.1 Polymeric hydrogels  40 
   1.9.3.2 Poly(methyl methacrylate (PMMA)  42 
   1.9.3.3 Poly(ether ether ketone) (PEEK) 42 
1.9.4 Composites  45 
   1.9.4.1 Carbon fiber reinforced PEEK 45 
   1.9.4.2 Hydroxyapatite reinforced PEEK 46 
1.9.5 Metallic biomaterials 47 
   1.9.5.1 Stainless steel  48 
   1.9.5.2 Cobalt alloys 48 
   1.9.5.3 Titanium and titanium alloys 49 
1.10 THESIS OVERVIEW 49 
1.11 REFERENCES	 50 
  
Chapter 2. Characterisation of a novel poly (ether 
ether ketone)/calcium sulphate composite for bone 
augmentation 
75 
2.0 ABSTRACT 76 
viii 
2.0.1 Background 76 
2.0.2 Experimental Methods 76 
2.0.3 Results 76 
2.0.4 Conclusions  77 
2.1 INTRODUCTION 77 
2.2 EXPERIMENTAL METHODS 81 
2.2.1 Standard fabrication of PEEK/CS cylinders  81 
2.2.2 Volumetric shrinkage  81 
2.2.3 Scanning electron microscopy (SEM)  82 
2.2.4 Fourier transform infrared (FT-IR) spectroscopy  82 
2.2.5 Dynamic ageing protocol  82 
2.2.6 X-ray diffraction (XRD)  83 
2.2.7 Porosity  83 
2.2.8 Mechanical testing  84 
2.2.9 Statistical analysis  84 
2.3 RESULTS AND DISCUSSION 85 
2.3.1 Physical and chemical assessment of PEEK/CS cylinders  85 
2.3.2 Characterisation of dynamically aged PEEK/CS specimens 90 
2.3.3 Mechanical properties of PEEK/CS specimens  98 
2.3.4 Mechanism of PEEK reinforcement of CS  100 
2.4 CONCLUSIONS 101 
2.5 ASSOCIATED CONTENT 101 
2.6 REFERENCES 101 
  
ix 
Chapter 3. Biologically analogous calcium phosphate 
tubes from a chemical garden 
108 
3.0 ABSTRACT 109 
3.1 INTRODUCTION 109 
3.2 EXPERIMENTAL METHODS 112 
3.2.1 Materials  112 
3.2.2 Preparation of CaPO4 tubes 113 
3.2.3 Measuring the gel mass gain/loss 113 
3.2.4 Measuring elution of Ca2+ 114 
3.2.5 Measuring PO43- in gel phase 114 
3.2.6 Scanning electron microscopy (SEM) 115 
3.2.7 X-ray diffraction (XRD)  115 
3.2.8 Micro- X-ray fluorescence (µ-XRF) 116 
3.3 RESULTS AND DISCUSSION 116 
3.3.1 Initial observations and understanding CaPO4 chemical 
garden growth regimes  
116 
3.3.2 Response of the gel phase to varying solute potential  120 
3.3.3 Ca2+ and PO43- ion transport  122 
3.3.4 Observing pH change as an indicator of ionic movement  123 
3.3.5 Microstructural and compositional evolution of CaPO4 tubes 126 
3.4 CONCLUSIONS 133 
3.5 ASSOCIATED CONTENT 135 
3.6 REFERENCES 135 
  
x 
Chapter 4. Interfacial mineral fusion and tubule 
entanglement as a means to harden a bone 
augmentation material 
141 
4.0 ABSTRACT 142 
4.1 INTRODUCTION 142 
4.2 EXPERIMENTAL METHODS 145 
4.2.1 Calcium loaded hydrogel fabrication and mineral initiation 145 
4.2.2 Human tissue model 146 
4.2.3 Scanning electron microscopy (SEM)  146 
4.2.4 Micro- X-Ray Fluorescence (µ-XRF) 146 
4.2.5 Micro- computed tomography (µ-CT) scanning 147 
4.3 RESULTS AND DISCUSSION 147 
4.4 CONCLUSIONS 154 
4.5 ASSOCIATED CONTENT 155 
4.6 REFERENCES 155 
  
Chapter 5. Development of a covalently bonded 
hydroxyapatite and poly(ether ether ketone) 
composite 
161 
5.0 ABSTRACT 162 
5.1 INTRODUCTION 162 
5.2 EXPERIMENTAL METHODS 165 
5.2.1 Materials 165 
5.2.2 Synthesis and fabrication methods 166 
xi 
   5.2.2.1 Synthesis of HA-SH derivative  166 
   5.2.2.2 Synthesis of PEEK-OH derivative  167 
   5.2.2.3 Synthesis of HA_L_ PEEK  167 
   5.2.2.4 Composite fabrication and acquisition of test specimens  167 
5.2.3 Chemical and physical characterisation methods  168 
   5.2.3.1 Raman spectroscopy 168 
   5.2.3.2 Powder X-ray diffraction (XRD) 168 
   5.2.3.3 Thiol group (-SH) quantification 168 
   5.2.3.4 Differential scanning calorimetry (DSC) 169 
   5.2.3.5 Thermal gravimetric analysis (TGA) 169 
   5.2.3.6 Scanning electron microscopy (SEM) 170 
   5.2.3.7 Fourier transform infrared (FT-IR) spectroscopy  170 
   5.2.3.8 Micro- X-ray fluorescence spectroscopy (µ-XRF) 171 
   5.2.3.9 Flexural 3-point bend testing  171 
5.2.4 Statistical analysis  171 
5.3 RESULTS AND DISCUSSION 172 
5.3.1 Synthesis of HA-SH  172 
5.3.2 Synthesis of PEEK-OH  174 
5.3.3 Synthesis of chemically linked HA_L_PEEK 176 
5.3.4 Composite characterisation  180 
5.3.5 Mechanism of composite enhancement by covalent bonding  182 
5.4 CONCLUSIONS 186 
5.5 ASSOCIATED CONTENT 187 
5.6 REFERENCES 187 
xii 
Chapter 6. Conclusions and future work 
 
6.0 GENERAL OVERVIEW 
195 
195 
6.1 STUDY LIMITATIONS AND FUTURE PERSPECTIVES 196 
6.1.1 Characterisation of a novel poly (ether ether ketone)/calcium 
sulphate composite for bone augmentation  
196 
6.1.2 Biologically analogous calcium phosphate tubes from a 
chemical garden 
198 
6.1.3 Interfacial mineral fusion and tubule entanglement as a 
means to harden a composite bone augmentation device  
199 
6.1.4 Development of a covalently bonded hydroxyapatite and 
PEEK composite 





Appendix Part 1 205 
Appendix Part 2 209 
Appendix Part 3 213 












LIST OF FIGURES 
 
Figure 1.1 Schematic of bone structure from the molecular to the 
macrosacle (Adapted from [40] with permission from Copyright © 
2014 Nature Publishing Group).  
11 
Figure 1.2 Osteonal microstructure of cortical bone imaged with 
synchrotron radiation-based computed tomography technique 
(Adapted from [55] with permission from Copyright © 2016 The 
Royal Society). 
13 
Figure 1.3 Reconstruction of the Haversian system in a 2.93 mm3 
sample of human femoral bone tissue imaged with synchrotron 
radiation-based computed tomography technique (Adapted from 
[57] with permission from Copyright © 2016 Anatomical Society). 
14 
Figure 1.4 Trabecular microstructure of cancellous bone imaged 
with back scattered scanning electron microscopy technique 
(Adapted from [55] with permission from Copyright © 2016 The 
Royal Society). 
15 
Figure 1.5 Howship’s lacuna develop where osteoclasts resorb 
bone (Adapted from [35] with permission from Copyright © 2008 
American Society of Nephrology).   
19 
Figure 1.6 Synthesis and deposition of collagenous bone matrix 
by osteoblast cells. As mineralisation proceeds, osteoblasts 
transform in osteocytes and become encapsulating in hard tissue 
(Adapted from [35] with permission from Copyright © 2008 
American Society of Nephrology).  
21 
xiv 
Figure 1.7 Bullet shaped spinal fusion cages designed for lumbar 
vertebral fusion fabricated from (a) PEEK and (b) titanium 
(Adapted from [102] with permission from Copyright © 2014 
Springer-Verlag Berlin Heidelberg). 
27 
Figure 1.8 Polymeric repeat units of some poly(aryl ether 
ketone)s, including (1) Poly(ether ketone ketone) (PEKK), (2) 
Poly(ether ketone) (PEK), and (3) Poly(ether ether ketone) (PEEK) 
(Adapted from [168] with permission from Copyright © 2012 Taylor 
and Francis). 
43 
Figure 1.9 Overview of techniques used to enhance the bioactivity 
of PEEK (Adapted from [176] with used under the Creative 
Commons Attribution License (CC BY 3.0)). 
44 
Figure 1.10 Fracture surface of a 20 vol% HA_PEEK composite 
specimen that shows evidence of HA particulate debonding from 
the PEEK matrix (Adapted from [182] with permission from 
Copyright © 2003 Elsevier Science Ltd). 
46 
  
Figure 2.1 (a) Chemical structure of the poly(ether ether ketone) 
repeat monomer unit. (b) PEEK/CS specimens post heat treatment 
(Scale bar is equal to 10 mm). (c) Volumetric shrinkage of 
PEEK/CS specimens due to heat treatment. Error bars represent 
standard deviation (n=3) and lines above data columns represent 
significant differences between groups based on PEEK wt% 
loading as found by post-hoc Tukey HSD tests following one-way 
85 
xv 
ANOVA analysis.  
Figure 2.2 SEM micrographs of a fracture surface of a 
20%PEEK/80%CS specimen prepared at a P:L ratio of 0.85 g/mL 
(a) prior to heat treatment and (b) after heat treatment. (c) FT-IR 
spectra between 500 cm-1 and 4000 cm-1 wavenumbers of PEEK 
and CSH (CaSO4.0.5H2O) starting powders, and a powdered 
20%PEEK/80%CS specimen after heat treatment.  
87 
Figure 2.3 SEM images of 20%PEEK/80%CS specimens after 
ageing in PBS media for (a) 7 Days, (b) 14 Days and (c) 21 Days. 
(d) XRD diffraction patterns between 2θ values of 5 o and 60 o of 
PEEK and CSH (CaSO4.0.5H2O) starting powders, and powdered 
20%PEEK/80%CS specimens after heat treatment prior to ageing 
(0 Days), and after 7 Days, 14 Days and 21 Days of ageing. An 
XRD pattern for PEEK from the literature confirmed the crystal 
structure of the polymer (, see [30]). ICDD patterns matching CSH 
(CaSO4.0.5H2O) (, ICDD pattern 01-081-1448), CSA (CaSO4) (, 
ICDD pattern 01-070-0909) and CSD (CaSO4.2H2O) (, ICDD 
pattern 00-033-0311) (CaSO4.0.5H2O, CaSO4 and CaSO4.2H2O 
phases respectively) are also provided to aid in CS phase 
identification.     
91 
Figure 2.4 (a) PEEK/CS specimen mass remaining expressed as 
percentage (%) calculated from dry measurements. (b) Changes in 
PEEK/CS specimen mass measured dry and (c) wet. (d) 
PEEK/CS specimen mass increase expressed as a percentage 
94 
xvi 
(%) calculated between difference in dry and wet mass 
measurements. Error bars represent standard deviation (n=3).  
Figure 2.5 (a) Changes in PEEK/CS specimen height measured 
dry and (b) wet. (c) Changes in PEEK/CS specimen mid-diameter 
measured dry and (d) wet. (e) Changes in PEEK/CS specimen 
end-diameter measured dry and (f) wet. Error bars represent 
standard deviation (n=3).  
96 
Figure 2.6 Direct pH measurements of PEEK/CS specimen PBS 
ageing supernatant before replenishment. PBS has a pH 7.4, and 
is shown in the figure by a purple dashed line as indicated by the 
legend. Error bars represent standard deviation (n=3). 
97 
Figure 2.7 (a) Compressive strength and (b) Compressive 
modulus of PEEK/CS specimens after heat treatment and during 
ageing. Bar colouration is representative of ageing time as 
indicated by the legend. Error bars represent standard deviation 
(n=10) and lines above data columns represent significant 
differences between groups based on PEEK wt% loading as found 
by post-hoc Tukey HSD tests following two-way ANOVA analysis.  
98 
  
Figure 3.1 Influence of PO43- concentration on CaPO4 tube 
formation. Visualisation of tube growth after 15 minutes, and 1 
hour in 0.25-2 M PO43- solutions (a), unstructured precipitate in 
0.25 M PO43- solution after 4 days (b), tube agglomeration and wall 
bound growth in 1 M PO43- solution after 4 days (c), thick budding 
117 
xvii 
tubes grown in 2 M PO43- solution after 4 days (d), sack-like 
morphologies grown in 2 M PO43- solution after 4 days (e).   
Figure 3.2 Top down view binary image of the typical CaPO4 
precipitation coverage formed upon the gel/solution interface for 
PO43- solutions of 0.25 and 0.5 M 1 minute after layering upon the 
gel surface.  
120 
Figure 3.3 Mass gain/loss profile of gels exposed to 1 and 5 M 
NaCl solutions between 0-120 minutes (error bars represent 
standard deviation for n = 3 measurements of individual samples, * 
= significance as determined by post hoc t-test analysis, where p = 
< 0.05). 
121 
Figure 3.4 Ca2+ release into bulk solution dependent on NaCl 
solution concentration (error bars represent standard deviation for 
n = 3 measurements of individual samples) (a) and PO43- ingress 
into the gel dependent on PO43- solution concentration (error bars 
represent standard deviation for n = 2 measurements of individual 
samples) (b). 
123 
Figure 3.5 Ca2+ rich solution as collected in a capillary tube placed 
at the gel/solution interface (a), followed by removal of the capillary 
tube and staining of the collected contents with universal pH 
indicator (b) (PO43- solution was drawn up the capillary tube on pull 
out). 
124 
Figure 3.6 Universal pH indicator stained gel layered with 0.5 M 
PO43- solution changing colouration in response to CaPO4 tubular 
126 
xviii 
formation (a). Gels stained with universal pH indicator and layered 
with 0.25-5 M PO43- solutions at 30 mins (Field of view ~30 mm) 
(b) and quantification of the colouration band depth (error bars 
represent standard deviation for n = 3 measurements of individual 
samples) (c).   
Figure 3.7 Micrographs of CaPO4 tubes grown in 0.5 M PO43- 
solutions extracted at 5 hours (a) and 24 hours (b), CaPO4 tubes 
grown in 1.25 M PO43- solutions (c), and CaPO4 tubes grown in 2 
M PO43- solutions (d) extracted at 10 days.  
127 
Figure 3.8 XRD diffraction patterns of the development of CaPO4 
precipitate grown for up to 48 hours in PO43- 0.5 M solutions (a), 
and after 30 days for CaPO4 precipitates grown in 0.25-1.5 M 
PO43- solutions (b). ICDD reference patterns for CaHPO4.2H2O, 
Ca10(PO4)6(OH)2, NH4H2PO4 and NH4NO3 matched to collected 
patterns (c).  
130 
Figure 3.9 µ-XRF maps of a CaPO4 tube structure grown in 0.5 M 
PO43- solution. Elemental mapping of calcium (a) and phosphorous 
(b). Elemental maps of calcium and phosphorus were combined; 
calcium and phosphorus Kα signal intensity of both elements was 




Figure 4.1 (a) Conventional experimental set-up (Reported in 
reference 30), which produces calcium phosphate tubules that are 
149 
xix 
structurally and compositionally similar to bone, providing the 
starting point for the work reported herein. (b) Schematic of 
fabrication method of calcium-loaded spheres, involving drop-wise 
addition of calcium loaded agarose hydrogel into a reservoir of 
liquid nitrogen. (c) Calcium loaded spheres before and after 
mineralisation, showing the ejection of tubular calcium phosphate 
mineral. (d) SEM micrograph showing the tubule microstructure, 
consisting of a bilayer tubule wall surrounding a hollow core. (e) 
SEM micrograph of tube wall bilayer structuring. (f) µ-XRF 
elemental mapping of a calcium phosphate tubule cross-section 
(Kα channels for calcium (red) and phosphorous (green) shown). 
Figure 4.2 (a) Fusion of two calcium loaded spheres in close 
proximity to one another during self-mineralisation. (b) µ-XRF 
elemental mapping of a calcium loaded sphere cross-section 
before and after inducing self-mineralisation (Kα channels for 
calcium (red) and phosphorous (green) shown) (c) Calcium loaded 
sphere pyramid construct before and after triggering self-
mineralisation, leading to complete unification. (d) µ-CT of calcium 
loaded sphere pyramid after submersion in phosphate solution. 
Colour scales in-set represent an increase in relative density of 
material from blue (calcium loaded sphere) to green and red 
(mineral).  
151 
Figure 4.3 (a) Schematic of calcium loaded spheres augmenting 
an ex vivo human bone defect, showing an empty bone defect, the 
153 
xx 
packing of spheres to augment the defect, and triggering of self-
mineralisation with 1 M phosphate solution. (b) µ-CT of human 
hard tissue model containing mineralised calcium loaded spheres 
that have deposited mineral and tubular structures within the 
defect. (c) µ-XRF elemental mapping of a cross-section of the 
human hard tissue defect (Kα channels for calcium (red) and 
phosphate (green) shown).   
  
Figure 5.1 (a) Hydrolysis and (b) condensation reactions of 
MPTES. (c) pH profile of the reaction between HA and MPTES to 
produce HA-SH. (d) Raman spectra and (e) XRD patterns of as 
received HA and following the synthesis of HA-SH.  
172 
Figure 5.2 (a) Reduction reaction of PEEK to PEEK-OH. (b) XRD 
patterns, (c) DSC traces and (d) TGA traces of as received PEEK 
and following reduction to PEEK-OH.  
176 
Figure 5.3 (a) Reaction between HA-SH and PMPI chemical linker 
and (b) between PEEK-OH and PMPI. (c) FT-IR spectrum for 
HA_L_PEEK.  
178 
Figure 5.4 SEM micrographs of (a) HA-SH, (b) PEEK-OH, (c) a 
mixture of HA-SH and PEEK-OH particulates, and (d) chemically 
linked HA-SH and PEEK-OH (additive material for HA_L_PEEK 
composites).   
179 
Figure 5.5 (a) 3-point bend test set-up (LVDT = Linear Variable 
Displacement Transducer). (b) Load displacement curves for 
181 
xxi 
PEEK, HA_PEEK and HA_L_PEEK materials. (c) Flexural strength 
box-plots for all groups calculated from the load displacement 
curves in (b) (n = 7) (* = p < 0.05 for PEEK vs. HA_PEEK and for 
PEEK vs. HA_L_PEEK). (d) Flexural modulus box-plot for all 
groups calculated from the load displacement curves in (b) (n = 7) 
(* = p < 0.05 for PEEK vs. HA_PEEK, ** = p > 0.05 for PEEK vs. 
HA_L_PEEK). 
Fig 5.6 µ-XRF elemental mapping of HA particulates within 
HA_PEEK and HA_L_PEEK materials following composite 
fabrication. (a) µ-XRF spectrum central to the Ca Kα signal. (b) µ-
XRF spectrum central to the P Kα signal. (c) µ-XRF spectrum 
central to the Si Kα signal. (d) Elemental map for a fracture 
surface of HA_L_PEEK with Ca and P Kα channels shown. (e) 
Elemental map for a fracture surface of HA_L_PEEK with Ca, P 
and Si Kα channels shown.  
183 
Figure 5.7 As fabricated surface of (a) PEEK, (b) HA_PEEK and 
(c) HA_L_PEEK. Fracture surface of (d) PEEK, (e) HA_PEEK and 







LIST OF TABLES  
Table 1.1 Mechanical properties of cortical and cancellous bone 
(Adapted from [37] with permission from Copyright © 2011 
Bentham Science Publishers). 
Table 1.2 Calcium phosphate phase compositions and their 
solubility’s (Adapted from [127] with permission from Copyright © 





Table 1.3 Calcium sulphate phase compositions and their 
solubility’s (+ Common names used in biomaterial literature, * 
Metastable in dry air, **Stable between 40-1180oC, ***Stable at 
>1180 oC) (Adapted from [129] with permission from Copyright © 
2015 Taylor & Francis). 
35 
 000 
Table 2.1 Porosity (%) of PEEK/CS specimens after heat 















LIST OF PAPERS 
 
Review papers 
Hughes EAB, Yanni T, Jamshidi P, Grover LM. Inorganic cements for 
biomedical application: calcium phosphate, calcium sulphate and calcium 




Hughes EAB, Grover LM. Characterisation of a novel poly (ether ether 
ketone)/calcium sulphate composite for bone augmentation. Biomater Res. 
2017;21:7. 
 
Hughes EAB, Williams RL, Cox SC, Grover LM. Biologically Analogous 
Calcium Phosphate Tubes from a Chemical Garden. Langmuir. 
2017;33(8):2059-67. 
 
Hughes EAB, Cox SC, Cooke ME, Williams RL, Hall TJ, Grover LM. 
Interfacial mineral fusion and tubule entanglement as a means to harden a 
bone augmentation material. Submitted.  
 
Hughes EAB, Parkes A, Williams RL, Jenkins MJ, Grover LM. Development of 






 This thesis presents four published or submitted papers that have been 
adapted into chapters. The author of this thesis is the first author of the 
adapted works presented herein. Conception of the experiments, undertaking 
of the experimental work, and manuscript writing was undertaken by the first 
author. Secondary authors are duly acknowledged for their contribution to the 
work through assistance with experimental work and help revising 
manuscripts. Industrial sponsors TWI Ltd approved the publication and 
submission of the manuscripts presented herein.  
 
1 
Chapter 1. Introduction 
 
1.0 RESEARCH AIMS AND OBJECTIVES 
The literature regarding the development of biomaterials consists of 
many decades worth of explorative research studies that focus on the 
formulation and employment of many different materials suitable for healing 
hard and soft tissues. Whilst the current cohort of clinically employed hard 
tissue biomaterials appears to result in widely positive restorative outcomes, it 
is recognised that both tissue derived and synthetic substitutes are unable to 
match or overtake bone in terms of mechanical and biological performance 
[1]. Therefore, the field of research continues to evolve as researchers 
innovate novel methods to fabricate and characterise biomaterials that aim to 
emulate the structure and properties of bone, in addition to furthering the 
understanding of the interactions between such biomaterials and the body.  
The aim of this thesis is to formulate calcium sulphate and phosphate 
based composites with enhanced physiochemical properties and structural 
features that can be utilised in applications including bone regeneration and 
hard tissue fusion. In order to achieve this aim, the following objectives will be 
addressed:  
• To identify the inherent shortcomings of biomaterials employed 
in bone defect augmentation and spinal fusion applications. 
• To overcome the identified shortcomings of these biomaterials 
by strategically formulating and fabricating novel composites 
that possess enhanced interfacial interactions between 
organic/inorganic interfaces present between dissimilar phases.  
2 
• To determine nature and significance of the organic/inorganic 
interactions relating to biomaterial property enhancement using 
an extensive array of advanced chemical and physical 
characterisation techniques. 
 
1.1 RESEARCH MOTIVATION 
1.1.1 Increasing and ageing population  
The global population crossed the 7.6 billion mark in mid-2017 and 
continues to grow at a staggering rate on a daily basis [2]. These numbers 
reflect the healthier lifestyles more people are choosing to adopt, advances in 
improved life expectancy, tackling infant mortality and increased longevity of 
the ageing population [3].  
Consequently, the incidence of age-related diseases associated with 
our bones, such as osteoporosis, which describes the loss and thinning of the 
bone structure, and osteoarthritis, which describes the loss of cartilage and 
stiffening of bony joints, are continually on the rise. In the UK alone, 
approximately 3.2 million and 8.75 million people suffer from osteoporosis and 
osteoarthritis respectively according to figures obtained earlier during this 
decade [4, 5].  
 
1.1.2 Occurrence  
1.1.2.1 Bone fractures 
Around 8 million people suffer a bone fracture in the United States 
every year, with up to approximately 10 % of cases resulting in persistence of 
3 
non-union, which can have negative implications for hard tissue function [6]. 
Younger people appear to be increasingly prone to muscoskeletal incidents 
that are normally associated with age due to lifestyle habits, such as 
participation in injury risk sports, as well as involvement in traffic accidents [7-
9]. For the elderly, risk factors include degenerative diseases (e.g. 
osteoporosis), muscle weakness and loss of balance leading to traumatic 
injury.  
Osteoporosis is a disease prevalent in the over 50’s population, and 
affects around 200 million people around the world [10]. The loss of bone 
mineral density and strength due to osteoporosis leads to greater risk of 
fracture with regards to weight bearing bones. This is a major concern as it is 
these members of the population who may be prone to accidental and minor 
falls, resulting in the fracture of bones, and in extreme circumstances, 
increase the chance of premature death by up to 20 % [11, 12]. Around 
300000 fragility fractures occur a year in the UK due to such incidences. For 
very frail individuals, 10 % to 20 % of these falls will result in hip fracture [13].  
1.1.2.2 Spinal conditions 
Lower back pain is a highly reported ailment that can advance to more 
serious spinal illnesses requiring medical attention, including degenerative 
disc disorder and disc herniation. Pain is felt as a consequence of pressure 
being applied to spinal nerves. This pain can also transcend to the legs in the 
case of radicular spinal nerve compression.  
Annually in the USA, over 65 million people experience and suffer 
lower back pain, and 85 % of the population will display evidence of disc 
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degeneration by the age of 50 [14]. In the UK, approximately 27 million people 
suffer lower back pain yearly and are typically aged between 40 and 60 years 
of age [15]. Herniated disc disease is most prevalent in the 30 to 50-year-old 
population, with 95 % of cases affecting the lower lumbar region of the spine 
[16].  
 
1.1.3 Prevention shortcomings 
1.1.3.1 Bone fractures  
 Systematic avoidance strategies may prevent 25 % of osteoporotic hip 
fractures [17, 18]. These include raising awareness of osteoporosis, better 
identification of those most at risk of fracture (e.g. do they have a parental 
history regarding fracture), provision of preventative drugs to aid those at risk 
(i.e. postmenopausal osteoporosis sufferers), encouraging individuals to 
perform a level of physical activity that maintains muscle strength and bone 
density from an early age as well as later in life, exposure to sunlight in order 
to increase vitamin D levels, and ensuring those receiving treatment are 
compliant over several years (i.e. following a course of prescribed medicine) 
[11, 19-26]. Despite following preventative measures however, bone fractures 
aren’t always avoidable and will require some form of intervention to repair or 
augment the damaged bone. Costs are further driven up by fracture 
reoccurrence, unforeseen circumstances, and fracturing other bones in the 




1.1.3.2 Spinal conditions 
Lower back pain is managed by an initial assessment followed by 
preventative measures. Preventative measures for spinal conditions include 
staying active, prescription of anti-depressants, bed rest, epidural injections, 
heat placement, ice placement, massages and traction [16]. These 
interventions aim to relieve pain, increase patient mobility, and improve quality 
of life. If pain persists, further non-surgical approaches to manage the 
condition may be carried out, including psychological therapy and 
acupuncture [15].  
Worryingly, preventive measures are recommended to last between 6 
to 12 months before surgical treatment is considered, whilst there is no 
evidence to prove the effectiveness of such treatments following a 6-week 
period [28]. This may be due to the historical attitude of healthcare 
professionals that spinal maintenance can be overcome by changes in 
lifestyle as opposed to the need to spend on healthcare resources [29]. 
Furthermore, a UK study conducted at the start of the decade found that only 
50 % of the 127 primary care organisations surveyed provided funding for 
acupuncture treatment and only 15 % offered acupuncture within the practice 
itself [15].  
Taken together, evidence worryingly suggests that the effectiveness of 
recommended early treatment strategies is unfounded, in addition to the fact 
that treatment guidelines may be seldom applied. Therefore, preventative 
measures for spinal conditions potentially offer a poor outlook for patients, 
increasing the likelihood of surgical intervention.  
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1.1.4 Socioeconomic demand 
1.1.4.1 Bone fractures  
Problematically, unlike younger individuals whose fractures tend to 
heal without complication, osteoporotic bone does not possess the 
regenerative capacity to heal fractures without major intervention.  
Fractures are extremely costly; the occurrence of approximately 75000 
hip fractures for instance in the UK costs as much as £2 billion per annum to 
treat [30]. Fractures incurred from osteoporosis are severe, as they will almost 
certainly require intervention and subsequent treatment to stabilise and 
replenish the damaged bone tissue. Over 500,000 operations in the USA per 
year require the use of bone graft, with 50 % of these being related to spine 
surgeries [31]. The provision of biomaterials that are able to stimulate healing 
in both healthy and diseased bone is therefore crucial, especially given that 
the economic burden of providing treatment for new and previous osteoporotic 
fractures in the UK is set to increase from £3.5 billion to £5.5 billion by the 
year 2025 [32].  
Furthermore, the pain associated with fractures can range from acute 
to chronic depending on severity [33]. Fractures are therefore not only 
considered a major economic burden, but also a detrimental burden to a 
person’s health and wellbeing. Consequently, the socioeconomic demand for 
biomaterials that are able to restore and regenerate bone tissue in a cost-
effective manner, so as to avoid reoccurrence and need for surgical revision, 
has never been greater.  
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1.1.4.2 Spinal conditions  
 Treatment of lower back pain is essential for a patient’s wellbeing. Not 
only is the suffering of pain uncomfortable, it can also lead to depression and 
anxiety. Spinal conditions can therefore be debilitating, often requiring 
sufferers to take leave from work for extended periods. In the UK, the 
treatment of back pain costs upward of £1 billion annually, and furthermore 
costs the economy £12.3 billion annually through people being unable to work 
[15]. These figures indicate that back pain is more of an economic burden 
compared to other illnesses, including heart disease, Alzheimer’s disease, 
and diabetes [34].  
 Surgical intervention with a spinal fusion procedure is recommended 
for pain alleviation. The frequency of such procedures has continually risen 
over recent decades, and is partially due to advancements in the technologies 
of the components, such as fixative screws and fusion cages, being employed 
[34]. As such, there is a growing demand to further evolve the technologies of 
spinal fusion components with increasing fusion efficacy.  
 
1.2 BONE  
1.2.1 Overview of bone  
Bone consists of a mineralised extracellular matrix, containing both 
organic and inorganic components, as well as active populations of cells 
responsible for maintaining a function and healthy tissue structure. Bone has 
a capacity to regenerate and repair itself, and can therefore be thought of as a 
dynamic living composite. The human body contains 206 individual bones, 
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made up of 126 bones of the appendicular skeleton, 74 bones of the axial 
skeleton, and 6 bones of the auditory ossicles [35].  
Bones of the human skeletal system are categorized as flat, long, 
short, irregular and sesamoid. Flat bones, which possess flattened 
morphologies, include the cranial and rib bones, and serve protective 
functions. Long bones are elongated structures and include the femur and the 
humerus. These bones typically facilitate movement through joints and bear 
load. Short bones provide a supportive role in combination with other bones, 
and are associated with little movement. Irregular bones exhibit irregular and 
complex structures, and include the vertebrae, a collection of 33 bones that 
constitute the human spine. Finally, sesamoid bones are embedded in 
tendons and protect them from stress. The kneecap, or patella, is an example 
of sesamoid bone.        
 
1.2.2 Bone properties and function 
Hierarchical structuring from the nano- to the macro- scale provides 
bone with impressive mechanical properties (Table 1.1), which means that it 
can provide structural support, facilitate movement through interaction with 
muscles, and protect organs. Bone also has less obvious, but equally 
important functions such as mineral and acid-base homeostasis. It also stores 
growth factors, and provides space for the generation of blood cells [35, 36]. 
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Table 1.1 Mechanical properties of cortical and cancellous bone (Adapted 
from [37] with permission from Copyright © 2011 Bentham Science 
Publishers).  
Property Cortical bone Cancellous bone 
Compressive strength (MPa) 100-230 2-12 
Flexural, Tensile strength (MPa) 50-150 10-20 
Strain to failure 1-3 5-7 
Tensile modulus (GPa) 7-30 0.05-0.5 
Fracture toughness (KIC) (MPa.m1/2)  2-12 - 
 
1.3 BONE COMPOSITION 
The composition of bone includes both organic and inorganic 
components that undergo constant structural re-modeling by cell-mediated 
processes.  
 
1.3.1 Organic components 
Organic components contribute to around 30 % of bone mass. 
Approximately 90 % of this mass is accounted for by type-1 collagen, with 
noncollagenous proteins (NCPs), lipids, and mass of hydration together 
making up the remaining 10 % mass [38, 39]. Collagen type I molecules 
consist of three polypeptide chains, specifically two alpha 1 chains and an 
alpha 2 chain, which self-arrange as triple helices that are 300 nm in length 
and 1.23 nm wide [40, 41]. This collagen structure is referred to as 
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tropocollagen. In bone, a spacing of 40 nm exists between the top and bottom 
of each segment of tropocollagen where mineralisation is initiated.  
This material is the basic building block of many human soft and hard 
tissues as well as bone, including skin, ligaments, tendons, and teeth [42].  
 
1.3.2 Inorganic components 
Up to 70 % of the remaining bone mass is apatitic calcium phosphate 
mineral, first identified in the 1920’s by X-ray diffraction, and later confirmed in 
the 1930’s [43, 44]. This mineral is generally identified as hydroxyapatite (HA) 
(Ca10(PO4)6(OH)2), however this form of the bulk phase of inorganic bone 
material is considered extremely pure [45]. Stoichiometric HA has a calcium to 
phosphorous (Ca/P) ratio of 1.67. In reality the naturally occurring composition 
of HA may deviate from this stoichiometry, being either calcium deficient 
(Ca9(PO4)5(HPO4)OH), or containing ionic substitutions. The most prevalent 
substitution of bone mineral is of the carbonate (CO32-) anion in place of either 
hydroxyl (-OH), or more commonly phosphate (PO4) groups, referred to as A 
type and B type substitution, respectively [46, 47]. Carbonate makes up 2 % 
to 8 % of bone mineral by mass [46, 47]. Additionally, minor concentrations of 
Mg, Na, as well as trace concentrations of Si, Sr, Zn, Pb, have been identified 
[45]. It is believed that these impurities and non-stoichiometric phases 
contribute to chemical changes in HA mineral in terms of surface reactivity 
and charge, and also make mineral more soluble such that the release of ions 
may promote bone remodeling and turnover [45].  
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 Moreover, despite the nanocrystalline nature of bone mineral, it is 
considered overall to be poorly crystalline due to the presence of an 
amorphous fraction. The presence of amorphous calcium phosphate (ACP) 
contributes to the low crystallinity, and it is thought that the formation of bone 
includes a step where ACP matures to form a more crystalline HA [48, 49].  
 
1.4 BONE ORGANISATION 
Bone is structured from the molecular to macroscales. These include 
tropocollagen organisation, micro fibrilous, fibrilous, lamellar, osteonal, and 
macroscopic levels [50]. The structure of bone at each length scale is shown 
in Figure 1.1. 
 
Figure 1.1 Schematic of bone structure from the molecular to the macrosacle 
(Adapted from [40] with permission from Copyright © 2014 Nature Publishing 
Group).  
 
1.4.1 Organisation of collagen 
With regards to bone, the organization of collagen is complex and has 
been thoroughly examined [51, 52]. On the molecular level, tropocollagen 
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molecules are assembled into triple helix structures that align in a quarter-
staggered array to form a microfibril.  
A collection of microfibrils constitutes a collagen fiber. In the formation 
of bone tissue, arrangements of mineralised collagen fibres may be 
disordered, resulting in woven bone structure, or be highly aligned, forming 
sheets of lamellar bone structure [39]. Disordered woven bone is remodeled 
to aligned lamellar bone, giving rise to trabecular and cortical bone structures 
(Figure 1.1).  
 
1.4.2 Organisation of apatite 
Apatitic mineral nucleates in the 40 nm spacing between the top and 
bottom of each tropocollagen segment, and extends into the 0.24 nm gaps 
that exist between parallel tropocollagen collagen molecules arranged within 
microfibrils and around them.  The resulting HA nanocrystals are described as 
platelets, which exhibit an irregular structure but are often assigned 
approximate dimensions of 50 nm x 25 nm x 3 nm, aligning on the c-axis 
parallel to the direction of collagen [40, 50]. It remains unknown as to the 
involvement of collagen in the processes by which amorphous mineral 
precursor evolves into highly orientated HA nanocrystals [53]. There are two 
trains of thought, the first being NCPs influence apatite nucleation, and the 





1.4.3 Cortical bone  
 
Figure 1.2 Osteonal microstructure of cortical bone imaged with synchrotron 
radiation-based computed tomography technique (Adapted from [55] with 
permission from Copyright © 2016 The Royal Society). 
 
Cortical bone is often referred to as compact bone due to its dense 
structuring and relatively low porosity ranging between 5 % and 10 % [35, 54, 
55] (Figure 1.2).  
Within cortical bone, collagen fiber sheets form concentric circular 
channels, termed osteons [39, 55, 56]. Osteons house a complex system of 
Haversian canals containing blood vessels that align parallel to the length of 
long bones [55-57] (Figure 1.3). Volkman’s canals are another type of 
vascular channel, which interconnect the vessels of the Haversian system 




Figure 1.3 Reconstruction of the Haversian system in a 2.93 mm3 sample of 
human femoral bone tissue imaged with synchrotron radiation-based 
computed tomography technique (Orange is representative of the outline of 
individual Haversian canals, whilst the multi-hued regions are representative 
of the osteonal morphology) (Adapted from [57] with permission from 
Copyright © 2016 Anatomical Society). 
 
1.4.4 Trabecular bone  
Trabecular, or spongy bone, is 50 % to 90 % porous, and is 
interspersed in the marrow compartment [35, 54, 55] (Figure 1.4). This type of 
bone architecture is encased by cortical bone structure. 
In the development of trabecular tissue, collagen fiber sheets align 
parallel to one another resulting in an open network structure of 
interconnected trabeculae. This bone tissue is subsequently referred to as 
spongy bone because of this structuring.    
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Figure 1.4 Trabecular microstructure of cancellous bone imaged with back 
scattered scanning electron microscopy technique (Adapted from [55] with 
permission from Copyright © 2016 The Royal Society). 
 
1.5 BONE CELLS  
Bone is a living tissue that undergoes constant remodeling by cellular 
processes. Several different cells are present in mineralized tissue, which 
include primarily osteoblasts, osteocytes and osteoclasts [58]. Generally, 
osteoblasts are responsible for the deposition of bone, whilst osteoclasts are 
responsible for its resorption [58, 59]. In order to balance deposition and 
resorption activities, signaling molecules are released by bone cells 
themselves that influence one another’s activity [59]. Osteoblasts secrete 
factors such as osteoprotegerin (OPG) that inhibit osteoclast cell function, and 
furthermore, osteocytes regulate both the activity of osteoblast and osteoclast 
cells [60]. The secretion of sclerostin from osteocytes, which are osteoblast 
cells that have become encapsulated in mineralized tissue, inhibits further 
bone formation from osteoblasts [61]. Immune cells also generate signaling 
molecules that enhance or lessen bone remodeling by cellular components 
[62].    
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1.5.1 Osteoblasts 
Osteoblast function is associated with bone production, with their main 
functions including osteoid deposition and the regulation of bone resorption 
[59]. Osteoblasts differentiate from pluripotent mesenchymal stem cells 
(MSCs), which also have the potential to develop into adipocytes, myocytes, 
and chondrocytes [63]. The differentiation to the osteoblast lineage is driven 
by runt-related transcription factor 2 (Runx2) and Osterix transcription factors 
[64, 65]. Canonical Wnt signaling has also been shown to be important for the 
fate of maturing pre-osteoblastic cells into osteoblasts [66]. The development 
of these cells promotes the development of osteoclast cells, as shown in 
experiments where mice devoid of early osteoblast cells did not develop a 
normal population of osteoclasts, suggesting that immature bone forming cells 
are partially responsible for the formation of their bone resorbing counterparts 
[63, 67].  
Osteoblasts can also influence osteoclast activity, promoting bone 
dissolution or reducing it, in coordination with their own functions. The release 
of receptor activator of nuclear factor κB ligand (RANKL) from osteoblasts 
promotes osteoclast differentiation and their breakdown of bone by binding to 
nuclear factor κB (RANK) on the surface of preosteoclasts [68]. Osteoblasts 
may also release OPG, which blocks the binding of RANKL with RANK 






Cells of the osteoblastic linage terminally differentiate into osteocytes 
when they become entrapped by a bony matrix, which are the most abundant 
cell found in bone tissue outnumbering osteoblasts by a factor of 10 in human 
bone [69]. During bone deposition, a population of osteoblasts becomes 
engulfed in the surrounding bone mineral. The resulting osteocytes occupy a 
space know as a lacuna, and possess dendritic spindles that extend and link 
to other osteocytes through canaliculi. These cells influence the remodeling 
process through the release of signaling molecules that stimulate bone 
formation or resorption processes in response to chemical and mechanical 
stimuli [60].  
 
1.5.3 Osteoclasts 
Bone apatite is dissolved by osteoclasts [70]. Osteoclast cells are 
members of monocyte/macrophage lineage and form from the fusion of 
mononuclear osteoclast precursors [70]. A complex mixture of hormones and 
mediators found in the bone matrix influences the development of osteoclast 
cells [71]. Once fully differentiated, these cells are relatively large, and can 
possess variable numbers of nuclei, typically between 3 and 20 [70, 72]. 
Pathological bone osteoclasts may contain even more nuclei, for instance in 
Paget’s disease, where over 100 nuclei have been observed [73].  
Osteoclasts can be characterized by their expression of several 
osteoclast markers, including tartrate resistant acid phosphatase (TRAP), 
matrix metalloproteinase (MMP), cathepsin K and others [71]. Both the 
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breaking down of bone mineral, as well as the organic matrix of bone, is 
accomplished by enzymatic degradation as determined by osteoclast activity.  
 
1.6 BONE REMODELING  
Bone remodeling involves a balancing act between bone formation and 
bone resorption. The process removes old bone tissue, replacing it with a new 
mineralizing collagenous matrix. This prevents long-term accumulation of 
micro damage, maintaining bone in terms of its structure, quality and strength 
[35, 39].  
In healthy adults, remodeling occurs through a series of systematic 
stages, beginning with activation, followed by resorption, reversal, and finally 
formation [35, 39]. These processes take place at the site of a basic 
multicellular unit (BMU), involving complex signaling pathways between 
osteoblasts, osteoclasts, and osteocytes [74]. Resorption processes are 
relatively fast in comparison to the development of new bone; it may take 
several weeks to resorb bone, however, it can take several months to deposit 
new mineral [59]. Pathological conditions associated with bone remodeling 
include osteoporosis, whereby osteoclast activity outweighs that of bone 
forming osteoblasts, resulting in a loss of bone mineral density [75].   
 
1.6.1 Activation  
Mechanical loads may activate remodeling non-specifically. Osteocytes 
are able to detect mechanical forces as shown by demonstrating a strong 
response to the flow of interstitial fluid within the lacuna and canaliculi spaces, 
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which results in the release of signaling molecules that influence bone 
remodeling [60, 76]. BMUs may be steered to specific areas of localised micro 
damage, targeting specific sites to remodel [77, 78].  
 
1.6.2 Resorption 
On the initiation of resorption, bone lining cells, which spread over bony 
surfaces, make-way for incoming osteoclasts [79, 80]. Osteoclasts form a 
sealing zone on the surface of bone. Adhesion can be influenced by surface 
energy [81]. Membrane bound molecules also ensure stable attachment of 
osteoclasts for bone resorption. Resorption is characterised by the formation 
of the ruffled border that is an intensely convoluted structure found at the 
sealing zone [82]. Its formation isn’t fully understood [82].  Calcium phosphate 
crystals localise at the ruffled border [83]. These crystals reveal distinctive 
alterations such as variation of shape and electron density due to bone 
resorption activities [83].  
 
 
Figure 1.5 Howship’s lacuna develop where osteoclasts resorb bone 
(Adapted from [35] with permission from Copyright © 2008 American Society 
of Nephrology).   
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The main two resorption processes, acid secretion and proteolysis, are 
believed to occur simultaneously [82]. Release of HCl promotes HA matrix 
dissolution. The high level of H+ ions that is needed comes from the catalysis 
of CO2 and H2O to form H2CO3 [82]. The H2CO3 then ionizes into H+ and CO3- 
ions [84]. The exchange of CO3- with Cl- ions provides the Cl- ions needed for 
acidification and break down of apatite [84]. Proteolysis and subsequent 
breakdown of collagen is due to the activity of cathepsin K, MMP, and 
gelatinase released from cytoplasmic lysosomes, all active at low pH levels 
[82, 85]. Resorption pits form where digestion takes place, referred to as 




Following resorption, an intermittent period in the remodeling process 
follows known as the reversal phase, which can last several weeks [79]. In 
this time, osteoclasts undergo apoptosis and the pro-osteogenic signals 
released from osteoclasts at the end of resorption stimulate pre-osteoblasts to 
differentiate into osteoblasts [79, 87]. A myriad of chemical signals and growth 
factors released during resorption may also stimulate pre-osteoblast 
recruitment and activity [62, 88]. Mononuclear cells also prepare the resorbed 
surface for bone deposition [62].  
 
1.6.4 Formation 
Osteoblasts replenish resorbed areas with osteoid, which consists of 
bone’s non-mineral components. An osteoblast may deposit 2 to 3 times its 
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volume in osteoid before it transforms into an osteocyte, effectively becoming 
cocooned in bone matrix post-mineralisation, or alternatively an osteoblast 
lining cell, covering the newly formed bone osteoid and forming networks to 
osteocytes via canaliculi channels [35, 89, 90] (Figure 1.6).   
 
Figure 1.6 Synthesis and deposition of collagenous bone matrix by 
osteoblast cells. As mineralisation proceeds, osteoblasts transform into 
osteocytes, becoming encapsulated in hard tissue (Adapted from [35] with 
permission from Copyright © 2008 American Society of Nephrology).  
 
Mineralisation of the osteoid ensues in a matter of days following its 
deposition, beginning with the precipitation of amorphous calcium phosphate 
mineral in between collagen arrangements as previously described, which 
matures into nanocrystalline hydroxyapatite [91]. An approximate 20 % 
fraction of the initial mineral remains amorphous and contributes toward 




1.7 BONE REPAIR 
In the event of fracture, the damage caused to bone may compromise 
the integrity of the skeletal system, cellular components and blood supply, all 
of which are addressed by healing. Healthy bone possesses an impressive 
healing capacity that does not leave a scar, and will heal without the presence 
of rigid fixation for defects up to 12 mm in length [92, 93]. Healing of fractures 
occurs in three stages, starting with inflammation, followed by repair, and 
finally remodeling, which when successful, replenish damaged bone with 
healthy mineralised tissue as to avoid a non-union scenario and restore 
function [92, 94].  
Enhanced bone healing can be facilitated through invasive techniques 
such as electrical stimulation, low intensity pulsed ultrasound, and externally 
applied shock waves, which promote mechanical and biological stimuli [95]. 
The natural bone healing processes may be impaired by disease, smoking, 
diabetes, and the position of the non-union [96].  
 
1.7.1 Inflammation 
The inflammatory response following fracture is immediate, peaking 
after a couple of days and lasting around a week in total [92]. During this time, 
the fracture site is both swollen and painful, which although uncomfortable, 
prevents unnecessary movement of the fracture site. At the start of the 
inflammation stage, disruption of the normal organisation of hard tissue 
results in breakage of vasculature, facilitating acute necrosis, acidosis and 
hypoxia of surrounding bone and tissue local to the fracture [97]. 
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Consequently, complex signaling cascades result in the release of specific 
chemotactic agents, which initiate the migration of platelets, neutrophils, 
macrophages, fibroblasts, blood monocytes, polymorphonuclear leukocytes, 
and undifferentiated cells toward inflamed tissue where a haematoma (blood 
clot) develops due to the accumulation of blood, which clots at the fracture 
site [92, 94].  
A cocktail of signaling molecules and growth factors are present within 
the resulting haematoma and are essential in bone healing by activating 
specific cellular processes [92, 94]. These molecular components are 
responsible for promoting the formation of extracellular matrix, angiogenesis, 
chemo attraction of immune and mesenchymal cells, and fibroblast 
recruitment [98]. For instance, cytokines IL-1 and IL-6 recruit the movement of 
mesenchymal cells that proliferate into chondrogenic and osteogenic cells [92, 
94, 98].  
 
1.7.2 Repair 
 The repair phase overlaps the inflammatory period, beginning after a 
few days and can continue for a few weeks [92, 99]. During the repair phase, 
the haematoma is first transformed to granulated tissue. This consists of 
fibrous tissue deposited by fibroblasts that bridges the junction of the fracture 
gap and contains a high concentration of new blood vessels. Despite being 
mechanically weak, the resulting soft callus supports the penetration of 
vasculature, restoring a blood supply to the healing space [92, 99] .  
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The soft callus transitions into a hard and bony callus by ossification 
processes. Ossification can take place through either an indirect (secondary) 
or direct (primary) pathway. Commonly, natural fracture healing proceeds 
through the indirect pathway, which involves endochondral and 
intramembranous ossification processes [92, 99]. Endochondral bone 
formation refers to bone formed through the ossification of intermediate 
cartilage tissue, which is transformed into woven bone. Intramembranous 
ossification describes bone formation within fibrous connective tissues, and 
occurs in the absence of cartilage. The endochondral and intramembranous 
ossification pathways employed to heal bone are also responsible for 
formation of bones during fetal development.  
 
1.7.3 Remodeling 
Eventually, the hard callus consists of entirely woven bone tissue that 
is converted to regular bone structure by osteoblast and osteoclast cells 
through the remodeling mechanism described previously. Following 
remodeling processes, the cortical and cancellous architecture and function of 
the bone is restored.  
 
1.8 BONE RELATED BIOMATERIALS APPLICATIONS  
Biomaterials related to bone are employed to repair and regenerate the 
skeleton when it is compromised by trauma, illness and/or age-related 
diseases in scenarios and natural healing processes alone are unable to 
replenish tissue and restore function. These materials interact with the body 
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directly in the form of an external system or implanted material or device to 
repair or replace bone.  
 
1.8.1 Bone graft 
The “self-healing” ability of bone means small defects can be 
replenished by new bone formation in response to the injury. However, not all 
defects will heal in this manner, instead being filled in with a fibrous tissue 
[100]. The minimal size of a bone defect that will not heal by itself naturally is 
defined as a critical size defect [100].  
Critical size defects may arise following the traumatic loss of bone, or 
tissue excision to remove an infected bone region, as well as benign and 
cancerous growths. The surgeon is left with a defect that is typically irregular 
and the size of which is difficult to predict prior to surgery. The formation of 
this fibrous tissue will weaken the overall structure of the bone and may result 
in permanent deformity. These defects must be augmented with suitable 
material to prevent fibrous ingress into the defect whilst contributing a degree 
of biomechanical stability. 
Bone regeneration materials need to be able to provide a scaffold 
capable of facilitating the healing of bone in scenarios that include fractures, 
large defects, and cavities resulting from the removal of bone tumors, as well 
as the fusing of adjacent vertebrae in the spine, whilst avoiding the 
development of fibrous tissues.  
Biomaterials are used in every reconstructive orthopedic surgical 
operation [101]. Bone grafts are biomaterials that can augment a defect or 
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void space of bone. Bone grafts provide orthopedic surgeons with tools for 
adjunctive fixation between bony tissues, such as where bone healing and 
filling of bone defects is sought. Bone grafts that provide a scaffold onto which 
newly forming hard tissue can be deposited are referred to as being 
osteoconductive. Osteoinductive materials can additionally stimulate bone 
formation through physical or chemical cues (e.g. release of growth factors) in 
a non-bony site. Additionally, these materials must also be well tolerated by 
the body (i.e. biocompatible), ideally resorbed, cost-effective, easily stored, as 
well as easy to apply in the clinical setting.  
 
1.8.2 Bone fusion	
Bone fusion is used as a means to prevent the specific pathologies that 
are associated with damage to the spinal column. In order to alleviate 
conditions concerning nerve root compression, arthrodesis of the spine, 
colloquially referred to as spinal fusion, is an acceptable treatment option 
when more preservative treatment measures are ruled out. Following the 
removal of compromised vertebral disc material, a spinal cage device is 
inserted into the disc space, restoring the spacing between vertebrae and 
relieving pressure upon trapped nerve roots.  
In addition to facilitating the fusion of adjacent vertebrae, the spinal 
cage maintains correct alignment and foraminal height of the spine. A 
successful procedure results in the alleviation of pain suffered by the patient, 
however the mobility of the spine is never fully recovered. Moreover, other 
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issues include cage subsidence, dislocation, and deviation from normal 
lordosis.  
 
Figure 1.7 Bullet shaped spinal fusion cages designed for lumbar vertebral 
fusion fabricated from (a) PEEK and (b) titanium (Adapted from [102] with 
permission from Copyright © 2014 Springer-Verlag Berlin Heidelberg). 
 
Spinal fusion devices have been in clinical use since the 1990’s [103]. 
These devices were first shown to be successful in the treatment of horses 
suffering from nerve root compression [104]. In humans, incorrect sizing of a 
fusion device can lead to poor clinical results, despite achieving fusion, due to 
incorrect lordosis of the spine [105]. Therefore, fusion devices are specifically 
designed for use in different localities of the spine, such as for lumbar or 
cervical implantation [102, 106]. 
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Conventional spinal fusion devices are fabricated from non-resorbing 
biomaterials such as poly(ether ether ketone) (PEEK) or titanium based alloy 
(e.g. Ti6Al4V), and typically incorporate a cavity space to accommodate for 
bone grafting material (Figure 1.7). A bone graft of choice may then be 
packed in by the surgeon, which when in contact with the bony surfaces of 
vertebra, aids in fusion and complete through growth of new bone. The ‘gold 
standard’ for decades has been autologous graft, which facilitates successful 
fusion with at least 90 % rate of success [107]. Alternatively some devices 
may be designed to accept pre-fabricated bone graft inserts that can be 
readily placed into the fusion device before implantation, such as Tribone 80 
for the Solis cervical cage system, consisting of β-TCP (80%) and HA (20%) 
[108].  
 
1.9 BIOMATERIALS FOR BONE REPAIR 
Several classes of materials are widely employed for the replacement 
and regeneration of bone tissue and facilitating bone fusion, including tissue 
derived, ceramic, polymeric, composite and metallic materials. 
 
1.9.1 Tissue derived biomaterials  
1.9.1.1 Autograft 
The long-standing ‘gold standard’ bone augmentation material is 
autologous bone. Autograft has been shown to outperform other tissue 
derived and synthetic bone graft materials based on histological comparison 
of new bone formation [109].  
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This bone graft is native to the patients themselves, and is taken from a 
second surgical site, typically the iliac crest. Employment of autologous bone 
removes concerns relating to immunological rejection. Requirement for a 
secondary surgical procedure, adds to additional surgery time and potential 
for blood loss, which can bring further pain and discomfort to the patient, as 
well as putting them at risk of contracting infection.  
Cortical bone graft is typically associated with poor cellular ingress and 
limited vascular ingress due to dense structuring [110]. Alternatively, autograft 
that exhibits structure similar to cancellous bone can facilitate cellular ingress 
and vascularisation due to the porous architecture of trabecular tissue, which 
provides an intricate 3D scaffold for bone formation [110].   
In some cases, surgeons may be limited by the availability and 
morbidity of bone that can be taken. Removing autologous tissue would likely 
cause further deterioration to the condition of a patient suffering with 
osteoporosis as it would increase their risk of fracture. Moreover, elderly as 
well as osteoporotic bone may possess deficient osteogenic potential needed 
for bone healing. Attention has therefore shifted toward the development and 
employment of alternative bone augmenting materials.   
 
1.9.1.2 Allograft 
Allograft is bone that is also human derived but has been harvested 
from another person, typically deceased, and is therefore acquired from a 
tissue bank [111]. This tissue derived bone graft has been demonstrated as a 
suitable alternative to autologous graft material in both orthopedic and 
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craniofacial surgeries [112-114]. Benefits include good availability and 
avoidance of further surgery to acquire grafting material.  
Forms of allograft include fresh, frozen and freeze-dried, which provide 
osteoconductive scaffolds for bone formation [115, 116]. Due to time required 
for disease screening and sterility procedures, fresh allograft is seldom 
employed. Frozen grafts are maintained below temperatures of -60 oC, which 
suspends enzymatic degradation of the material. Freeze-dried allografts 
include freeze-dried bone allograft (FDBA) and demineralised freeze-dried 
bone allograft (DFDBA), which has been stripped of calcium phosphate 
content, leaving being a material consisting of collagen, non-collagenous 
proteins and bone growth promoting factors (e.g. bone morphogenic proteins 
(BMPs)) [115]. Mineral content is removed with hydrochloric acid treatment to 
produce a demineralized bone matrix (DBM) [111]. Being in possession of 
bone growth promoting agents, including growth factors and proteins, means 
DFDBA is considered to possess osteoinductive properties in addition to 
being osteoconductive [111, 116]. 
Tissue banks provide powdered forms of DFDBA that range in particle 
size between 250-750 µm [116]. DFDBA particulates of 100-300 µm have 
been shown to be more osteogenic compared to larger particles of 1000-2000 
µm, as demonstrated through enhanced healing of femur fractures in Rhesus 
monkeys [117]. This may be due to the increased surface area of smaller 
particles, which facilitates greater interaction with cells involved in bone 
formation.     
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Concerns with bone allograft include the risk of disease transmission 
(e.g. HIV), expensive processing costs, and potential toxicity of chemical 
remnants present after de-calcification [115].  
 
1.9.1.3 Xenograft  
Xenograft refers to tissue originating from another species, such as 
bovine or porcine derived bone, and is also inclusive of mineralised corals and 
algae. Issues with these materials includes cross species disease 
transmittance and ethical concerns [118, 119]. 
Commercial xenograft products, including blocks and powdered forms, 
are void of organic components to help reduce negative immune response 
following implantation [115]. Examples of a commercially available xenograft 
include bovine derived Bio-Oss®, and coral derived Pro-Osteon®. Despite not 
being wholly resorbed in vivo, Bio-Oss® facilitates substantial bone ingrowth 
[120]. Pro-Osteon® can achieve significantly higher bone ingrowth compared 
to DBM bone graft, demonstrated in a rabbit femoral defect model [121].  
 Xenograft offers a cheaper alternative to allograft that is just as 
effective. For the treatment of calcaneal fractures, equine derived xenograft 
was shown to perform as well as allograft bone tissue [122].  
 
1.9.2 Ceramic biomaterials 
For bone graft applications, much attention has focused on ceramic 
materials that are chemically comparable to the inorganic mineral found in 
bone. Many inorganic calcium based salts have been used for the 
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augmentation of hard tissues. Concerns regarding disease transmission are 
eliminated in synthetic forms of these materials, which are synthesised in 
specialist laboratories as opposed to being harvested from a biological donor.   
 
1.9.2.1 Bioglass	
Since the discovery of Bioglass by Hench et al. in 1971, various types 
of biomaterials containing CaO-SiO2 have been investigated as biomaterials 
for hard tissue repair or replacement [123]. The element silicon is an 
important trace element in the early stages of bone formation. The soluble 
form of silicon may contribute to the stimulation of type I collagen synthesis 
and osteoblastic differentiation in human osteoblast-like cells [124]. It is 
shown that biomaterials containing CaO-SiO2 have excellent bioactivity and 
can bond to both hard and soft tissues through the development of a biologic 
apatite layer on the surface of the implanted material [125]. 
 
1.9.2.2 Calcium phosphates 
Calcium phosphates include hydroxyapatite (HA) (Ca10(PO4)6(OH)2), α- 
and β- phases of tricalcium phosphate (TCP) (α-/β- Ca3(PO4)2), brushite or 
dicalcium phosphate dihydrate (DCPD) (CaHPO4.2H2O), and calcium 
deficient hydroxyapatite (CDHA) (Ca9(HPO4)(PO4)5OH), which are reported to 
be well tolerated by the body and provide an osteoconductive scaffold, or 
osteoinductive platform (depending on the inclusion of bone promoting 
factors) for the regeneration of bone [126]. Table 1.2 provides a summary of 
calcium phosphate phases.  
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Table 1.2 Calcium phosphate phase compositions and their solubility’s 
(Adapted from [127] with permission from Copyright © 2008 American 
Chemical Society). 
Molecular formula Molecular 
mass (g mol-1) 














CaHPO4 136.1 1 6.90 Monetite, dicalcium 
phosphate anhydrate 
(DCPA) 
CaHPO4.2H2O  172.1 1 6.59 Brushite, dicalcium 
phosphate dihydrate 
(DCPD) 
Ca8(HPO4)2(PO4)4.5H2O 982.5 1.3 96.6 Octacalcium 
phosphate (OCP) 
α-Ca3(PO4)2 310.2 1.5 25.5 Alpha-tricalcium 
phosphate (α-TCP) 
β-Ca3(PO4)2 310.2 1.5 28.9 Beta-tricalcium 
phosphate (β-TCP) 
Ca10(PO4)6(OH)2 1004.6 1.67 116.8 Hydroxyapatite (HA) 
Ca4(PO4)2O 366.3 2 38.0 Tetra-calcium 
phosphate (TTCP) 
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The soluble nature of some calcium phosphates results in their 
dissolution and subsequent resorption following implantation. Calcium and 
phosphate ions are the primary dissolution products, which may be utilised in 
the formation of new bone mineral. The solubility of calcium phosphates 
correlates to the Ca/P ratio. Generally, the lower the Ca/P, the higher the 
solubility of the calcium phosphate phase in water at 25oC. Calcium 
phosphate solubility decreases in the order 
MCPA=MCPM>DCPD>DCPA>OCP>α-TCP>β-TCP >HA.  
 
1.9.2.3 Calcium sulphate	
Additionally, calcium sulphate (CS) based phases are a safe and 
cheap alternative to calcium phosphate that exists in three main forms, 
including fully hydrated (CaSO4.2H2O), partly hydrated (CaSO4.0.5H2O), and 
fully anhydrous (CaSO4). These phases are also referred to as dihydrate, 
hemihydrate and anhydrite CS respectively, which exist as sub forms 
summarised in Table 1.3.  
Since its first use in vivo in 1892 by Dressmann to treat tuberculous 
osteomyelitis, CS has been used for filling bone defects [131]. In the 1950’s, 
Peltier demonstrated use of CS to repair large bone defects, including that of 
the tibiae of dogs	 [132]. The treated area displayed new bone formation. This 
work demonstrated CS is partially or completely resorbed with no foreign body 
reaction elicited, indicating it is well tolerated by local tissues in vivo. Peltier 
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and Jones used CS to fill cavities left over from removal of bone cysts [133]. 
The patients discussed had cavities filled with CS pellets, which were 
absorbed and replaced by new bone. Minimal side effects were reported. 
Early CS reports should be treated with caution due to variance of reported 
outcomes, possibly from inconsistent crystal structure, purity and CS quality 
being assessed at the time [134]. 
 
Table 1.3 Calcium sulphate phase compositions and their solubility’s (+ 
Common names used in biomaterial literature, * Metastable in dry air, **Stable 
between 40-1180oC, ***Stable at >1180 oC) (Adapted from [129] with 




mass (g mol-1) 
Forms -log (Ksp) at 25oC 
[130] 
Common names 






CaSO4.0.5H2O 145.1 Alpha* 
Beta* 
 
6.5 Calcium sulphate 
hemihydrate+ 



































4.3 Calcium sulphate 
anhydrite+ 
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1.9.2.4 Calcium silicate 
Calcium silicate has been well known as the main component in 
Portland cement, but has only two decades of history as a biomaterial. 
Depending on Ca/Si molar ratio, there are three kinds of calcium silicate: 
monocalcium silicate (CaSiO3, MCS), dicalcium silicate (Ca2SiO4, C2S), and 
tricalcium silicate (Ca3SiO5, C3S). C2S and C3S, which are the main 
components of Portland cement, are hydraulic and can be hydrated and 
hardened when mixed with a liquid phase. C2S have been known to have five 
polymorphs, designated by using the symbols α, α’H, α’L, β and γ.  
Calcium silicate cements have attracted attention in the field of bone or 
dental repair and drug delivery since they showed good biocompatibility, 
bioactivity, excellent marginal adaptation and sealing ability [135, 136]. 
 
1.9.2.5 Pre-sets 
Bioceramic compositions have been employed as both granules and 
pellets to fill critical sized defects, which are supplied as pre-set materials that 
may be readily implanted. Granules are often pre-fabricated particles of 
millimeter scale. Irregular packing can lead to migration from the implant site.   
Pre-set CS poses minimal risk of in vivo side effects [137, 138]. 
However, it has been reported that severe inflammation is experienced in 
20% of patients when treated with OSTEOSET®T pellets [139-142]. The 
relatively short time frame it takes CS to undergo in vivo dissolution could lead 
to inflammation from resulting calcium rich fluids. Transient hypercalcemia is 
an expected side effect [143]. Further research has attributed these 
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complications to impurities. Similar CS OSTEOSET® pellets were used by 
Stubbs et al., with no inflammation [144]. Wilkins et al., report of 50 patients 
treated with CS OSTEOSET® pellets; no complications arose [145].  
 
1.9.2.6 Cements  
Calcium phosphate, sulphate and silicate can form cement. Cements 
overcome migration issues as they can be applied as a paste that fills the 
defect entirely followed by hardening to provide both mechanical and 
biological functions. Typically, one or more cement precursors are mixed with 
solvent in which they are not thermodynamically stable. Reactants 
subsequently dissolve and the salt most stable at that stoichiometry and pH 
value is usually precipitated, hardening to form a solid cement matrix.   
The credit for the formulation of the first calcium phosphate cement 
applicable for use in the clinical setting is rightly given to Brown and Chow of 
the Paffenbarger Dental Institute	 [146]. These researchers observed that 
combinations of tetracalcium phosphate (TTCP) (Ca4(PO4)2O) and brushite, 
or dicalcium phosphate dihydrate (DCPD) (CaHPO4.2H2O), intended for use 
as a remineralising paste hardened when allowed to stand on the laboratory 
bench overnight.  In years prior to this, other researchers including Monma 
had identified that the combination of calcium phosphate salts such as α-
tricalcium phosphate (α-TCP) (α-Ca3(PO4)2) with water formed a hardened 
product [147]. Despite the findings, these researchers did not report the first 
calcium phosphate cement in the modern literature. Indeed, in his seminal 
paper in 1950, Kingery demonstrated that the combination of CaO and H3PO4 
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enabled the formation of a hardened product that consisted of monocalcium 
phosphate monohydrate (MCPM) (Ca(H2PO4)2.H2O) [148]. The soluble and 
acidic nature of this compound would not have made this material useful for 
biomedical application.  
The majority of the early work on calcium phosphate cements focused 
on the optimisation and application of apatite forming materials; the rationale 
being that apatite is the main constituent of bone mineral and the hardening of 
this material, in contrast to brushite cements, does not require the use of 
acidic pH values. Modern calcium phosphate cements harden to form one of 
only two products, as determined by kinetic and thermodynamic factors 
heavily influenced by pH [48, 127]. If the cement paste has a pH value > 4.2, 
hydroxyapatite (HA) (Ca10(PO4)OH2) or more likely the calcium deficient form 
of the salt (Ca9(PO4)5HPO4OH) is favoured and if the cement has a pH < 4.2, 
brushite or dicalcium phosphate dihydrate (DCPD) (CaHPO4.2H2O) is 
favoured, which under certain conditions may dehydrate to form monetite, 
otherwise known as dicalcium phosphate anhydrate (DCPA) (CaHPO4) [149-
151].  
Adding water to an anhydrous form of CS will rapidly lead to the 
solution becoming supersaturated with CaSO4.2H2O, which precipitates out 
via crystal nucleation and growth, which continues until a point below 
saturation. A cycle of dissolution and precipitation repeats, eventually 
resulting in a solid material consisting of hydrated CS [152]. Setting time is 
relatively fast. Korte and Brouwers have modeled CS hydration to provide 
more understanding of this mechanism [153]. Setting kinetics can be 
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quickened or disrupted by additives termed accelerators and retardants 
respectively [154]. 
 
1.9.3 Polymeric biomaterials  
Both naturally occurring and synthetic polymers can be applied to bone 
repair applications. Synthetic polymers have many key advantages in a range 
of applications as biomaterials due to their tunable physical, chemical and 
degradation properties.   
 
1.9.3.1 Polymeric hydrogels  
Polymeric hydrogels are highly hydrated structures on to which cells 
may adhere or be encapsulated within, serving as a 3D scaffold for tissue 
formation. Owing to high water content and tissue-like structuring, hydrogels 
are attractive regenerative materials for several tissues, including skin, 
cartilage and bone [155]. Both fabricated forms and injectable formulations 
have been researched, covering biomaterials applications including bone 
grafting and anti-scarring wound dressings [94, 156].  
Cell adhesion upon hydrogel surfaces is dependent upon interrelated 
factors including surface chemistry, surface energy, surface charge density, 
and surface topology [157]. Poly(ethylene glycol) (PEG), an FDA approved 
hydrogel for medical applications, is surprisingly cell adhesion resistant. The 
inclusion of adhesion promoting molecules in the bulk of the gel, attachment 
of such molecules to the gel surface, and modification of surface topology 
have been investigated to enhance cell attachment to PEG based gels [158]. 
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Cell encapsulation is generally achieved by the gelation a liquid 
precursor containing a suspension of cells, with conditions being benign 
toward the biological components within, avoiding cytotoxicity [157]. Gelation 
mechanisms based on radical polymerisation and chemical crosslinking are 
widely employed in the encapsulation of many cell types (e.g. chondrocytes, 
fibroblasts, and stem cells etc.), in various gel networks (e.g. chitosan, 
alginate-co-gelatin, PEG, hyaluronic acid etc.) [157].  
Hydrogels are dynamic structures that exhibit swelling and diffusion 
dependent on the surrounding environment. Such properties can be 
influenced by ionic and pH gradients, and furthermore may be exploited to 
control the release kinetics of soluble therapeutics and ionic species [159]. Ion 
exchange processes can facilitate biologically relevant mineralisation 
reactions between calcium and phosphate ion species either side of the 
gel/solution interface, promoting the formation of mineral either within or from 
the surface of hydrogel. These processes have extended the application of 
hydrogels for the fabrication of potential bone graft biomaterials, such as the 
formation of tubular calcium phosphate structures from calcium loaded agar 
gel in contact with phosphate solution [160, 161].   
Typically, most hydrogels are limited by weak mechanical properties, 
which are essential to muskoskeletal load bearing applications. To overcome 
this, bioactive ceramic particles can be added to hydrogel matrices to 




1.9.3.2 Poly(methyl methacrylate (PMMA)  
Poly(methyl methacrylate (PMMA) is commonly employed as a fixative, 
its primary purpose to facilitate the transfer of mechanical loadings from bone 
to implant prosthesis. It was first used in 1958 in a total hip replacement 
operation [164]. This material does not form a direct bond with bone, relying 
on mechanical interlocking [165]. Strategies to improve integration with bone 
include the addition of bioactive particulates such as HA [166]. 
PMMA is a cementitious polymer that dissolves in its own monomer, a 
liquid MMA component, before hardening [165]. It can therefore be injected 
directly into defect spaces. There are concerns regarding toxicity of reaction 
products and its exothermic setting reaction, which can generate 
temperatures of 90 oC or greater whilst in close contact with tissue leading to 
potential tissue necrosis [167].  
 
1.9.3.3 Poly(ether ether ketone) (PEEK) 
 Poly(ether ether ketone) (PEEK) is a semi crystalline engineering 
polymer. The polymer belongs to a family of poly(aryl ether ketone)s (PAEKs). 
Other structures within the PAEK family also include poly(ether ketone) (PEK) 
and poly(ether ketone ketone) (PEKK). These polymers are distinguishable by 
their chemical structure consisting of chains of benzyl ether and benzyl 
aldehyde subunits in specific arrangements (Figure 1.8).  
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Figure 1.8 Polymeric repeat units of some poly(aryl ether ketone)s, including 
(1) Poly(ether ketone ketone) (PEKK), (2) Poly(ether ketone) (PEK), and (3) 
Poly(ether ether ketone) (PEEK) (Adapted from [168] with permission from 
Copyright © 2012 Taylor and Francis). 
 
The use of PEEK is widespread. It has been used in industries such as 
aerospace, oil & gas, automotive, electronic, energy and medical applications 
due to its impressive properties, such as thermostability, and resistance to 
degradation when in prolonged contact many organic solvents [168]. Over 
recent decades, PEEK has become an increasingly important and relied upon 
biomaterial for the medical sector, particularly in bone regeneration 
applications, seeing extended use in orthopedic, maxillofacial and, spinal 
surgeries [169, 170]. 
PEEK is physically ideal for the role of spinal implants, exhibiting 
physical properties, such as modulus, close to that of bone (3 GPa to 4 GPa), 
as well being well tolerated by the body [169]. It has also been proven in this 
application in both animal models and humans [106, 171-175]. Despite this, 
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alternative metallic counterparts, such as titanium alloy (Ti6Al4V), have been 
shown to outperform PEEK in terms of fusion capability.  
 
Figure 1.9 Overview of techniques used to enhance the bioactivity of PEEK 
(Adapted from [176] with used under the Creative Commons Attribution 
License (CC BY 3.0)). 
 
Novel processing, surface treatments and composite formulations have 
therefore been applied to PEEK to enhance its bioactive properties (Figure 
1.9). In the case of PEEK spinal fusion devices, applying these chemical, 
physical and compositional alterations may improve the interaction of the 





1.9.4 Composites  
Advancements in materials engineering now frequently allow for the 
combination of polymer and ceramic materials into a single composite 
formulation. Composites have the potential to possess the sum of favourable 
properties that originate from the constituent phases.   
Composites are an interesting prospect for biomedical applications. 
Blending a polymer with bioactive particles can engender a typically inert 
material with bioactive properties through the addition of the secondary 
bioactive phase. These formulations are developed to enhance adherence 
with adjacent bone tissue. It is therefore possible to improve on the properties 
of a given polymer through blending with a bioactive ceramic material such as 
HA. Whilst this can improve biocompatibility, it is potentially at a cost to the 
strength of the polymer if a high volume fraction of a brittle phase is added 
[169]. 
 
1.9.4.1 Carbon fiber reinforced PEEK 
Carbon fiber reinforced PEEK (CFR_PEEK) has been successfully 
applied as spinal rods and cages. In the role of spinal cages, CFR_PEEK 
achieves high rates of fusion and is rarely associated with negative 
complications, including subsidence and neurological issues [177].  
 Commercial carbon fibre reinforced PEEK is available from several 
manufactures, including Invibio®, who market it under the trade name CFR 
PEEK-OPTIMA® [178].   
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1.9.4.2 Hydroxyapatite reinforced PEEK 
The addition of HA to inert PEEK can produce a bioactive composite 
material (HA_PEEK). HA exposed on the surface of HA_PEEK contributes to 
increasing bioactivity [179]. As a reflection of the bioactivity properties HA 
introduces, apatite has been shown to develop on the surface of HA_PEEK 
submerged in simulated body fluid (SBF) [180]. HA particulates surrounded by 
polymeric matrix and not exposed on the surface do not contribute to apatite 
formation [181]. Compared to unfilled PEEK, HA_PEEK has been shown to 
enable better integration with surrounding bone [182]. Design considerations 
for polymer composites include polymer orientation, the interface between 
filler and polymer, loading level, morphology, orientation, and size [183].  
 
Figure 1.10 Fracture surface of a 20 vol% HA_PEEK composite specimen 
that shows evidence of HA particulate debonding from the PEEK matrix 
(Adapted from [182] with permission from Copyright © 2003 Elsevier Science 
Ltd) 
 
Inclusion of bioactive HA particulates from between 2.5 to 7.5 vol% to 
PEEK can provide a slight improvement to mechanical attributes. However, 
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increasing the bioactivity of composites by the addition of greater loadings of 
bioactive particulates results in a trade-off in mechanical properties. At HA 
loadings > 10 vol %, the tensile properties are severely compromised due to 
HA particle debonding [179, 182] (Figure 1.10).  
Additions of high weight fractions of bioceramic particles in a polymeric 
matrix can result in a brittle material, diminishing mechanical performance of 
such composites. In the absence of strong interfacial interactions between the 
bioceramic and polymer matrix, forces are unable to transfer effectively 
between brittle additive and the surrounding ductile matrix, causing the 
particulates to act as stress-raisers. Indeed, HAPEXTM, a 40 % HA in 60 % 
high density polyethylene blend, is brittle due to high amount of filler, 
however, it is only bioactive at 40 % HA incorporation [184]. Moreover, high 
levels of HA incorporation can result in the formation of filler particle 
agglomerates, which display weak interactions at the polymer filler interface 
[179, 182].  
Therefore, improving the strength of the interface between the HA and 
PEEK polymeric matrix beyond simple mechanical interlocking should enable 
the production of a stronger composite material at greater HA loadings.  
 
1.9.5 Metallic biomaterials 
Metals have the longest history amongst modern biomaterials and are 
generally used for replacement of hard tissues [185]. 
Metallic plates were first employed for the fixation of long bones over a 
century ago [186, 187]. Metals continue to be used as biomedical screws and 
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fixative aids in orthopaedic surgery. Because of their high strength and 
stiffness, metallic biomaterials are also routinely employed in replacement and 
repair applications associated with high biomechanical stresses, such as hip 
replacement, knee replacement and spinal fusion [188, 189].  
Common metal and metal alloys for used for biomaterials application 
includes stainless steel, cobalt alloys, and titanium alloys (e.g. Ti6Al4V). 
 
1.9.5.1 Stainless steel  
A combination of mechanical properties, corrosion resistance and cost 
effectiveness means stainless steel is a desired material for fixation devices 
[190]. It possesses a high ductility compared to other metallic biomaterials, 
which makes it an ideal candidate for forming bone plates [191].  
 
1.9.5.2 Cobalt alloys 
The first cobalt-based alloys were found to resist degradation within an 
oral environment and so were used for dental implants [192]. Cobalt alloys are 
currently utilised in prosthesis of the knee, shoulder and hip [192]. However, 
there is growing body of evidence that the release of cobalt wear debris from 
metal-on-metal implants has adverse consequences toward adjacent tissues 
and potentially introduces cytotoxic levels of cobalt ions into the bloodstream 





1.9.5.3 Titanium and titanium alloys 
Titanium plates and screws are commonly employed as implant fixation 
aids [190]. The unalloyed metal is very biocompatible and rarely initiates 
allergic reactions when inside the body [195]. 
Titanium alloys were developed in order to improve upon the properties 
of titanium to ultimately improve an implant’s longevity and performance. 
Ti6Al4V is considered a dominant titanium alloy in the biomedical field 
(Ratner, 2004). The pro-osteogenic potential of Ti6Al4V coatings and titanium 
foams is highly promising for developing more effective spinal fusion devices 
[196, 197].  
 In fact, compared to PEEK polymer surfaces, both smooth and 
roughened Ti6Al4V surfaces have been shown to stimulate the secretion of 
bone morphogenic proteins (BMPs) 2, 4, and 7 at significantly high levels from 
human MG63 osteoblast-like cells. These molecules promote the 
development of an osteogenic bone-forming environment [196].  
 
1.10 THESIS OVERVIEW 
In this thesis, several calcium based composite biomaterials will be 
developed for bone graft and spinal fusion applications. Each chapter will 
disseminate the formulation and characterisation of the systems. The main 
body of the thesis consists of four research chapters that are presented as 
published papers or papers in submission (Chapters 2 through to 5). 
Chapter 2 is titled “Characterisation of novel poly (ether ether 
ketone)/calcium sulphate composite for bone augmentation” and will focus on 
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the reinforcement of biomedical calcium sulphate (CS) cement for use as a 
bone graft material. Chapter 3 is titled “Biologically analogous calcium 
phosphate tubes from a chemical garden” and will investigate the interface 
between calcium loaded agar based hydrogel and phosphate solutions that is 
able to produce tubular calcium phosphate structures. Chapter 4 is titled 
“Interfacial mineral fusion and tubule entanglement as a means to harden a 
bone augmentation material” and will explore the formulation of a bone graft 
technology that is able to harden in situ through generating biologically 
analogous tubular calcium phosphate structures introduced in Chapter 3. 
Chapter 5 is titled “Development of a covalently bonded hydroxyapatite and 
poly(ether ether ketone) composite” and will explore the development of a 
covalently linked PEEK and hydroxyapatite (HA) composite material for spinal 
fusion devices.  
 Lastly, Chapter 6 provides an account of the overall conclusions of the 
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Calcium sulphate (CS) has been used in bone grafting since the 1800s.  
It has not replaced autograft as the gold standard, however, since its 
dissolution occurs rapidly in bodily fluids, meaning that the material cannot 
support long-term bone growth. Here, the polymer poly(ether ether ketone) 
(PEEK) was used to slow dissolution in in vitro physiological environments 
and augment the mechanical properties of the material. 
 
2.0.2 Experimental Methods 
PEEK/CS specimens were fabricated by combining powders of PEEK 
and CS with water, resulting in a hardening paste. To enhance physical 
interactions between phases, cylindrical specimens were heat-treated to melt 
and fuse the PEEK. Following analysis of physical and chemical interactions 
by SEM and FT-IR respectively, dynamic ageing in PBS and compression 
testing was undertaken to measure how the PEEK influenced the mechanical 
properties of the final parts. Changes in structure and chemistry were 




Powders of PEEK and CS hemihydrate (CSH) (CaSO4.0.5H2O) were 
combined with PEEK at 0 wt%, 2.5 wt%, 20 wt%, 40 wt% and 80 wt% and at 
a P:L ratio of 0.85 g/mL. The subsequently hardened structures were heat-
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treated, which initiated the melting of PEEK and dehydration of CSD 
(CaSO4.2H2O) to the CS anhydrite (CSA) (CaSO4) phase, which changed 
colour and apparent volume. FT-IR and SEM analysis revealed heat 
treatment of PEEK/CS specimens facilitated both physical and chemical 
interactions between phases. Over a period of 21 days of ageing in PBS, the 
hydration of CS was determined by XRD and improved specimen longevity at 
all levels of PEEK wt% loading was measured compared with the control. 
Importantly, increasing PEEK wt% loading resulted in a marked increase in 
the mechanical properties of PEEK/CS specimens in terms of both 
compressive strength and modulus. 
 
2.0.4 Conclusions  
Reinforcement of CS with PEEK significantly enhanced in vitro 
dissolution resistance, in addition to enhancing mechanical properties. This 




Bone graft materials should support the attachment and proliferation of 
osteoblast cells, and facilitate the deposition of new hard tissue in bone 
defects [1]. Ideally, these materials allow for the conduction of new mineral 
deposition and demonstrate good integration with adjacent bony tissues [2]. 
Increasingly, synthetic minerals are chosen over bone harvested from the 
patient’s own body. This is despite autologous bone graft being considered 
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the “gold standard” graft material, due to the low risk of immunological 
rejection associated with its use [3, 4]. The reasons for alternative bone graft 
selection are that the volume of autologous bone is limited and requires 
additional surgery to obtain, which poses further risk to a patient in terms of 
contracting an infection, blood loss and experiencing unnecessary discomfort 
thereafter [4]. In addition, allograft tissue suffers drawbacks in terms of 
disease transmission and possible rejection [4].  
Synthetic bioceramic materials, particularly calcium (Ca2+) salts of 
phosphate (PO43-), pyrophosphate (P2O74-), sulphate (SO42-) and silicate 
(SiO44-) are proven examples of minerals that are able to regenerate areas of 
removed or diseased hard tissue [5-11]. Moreover, these materials can be 
employed directly and are available in a variety of forms that includes 
granules and injectable cementitious pastes, allowing surgeons to select the 
most appropriate product on a case-by-case basis.  
The first ceramic material in widespread use for skeletal regeneration 
was calcium sulphate (CS). The ability of CS to be set in situ or applied 
directly as granules means that the material can be delivered in a number of 
ways [12, 13]. CS hemihydrate (CSH) (CaSO4.0.5H2O) and CS anhydrite 
(CSA) (CaSO4) forms cement when mixed with water, which hardens to form 
CS dihydrate (CSD) (CaSO4.2H2O) (Equation 2.1 and 2.2). The interaction 
between phases is reversible, as the water of crystallization can be removed 
by heating CSD (CaSO4.2H2O)  (Equation 2.3 and 2.4). CS was first used at 
the end of the 19th century to provide a fully resorbable osteoconductive 
scaffold capable of facilitating new bone formation in the diseased tissue of 
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human tuberculosis sufferers [9]. CS is able to facilitate cavity healing 
incurred from curettage of bone cysts, as well as being used successfully to 
augment osteoportic bone to allow for mechanical fixation of pedicle screws 
[10, 11, 14]. 
 
CaSO4.0.5H2O+ 1.5H2O à CaSO4.2H2O + heat  (Equation 2.1) 
CaSO4 + 2H2O à CaSO4.2H2O + heat    (Equation 2.2) 
CaSO4.2H2O + heat à CaSO4.0.5H2O + 1.5H2O    (Equation 2.3) 
 
CaSO4.2H2O + heat à CaSO4 + 2H2O    (Equation 2.4)    
 
Whilst resorbable graft materials are desirable, CS has been limited in 
its application since it undergoes rapid dissolution by hydrolytically driven 
degradation when placed in the body [15-17]. In contrast, biominerals such as 
hydroxyapatite (Ca5(PO4)3OH) (HA) are considerably less soluble in 
physiological conditions, offering a more stable network to support bone 
formation [18, 19]. Given that newly forming bone may take several weeks to 
fill a defect, these more stable calcium phosphate ceramics are favoured over 
CS for defect augmentation [6, 13]. 
Strategies to improve the degradation behavior of CS include 
combination with less soluble mineral phases and additives to form 
composites that possess enhanced properties. In combination with β-
tricalcium phosphate (β-TCP) CS still undergoes dissolution but the calcium 
phosphate mineral is able to remain at the implant site for a longer period [20]. 
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Composites containing CS can be modified to adjust degradation rate whilst 
dampening the production of acidic dissolution products [17, 21].  The addition 
of other phases can also augment the mechanical properties of the graft 
materials, with previous work showing that HA addition to CS may significantly 
enhance mechanical properties [22]. Attempts to combine CS 
with carboxymethylcellulose and hyaluronan improved mechanical properties 
of the material but at a cost of faster dissolution [23].   
It was postulated that combination of CS with an engineering polymer 
phase could allow for tunable hydrolytic degradation and mechanical 
attributes without trade-off, extending the capability of CS as a bone graft.  
One such polymer is poly(ether ether ketone) (PEEK) (Figure 2.1a).  PEEK is 
a high strength, high performance aromatic thermoplastic polymer that is 
widely considered to cause no detrimental biological response when 
implanted in the body and is resistant to both hydrolytic and oxidative 
degradation mechanisms at temperatures far exceeding that required for 
medical materials within the body [24, 25]. It is utilised widely for load bearing 
and high-wear resistant medical devices such as spinal implants and 
acetabular cups [25, 26]. Availability of powdered PEEK means combination 
with CS powders is a viable strategy for the fabrication of reinforced 
composites that has not yet been reported. This work describes the 
production of a composite PEEK/CS material through the combination of 
PEEK and CS powders prior to hardening and consolidation of the PEEK 
phase through heating. We describe how the addition of PEEK in this manner 
modifies the degradation and mechanical properties of the materials. 
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2.2 EXPERIMENTAL METHODS 
2.2.1 Standard fabrication of PEEK/CS cylinders  
Double Ground Alpha Base Crystacal (calcium sulphate hemihydrate, 
CSH) (CaSO4.0.5H2O) (Saint-Gobain Formula, France) and 150XF PEEK 
(Victrex, UK) powders were combined with 0 wt%, 2.5 wt%, 20 wt%, 40 wt% 
and 80 wt% PEEK by mass. Pastes of each mixture were produced under 
manual stirring with distilled water acquired from an arium® advance EDI pure 
water system (Sartorius, Germany) at a powder:liquid (P:L) ratio of 0.85 g/mL, 
before being poured into a mold to create cylindrical specimens of dimensions 
12 mm x 6 mm. The mold was then placed upon a Denstar-500 vibrating plate 
(Denstar, South Korea) set at high frequency to remove air bubbles. After 10 
minutes, the mold was transferred to an Incu-line incubator (VWR 
International, UK) at 37oC. After 1 hour, specimens were carefully removed 
from the mold and heated at a ramp rate of 5 oC and held at 380 oC for 2.5 
hours in a CWF 1300 furnace (Carbolite, UK). Specimens were then stored in 
ambient conditions.  
 
2.2.2 Volumetric shrinkage  
Cylinder volume of PEEK/CS specimens (n=3) before heat treatment 
and following heat treatment was calculated from geometric measurements 





2.2.3 Scanning electron microscopy (SEM)  
Secondary electron scanning electron microscopy (SEM) images of the 
fracture surfaces were obtained using a Sigma FE-SEM (Zeiss, Germany) 
operating at 15 kV under vacuum. PEEK/CS specimens with fracture surface 
exposed were secured firmly upon double adhesive carbon tapes attached to 
aluminium stubs and gold coated under vacuum for 2 minutes using a K550X 
sputter coater (Quorum Technologies, UK) before images were acquired.  
 
2.2.4 Fourier transform infrared (FT-IR) spectroscopy  
Fourier transform infrared spectroscopy between 500 cm-1 and 4000 
cm-1 was undertaken using a Nicolet 380 FT-IR spectrometer (Thermo-
Scientific, USA). For sample preparation, 2 mg starting powders and 
powdered PEEK/CS specimens were mixed with 198 mg KBr (99.99 % trace 
metals basis, Sigma-Aldrich, UK) and pressed into 13 mm diameter discs 
using a evacuable pellet die (Specac, UK) under a 10 ton force for 30 
seconds with a hydraulic press (Specac, UK).    
 
2.2.5 Dynamic ageing protocol  
Ageing was undertaken on n=33 specimens per composition prepared 
as standard, with a further n=10 specimens per composition not subjected to 
ageing as a control group. Individual PEEK/CS specimens were submerged in 
10 mL of calcium and magnesium free Dulbecco’s phosphate buffered saline 
(PBS) solution (Sigma-Aldrich, UK) in screw cap 60 mL capacity clear 
vessels. For a fixed set of n=3 specimens, a daily record of PBS supernatant 
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pH value, wet mass, dry mass, wet height, dry height, wet mid-diameter, dry 
mid-diameter, wet end-diameter and dry end-diameter was recorded. 
Supernatant pH values were measured using a S220 SevenCompact™ 
pH/Ion meter (Mettler Toledo, USA) equipped with InLab Expert Pro-ISM pH 
electrode (Mettler Toledo, USA). PBS supernatant was drained from every 
specimen vessel and replenished with a further 10 mL. At 7 day intervals, 
n=10 specimens per composition were removed from the ageing protocol until 
day 21.    
 
2.2.6 X-ray diffraction (XRD)  
Powder X-ray diffraction (XRD) patterns were acquired using a D8 
Autosampler Powder Diffractometer (Bruker, USA) with Cu Kα line (0.154 
nm).  Data was collected between 5 o and 60 o 2θ with a 0.02 o step-size and 
a step time of 0.5 s/o.  Background signal was removed and intensity 
normalised for each scan.  Patterns were matched to those stored by the 
International Centre for Diffraction Data (ICDD) database. 
 
2.2.7 Porosity  
Apparent specimen density was calculated from geometrical 
measurements of n=10 heat-treated PEEK/CS specimens before and during 
ageing. True specimen density was obtained for the same specimens using 
an AccuPyc II 1340 helium pycnometer (Micrometrics, USA) over 5 cycles of 
5 purges. The relative density and porosity were then calculated (Equation 
S2.2 and S2.3).  
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2.2.8 Mechanical testing  
Prior to mechanical testing, geometrical measurements of PEEK/CS 
specimen diameter and height were made to allow for calculations of contact 
area and test start height.  Compression tests were undertaken on n=10 
specimens per composition with their long-axis perpendicular to the 
compression platen using a Z030 universal testing rig (Zwick/Roell, USA) 
equipped with a 50 kN load cell at a compression rate of 2 mm/min until 
specimen failure. Compressive strength values were determined by 
converting values of force into stress and plotting stress vs. strain curves from 
which the maximum value of stress corresponding to specimen failure could 
be obtained (Equations S2.4 and S2.5)(Figure S2.1). Compressive modulus 
was determined by obtaining the slope of the aforementioned curves within 
the elastic region (Equation S2.6)(Figure S2.1). 
 
2.2.9 Statistical analysis  
Statistical analysis of data sets was conducted using StatPlus software. 
One-way ANOVA and post-hoc Tukey honest significant difference (HSD) 
testing was applied to compare volumetric shrinkage of specimens after heat 
treatment based on PEEK wt% loading.  Two-way ANOVA and post-hoc 
Tukey HSD testing was applied to compare mechanical data of specimens 
based on PEEK wt% loading and ageing time.  Differences were deemed 




2.3 RESULTS AND DISCUSSION 
2.3.1 Physical and chemical assessment of PEEK/CS cylinders  
 
 
Figure 2.1 (a) Chemical structure of the poly(ether ether ketone) repeat 
monomer unit. (b) PEEK/CS specimens post heat treatment (Scale bar is 
equal to 10 mm). (c) Volumetric shrinkage of PEEK/CS specimens due to 
heat treatment. Error bars represent standard deviation (n=3) and lines above 
data columns represent significant differences between groups based on 
PEEK wt% loading as found by post-hoc Tukey HSD tests following one-way 
ANOVA analysis.  
 
Following addition of water to starting powders a paste was formed, 
which hardened to form the composite material in accordance with Equation 
2.1. Prior to heat treatment, cylindrical specimens of each composition 
appeared almost identical up to the point of heat treatment (Figure 2.1b). Heat 
treatment of PEEK/CS specimens initiated melting of PEEK and dehydration 
of CSD (CaSO4.2H2O) to CSA (CaSO4) (Equation 2.4).  These changes 
resulted in an alteration in both colour and apparent volume.  Starting 
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powders of both CSH (CaSO4.0.5H2O) and PEEK were both cream in 
colouration. Specimens containing no PEEK (0% PEEK/100%CS) remained 
similar in appearance after heat treatment. Specimens of 2.5%PEEKCS 
acquired brown speckles but still retained some cream colouration. 
Specimens of 20%PEEK/80%CS and 40%PEEK/60%CS became fully brown, 
whilst specimens of 80%PEEK/20%CS became dark brown. Although the 
recommended processing temperature for PEEK of 380 oC was employed, 
polymer chain degradation can still occur leading to discoloration, which was 
evidently more extensive with greater loadings of PEEK (Figure 2.1b). 
Volumetric shrinkage of specimens also occurred as a consequence of 
heat treatment (Figure 2.1c). Specimens with PEEK loading between 0 wt% 
and 40 wt% underwent a volumetric shrinkage of between approximately 9 % 
and 15 %. Specimens of 80%PEEK/20%CS however appeared significantly 
smaller and were confirmed to undergo the greatest extent volumetric 
shrinkage of 39.7±0.7 %. One-way ANOVA analysis confirmed that significant 
differences in volumetric shrinkage existed between groups based on PEEK 
wt% loading (F(4,10) = 87.3, p=9.8x10-8). Post-hoc analysis utilising Tukey 
HSD tests found no significant differences between groups with PEEK loading 
between 0 wt% and 40 wt% (p>0.05), however significant differences did exist 
between these groups and that of specimens loaded with 80 wt% PEEK 
(p<0.001).  It is recommended that fractions of CS between 60 to 100 wt% are 
required to maintain volumetric structure that undergoes no significant 




Figure 2.2 SEM micrographs of a fracture surface of a 20%PEEK/80%CS 
specimen prepared at a P:L ratio of 0.85 g/mL (a) prior to heat treatment and 
(b) after heat treatment. (c) FT-IR spectra between 500 cm-1 and 4000 cm-1 
wavenumbers of PEEK and CSH (CaSO4.0.5H2O) starting powders, and a 
powdered 20%PEEK/80%CS specimen after heat treatment.  
88 
Fracture surfaces of a 20%PEEK/80%CS specimen showed good 
dispersion of globular PEEK particles (approximately 5 µm to 10 µm) situated 
within a dense network of needles with high aspect ratio (approximately 20 
µm by 2 µm) typical of the reported morphology for CSD (CaSO4.2H2O) 
(Figure 2.2a). Following heat treatment, there was a change to a more flake-
like morphology in addition to needles (Figure 2.2b). The powdered polymeric 
particles were no longer apparent, since the PEEK phase had fully melted and 
integrated with CS crystals. 
FT-IR spectra of PEEK contained peaks indicative of the chemical 
moieties present in its chemical structure (Figure 2.1a and 2.2c), including 
aromatic and carbonyl groups [27-30]. Peaks associated with aromatic groups 
are located at 3072 cm-1 and 3034 cm-1 representative of =C-H stretching, 
and at 1592 cm-1 and 1486 cm-1 due to C=C stretching. Additional peaks at 
850 cm-1 and 832 cm-1 are indicative of ring deformation vibrational modes. 
Peaks corresponding to carbonyl groups are found at 1652 cm-1, 1647 cm-1 
and 1257 cm-1. Due to peak overlap at 1652cm-1 and 1647cm-1, separate 
bands are hard to distinguish, but indicates carbonyl stretching in amorphous 
and crystalline regions of PEEK respectively.  
Vibrational modes of the SO42- anion within CSH (CaSO4.0.5H2O) were 
identified on the corresponding FT-IR spectrum [31-33] (Figure 2.2c). A peak 
at approximately 1010 cm-1 can be assigned to SO32- symmetric stretching.  
Peaks at 1114 cm-1 and 1080 cm-1 are assignable to SO42- anti-symmetric 
stretching, whilst peaks at 658 cm-1 and 596 cm-1 are present due to SO42- 
anti-symmetric bending. Peaks relating to O-H stretching can be found 
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between 3000 cm-1 and 3800 cm-1; peaks in the spectrum of CaSO4.0.5H2O 
are located at 3603 cm-1 and 3551 cm-1. A singular O-H vibrational band is 
also present at 1620 cm-1, indicative of CSH (CaSO4.0.5H2O) hydration 
degree.  
Vibrational bands relating to both PEEK and SO42- anions are present 
in the spectrum of 20%PEEK/80%CS. The symmetric stretching peak of SO42- 
remains located at approximately 1010 cm-1, consistent with spectra of both 
CSA (CaSO4) and CSH (CaSO4.0.5H2O). Substantial reduction of O-H 
stretching peak intensity between 3000 cm-1 and 3800 cm-1 indicates 
dehydration of CS phase as expected (Equation 2.4). The singular O-H 
vibrational band found at 1620 cm-1 in the spectrum of CSH (CaSO4.0.5H2O) 
is no longer visible and is instead overlapped by peaks indicative of C=C 
stretching (1592 cm-1) and carbonyl stretching (1652 and 1647 cm-1) of PEEK 
polymer chains. Shaping of antisymmetric SO42- bending modes between 550 
cm-1 and 750 cm-1, consisting of 4 overlapping bands (591 cm-1, 612 cm-1, 667 
cm-1 and 671 cm-1) suggests a mixture of CSA (CaSO4) and CSH 
(CaSO4.0.5H2O). Peaks previously assigned within the FT-IR spectrum of 
PEEK are visible in the spectrum of 20%PEEK/80%CS including ring 
deformation peaks at 850 cm-1 and 832 cm-1, the C=C stretching peak at 1592 
cm-1 and carbonyl stretching peaks 1652 cm-1 and 1647 cm-1 appeared at a 
relatively lower intensity, compared to in the spectrum of PEEK starting 
powder (Figure 2.2c). Unexpectedly, this suggests PEEK is able to interact 
with CSA (CaSO4) not only physically, but also chemically through highly 
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electron rich regions of PEEK polymer, including aromatic rings and carbonyl 
groups.  
 
2.3.2  Characterisation of dynamically aged PEEK/CS specimens  
Fracture surfaces of 20%PEEK/80%CS specimens after ageing in PBS 
undergo extensive microstructural transformations (Figure 2.3a-c). Ageing 
promotes development of plate like crystal structures that are visible at Day 7 
onwards, indicative of newly forming crystalline phases. This may be due to 
the hydrating environment provided by PBS media, promoting CS conversion 
from CSA (CaSO4) to CSD (CaSO4.2H2O) (Equation 2.2). Crystal structures 
are surrounded by a polymeric network of PEEK, distinguished by non-
crystalline material interacting with crystal structures through both direct 
contact and coating.       
Powder XRD patterns were acquired in order to assess CS phase 
changes as a consequence of ageing (Figure 2.3d). The powder XRD pattern 
for PEEK consisted of broad peaks in keeping with PEEK’s semi-crystalline 
nature. Peaks located at 2θ values of 19 o, 21 o, 23 o and 29 o are in-keeping 
with those reported in the literature for PEEK [30]. Sharp and narrow peaks 
within the CSH (CaSO4.0.5H2O) pattern indicated a crystalline material that 
matched to ICDD pattern 01-081-1448. Following heat treatment, the 
corresponding powder XRD pattern of a 20%PEEK/80%CS specimen 
contained peaks corresponding to both PEEK and CS phase components, 
namely CSA (CaSO4) and CSH (CaSO4.0.5H2O) matching ICDD patterns 01-
070-0909 and 01-081-1448 respectively. After 7, 14 and 21 days of ageing, 
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powder XRD patterns of 20%PEEK/80%CS specimens possessed peaks 
corresponding to CSD (CaSO4.2H2O), which were matched to ICDD pattern 
00-033-0311, in addition to peaks corresponding to PEEK.  
 
Figure 2.3 SEM images of 20%PEEK/80%CS specimens after ageing in PBS 
media for (a) 7 Days, (b) 14 Days and (c) 21 Days. (d) XRD diffraction 
patterns between 2θ values of 5 o and 60 o of PEEK and CSH 
(CaSO4.0.5H2O) starting powders, and powdered 20%PEEK/80%CS 
specimens after heat treatment prior to ageing (0 Days), and after 7 Days, 14 
Days and 21 Days of ageing. An XRD pattern for PEEK from the literature 
confirmed the crystal structure of the polymer (, see [30]). ICDD patterns 
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matching CSH (CaSO4.0.5H2O) (, ICDD pattern 01-081-1448), CSA (CaSO4) 
(, ICDD pattern 01-070-0909) and CSD (CaSO4.2H2O) (, ICDD pattern 00-
033-0311) (CaSO4.0.5H2O, CaSO4 and CaSO4.2H2O phases respectively) 
are also provided to aid in CS phase identification.     
 
 Submergence of heat treated PEEK/CS specimens in PBS media 
initiated an immediate degradation state in specimens loaded with 0 % and 
2.5 % PEEK, however a low loading level of 2.5 %, PEEK increased calcium 
CS longevity overall; complete deterioration of 2.5%PEEK/97.5%CS 
specimens did not occur until day 17 (Figure S2.2). Mass remaining profiles 
calculated from dry measurements showed consistent day to day mass loss 
with regards to 0%PEEK/100%CS and 2.5%PEEK/97.5%CS specimens, 
equivalent to degradation rates of 14.1 %/day of ageing (r2 = 0.99) and 7.9 
%/day of ageing (r2 = 0.97) respectively. This resulted in 16.9±5.4 % mass 
remaining after 6 days and 25.4±15.5 % mass remaining after 9 days of 
unreinforced PEEK/CS specimens and 2.5 wt% PEEK loaded specimens 
respectively (Figure 2.4a). In contrast, 20%PEEK/80%CS and 
40%PEEK/60%CS specimens increased in mass up to 17.6±1.9 % and 
9.7±1.8 % respectively over the course of ageing duration (Figure 2.4a). 
Deterioration of 20%PEEK/80%CS, 40%PEEK/60%CS and 
80%PEEK/20%CS specimens was not evident at any stage of ageing, due to 
increased physical and chemical interactions between PEEK and CS (Figure 
S2.2). Interestingly, PEEK reinforcement was shown to facilitate CS phase 
change from CSA (CaSO4) and CSH (CaSO4.0.5H2O) to CSD (CaSO4.2H2O) 
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leading to a mass increase (Equation 2.1 and 2.2)(Figure 2.3d and 2.4a). 
Theoretically, from known mass of CSA (CaSO4) consistuting each composite 
composition, calculations of maximum mass increase due to crystal hydration 
were 21.2 % for 20%PEEK/80%CS and 15.8 % for 40%PEEK/60%CS 
specimens, which is consistent with observed increases of 17.6±1.9 % and 
9.7±1.8 % respectively. Mass changes experienced by 80%PEEK/20%CS 
specimens were found to be negligible, and never deviated by more than 0.5 
% either side of 100 % of original specimen mass (Figure 2.4a). 
Simultaneously, between 5 % to 10 % decreases in porosity were measured 
for 20%PEEK/80%CS, 40%PEEK/60%CS and 80%PEEK/20%CS specimens 
after 21 days ageing (Table 2.1), possibly arising from crystal hydration of CS 
and a decrease in microstructure free volume.     
 
Table 2.1 Porosity (%) of PEEK/CS specimens after heat treatment and 
during ageing (n=10). 
Ageing 
time (Days) 
PEEK content (%) 
0 2.5 20 40 80 
0 70.7±3.15 72.1±0.49 73.9±1.3 73.5±1.6 54.6±3.4 
7 - - 65.8±2.4 67.7±1.4 52.0±3.9 
14 - - 68.0±1.0 68.2±2.9 50.0±2.8 




Figure 2.4 (a) PEEK/CS specimen mass remaining expressed as percentage 
(%) calculated from dry measurements. (b) Changes in PEEK/CS specimen 
mass measured dry and (c) wet. (d) PEEK/CS specimen mass increase 
expressed as a percentage (%) calculated between difference in dry and wet 
mass measurements. Error bars represent standard deviation (n=3).  
 
PEEK/CS specimen mass was consistently greater with regards to wet 
measurements compared to dry measurements (Figure 2.4b,c). Specimens of 
0%PEEK/100%CS and 2.5%PEEK/97.5%CS experienced daily increases in 
mass averaging 81.3±9.4 % over 6 days and 88.8±10.1 % over 9 days of 
ageing respectively (Figure 2.4d). Specimens of 20%PEEK/80%CS, 
95 
40%PEEK/60%CS and 80%PEEK/20%CS experienced lower average daily 
increases in mass of 35.7±1.3 %, 42.4±2.8 % and 30.8±3.8 % respectively 
over 21 days of ageing (Figure 2.4d). Nonetheless, this was considered as a 
reflection of absorptive capability and porous nature of PEEK/CS specimens, 
as PEEK/CS specimen height, mid-diameter and end-diameter showed no 
substantial differences between wet and dry measurements (Figure 2.5a-f). 
Exploitation of absorbance capacity in situ may facilitate localisation of 
nutrients from adjacent tissues beneficial to osteoblast viability [34]. A feasible 
avenue of further investigation may be the loading of soluble therapeutics 
through liquid exchange with PEEK/CS materials to aid bone regeneration 
[35, 36]. Specimens of 0%PEEK/100%CS and 2.5%PEEK/97.5%CS 
experienced substantial losses to cylindrical dimensions in terms of height 
and both mid-diameter and end-diameter.  
Direct measurements of PBS pH were indicative of material 
degradation (Figure 2.6)(Figure S2.2). Specimens of 0%PEEK/100%CS and 
2.5%PEEK/97.5%CS lowered PBS pH from 7.4 to between 5 and 6. Such an 
environment can beneficially demineralise adjacent bone, in-turn releasing 
growth factors (i.e. bone morphogenic protein) that contribute to 
mesenchymal cell differentiation into osteoblasts, which may encourage the 
deposition of new bone [37, 38]. However, rapid 0%PEEK/100%CS and 
2.5%PEEK/97.5%CS degradation before bone formation can occur and would 
be a significant concern that would limit the application of these particular 
compositions of composite. 
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Figure 2.5 (a) Changes in PEEK/CS specimen height measured dry and (b) 
wet. (c) Changes in PEEK/CS specimen mid-diameter measured dry and (d) 
wet. (e) Changes in PEEK/CS specimen end-diameter measured dry and (f) 




Figure 2.6 Direct pH measurements of PEEK/CS specimen PBS ageing 
supernatant before replenishment. PBS has a pH 7.4, and is shown in the 
figure by a purple dashed line as indicated by the legend. Error bars represent 
standard deviation (n=3). 
 
With regards to 0%PEEK/100%CS and 2.5%PEEK/97.5%CS, the pH 
value of supernatant was found to decrease less extensively on a daily basis 
in accordance with the reducing mass of specimens due to dissolution of CS 
content and replenishment of PBS media (Figure 2.4a-c and 2.6)(Figure 
S2.2). Specimens of 20%PEEK/80%CS, 40%PEEK/60%CS and 
80%PEEK/20%CS had little affect on pH of PBS ageing supernatant as 






2.3.3 Mechanical properties of PEEK/CS specimens  
 
Figure 2.7 (a) Compressive strength and (b) Compressive modulus of 
PEEK/CS specimens after heat treatment and during ageing. Bar colouration 
is representative of ageing time as indicated by the legend. Error bars 
represent standard deviation (n=10) and lines above data columns represent 
significant differences between groups based on PEEK wt% loading as found 
by post-hoc Tukey HSD tests following two-way ANOVA analysis.  
 
The compressive strength and modulus of CS (typically hydrated CSD 
(CaSO4.2H2O)) is typically in the range of 10 MPa to 20 MPa and between 3 
GPa and 6 GPa respectively when prepared at P:L ratios between 1.5 g/mL 
and 2 g/mL [39, 40]. Critically, the mechanical properties of CS in this study 
were several orders of magnitude lower, resulting in compressive strength of 
1.2±0.3 MPa and compressive modulus of 0.084±0.1 GPa. Preparation of 
pastes at P:L ratio of 0.85 g/mL (greater volume liquid fraction) evidently 
introduces porosity and areas of poor resistance to stress (Table 2.1).  Further 
optimization of the composite may be enabled by increasing P:L ratio during 
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PEEK/CS fabrication [41]. Furthermore, compressing specimens prior to heat 
treatment, and preparing pastes under vacuum may both lower the relatively 
high porosity of structures prior to ageing and provide additional mechanical 
stability during exposure to in vitro physiological conditions [42, 43].   
Importantly, our findings show PEEK is able to bring about significant 
gains in CS composite compressive strength based on PEEK wt% loading 
(Figure 2.7a). Specimens of 20%PEEK/80%CS and 40%PEEK/60%CS 
provided approximately 3-fold and 4-fold increases in compressive strength 
respectively prior to ageing. Interestingly, 80 wt% PEEK loading provides a 
further substantial rise in compressive strength of 26.6±3.9 MPa prior to 
ageing, equating to an approximate 22-fold gain. A significant increase was 
not found between groups of specimens based on ageing time (F(3,12) = 2.1, 
p=0.16), indicating specimens did not weaken notably due to prolonged 
submergence in PBS media in terms of compressive strength. Promisingly, 
ageing did not significantly alter compressive strength of specimens over 21 
days (Figure 2.7a). Despite this, compressive modulus generally decreased 
with ageing time (Figure 2.7b). Evidently, a complex relationship exists 
between the physical and chemical interactions of PEEK with CS, such that 
mechanical reinforcement is provided but not necessarily maintained during 






2.3.4 Mechanism of PEEK reinforcement of CS  
We propose that the strengthening and subsequent augmentation of 
degradation behaviour of PEEK/CS composites is due to enhanced 
interactions between CS crystals from the physical and chemical intercalation 
of PEEK following heat treatment. Without PEEK, CS is unable to retain its 
structure during microstructural and phase transitions initiated by PBS media. 
0%PEEK/100%CS specimens likely fall apart from the infiltration of PBS 
solution that initiates dissolution. Heating the composites containing PEEK 
allows the polymer content to coat the CS crystal matrix. Even at low loadings 
of PEEK, such as 2.5 wt%, composites demonstrate enhanced strength and 
degradation response when compared to 0%PEEK/100%CS. However, the 
further physiochemical improvements observed at PEEK loadings of at least 
20 wt% suggests that at these levels the polymer phase is able to infiltrate the 
entirety of structures and form a polymeric reinforcing network that binds to 
crystalline structures. As PEEK does not deteriorate in hydrolytic 
environments, the PEEK network retains structural dimensions of composites 
whilst protecting CS crystals from rapid deterioration in PBS media. 
Additionally, PEEK allows microstructural and compositional phase 
conversion of CS material from CSA (CaSO4) to CSD (CaSO4.2H2O) 
(Equation 2.2), which suggests that some CS crystals remain exposed to 
PBS. Positively therefore, bone-forming cells may still utilise the resorbable 
CS content available within PEEK/CS composite materials as an osteogenic 




Physical interactions between PEEK and CS were achieved by heating 
of PEEK/CS specimens. Consequentially, this led to specimen discoloration 
regarding specimens that contained PEEK, as well as volumetric shrinkage. 
Excitingly however, evidence of chemical interactions between PEEK with CS 
through aromatic and carbonyl moieties of the polymer chain were found to 
exist. The nature of these interactions significantly retards in vitro dissolution 
and enhances physical attributes. As such, PEEK can be utilised to 
fundamentally improve CS attributes directly relevant to bone graft 
requirements, especially considering large defect volumes that require a 
protracted presence of osteogenic scaffold and mechanical stability.  
 
2.5 ASSOCIATED CONTENT 
Supporting figures and equations are included in Appendix Part 1.  
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Calcium phosphate (CaPO4) tubes with features comparable to 
mineralised biological microstructures, such as Haversian canals, were grown 
from a calcium gel/phosphate solution chemical garden system. A significant 
difference in gel mass in response to high and low solute phosphate 
equivalent environments existed within 30 minutes of solution layering upon 
gel (p = 0.0067), suggesting the nature of advective movement between gel 
and solution is dependent on solution concentration.  Transport of Ca2+ and 
PO43- was quantified and changes in pH were monitored to explain 
preferential formation of tubes within a PO43- concentration range of 0.75-1.25 
M. Ingress from the anionic solution phase into the gel followed by liberation 
of Ca2+ ions from the gel was found to be essential for acquiring self-
assembled tubular CaPO4 structures. Tube analysis by scanning electron 
microscopy (SEM), X-ray diffraction (XRD), and micro X-ray florescence (µ-
XRF) revealed hydroxyapatite (HA, Ca10(PO4)6(OH)2) and dicalcium 
phosphate dihydrate (DCPD, CaHPO4.2H2O) phases organised in a 
hierarchical manner. Notably the tubule diameters ranged from 100 to 150 
µm, an ideal size for permeation of vasculature in biological hard tissue. 
 
3.1 INTRODUCTION 
Tubular mineralised structures that contribute to intricate arrangements 
and networks are found throughout nature, forming in bamboo, 
coccolithophores, corals, and exotic architectures such as the central rose of 
water-pot shell [1-7]. Tube-like motifs are also found in the hard tissues of 
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mammals, including dentinal tubules in teeth and Haversian canals in bone [1-
4]. These features are not random, functioning to enable gases and nutrients 
to pass through tissues of relatively low pore volume and maintain the viability 
of embedded cell populations. Many presume that the formation of these 
tubes is entirely biologically driven by cellular processes [8, 9].  Odontoblasts 
for instance are thought to play a significant role in guiding the formation of 
dentinal tubules [10]. Although often over looked, physical processes, such as 
the fluid flow, play a crucial role in the development of ear, kidney and brain 
tissue [11]. A better understanding of these processes in terms of guiding 
mineral formations is desirable and may even assist in attempts to replicate 
hard tissue structure more closely for the purpose of advanced regenerative 
biomaterials. Disease processes may also be better understood. Osteophytes 
for instance are organised extrusions of mineral that extend from subchondral 
bone into the joint space and are pathological in osteoarthritis [12].  
A chemical garden commonly refers to solid elongated structures that 
form from the surface of a metal ion monolith when added to silicate solution 
[13]. Such systems remain of great interest to scientists since their conception 
in the early 17th century, having first been observed by German-Dutch 
alchemist Johann Glauber in 1646 [14]. Fascination stems from their likeness 
to aforementioned mineralised structures that originate from both biotic and 
abiotic systems. Many combinations of reactive species can be combined in 
these systems, including but not limited to metallic cations of calcium, 
strontium, copper, iron and cobalt with anionic species of silicate, carbonate, 
borate and phosphate [13-18]. Complex osmotic processes drive the 
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formation of these life-like tubular precipitates, as understood through 
research predominantly undertaken in the 19th and 20th centuries [14, 19]. 
Work by Kamiya et al., and more recently Steenbjerg Ibsen et al., 
disseminated important mechanistic understanding of tubular architectures 
grown from at a gel/solution interface, which form similarly to that of a 
chemical garden [20, 21]. Formation begins when a semi-permeable 
membrane is formed over the gel phase due to the initial reaction between 
cationic species in the gel and anions in the solution phase resulting in an 
insoluble reaction product. When osmotic forces allow, fluid rich in metal ions 
is liberated from the gel into the ionic solution phase, which self assembles 
into hollow tubes whereby the gel pores serve as an initial template [20, 22]. 
Continuous growth is confirmed to occur at the tips of already established 
tubes, maintained through repeating cyclic build-ups of osmotic pressure and 
release of cation rich solution through a point of rupture.  The necessary mass 
transport is facilitated by dis-equilibrium between species present on either 
side of the established semi-permeable membrane [18].  
Despite this understanding, quantitative analysis surrounding chemical 
gardens remains unfortunately sparse [23-25]. Factors that determine tube 
growth rate are poorly understood, but may be better explained through 
studying the rates of precipitation and advective transport, providing 
complementary data to previous work on how precipitates form at gel/solution 
interfaces [20, 21, 26]. The gel/solution set-up offers the opportunity for 
quantitative parameters to be measured that can be linked back to theoretical 
expectations of tube formation.  In this paper, the formation of tubules of 
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calcium phosphate (CaPO4) at the gel/solution interface was investigated. 
Solution movement in and out of a 1 M calcium (Ca2+) loaded agar gel was 
monitored in a phosphate (PO43-) rich environment, and the dependence of 
this exchange on tubule development by differing solute potential 
environments was investigated.  
Whilst osseous tissue scaffolds that are able to support the production 
of bone extra cellular matrix (ECM) have been developed, they suffer from 
poor vascularisation [27-29]. CaPO4 tubes however may possess high surface 
area, narrow pore distribution, and mass transport viability, offering enhanced 
cellular ingress and facilitation of directed angiogenesis and tubulogenesis for 
generation of bony tissue in comparison to the current cohort of scaffold and 
unstructured calcium based augmentation minerals [29-32]. Recent work 
regarding calcium silicate-phosphate tubes demonstrates the high potential of 
chemical garden structures to support the attachment and viability of 
mammalian cell cultures [33]. Microstructural and compositional 
characterisation of CaPO4 tubes was undertaken to assess their similarity to 
chemical garden structures, understand how they develop during formation 
and assess their potential suitability to be explored further as an osteogenic 
self-assembling biomaterial.  
 
3.2 EXPERIMENTAL METHODS 
3.2.1 Materials  
Calcium nitrate tetrahydrate (Ca(NO3)2.4H2O, 99 %, ACS reagent), 
agar ((C12H18O9)n, for microbiology), ammonium phosphate dibasic 
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((NH4)2HPO4, ≥98.0 %, reagent grade), and sodium chloride (NaCl, ≥99 
%, ReagentPlus®) were acquired from Sigma-Aldrich (UK). Distilled water was 
acquired from an Arium® advance EDI system.  
 
3.2.2 Preparation of CaPO4 tubes 
Ca(NO3)2.4H2O was dissolved in 0.1 L distilled water to the 
concentration of 1 M (or NaCl in the case of PO43- in gel measurements to the 
concentration of 2 M) and 5 g of agar added (with 250 µL of universal pH 
indicator (British Drug Houses Ltd, UK) for a selection of studies). The mixture 
was stirred at 250 rpm and heated to 80-90 oC on a MR Hei-Standard 
magnetic stirrer hotplate (Heidolph, Germany). After sufficient time to allow for 
the dissolution of the gel precursor, 2.5 mL of the gel mixture was syphoned 
into clear cylindrical tubes. The mixture was given 24 hours to complete 
gelation. (NH4)2HPO4 (or NaCl for Ca2+ elution measurements) solutions were 
prepared as required and 3 mL was layered over the set Ca2+ containing 
gel.  pH was monitored using a calibrated S220 Seven Compact™ pH/ion 
meter equipped with an InLab Expert Pro pH probe (Mettler Toledo, USA). 
 
3.2.3 Measuring the gel mass gain/loss 
Ca2+ gel mixture was syphoned into an in house mold to produce 6 mm 
x12 mm cylindrical specimens that were easy to handle (Figure S3.1a). 
Specimens were first individually weighed before submerging in 7.5 mL of 
either 0.5 M or 5 M NaCl solutions (Figure S3.1b). After desired times of 
submersion, specimens were dabbed dry and re-weighed.  
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3.2.4 Measuring elution of Ca2+ 
Ca2+ gels prepared as standard were layered with 20 mL NaCl 
solutions of 0.5 M, 1 M, 2 M, 3 M, 4 M and 5 M (n=3 per NaCl solution 
employed). In each system, the elution of Ca2+ into solution phase was 
tracked by collecting a 2 mL solution sample at a desired time point and 
directly measuring the Ca2+ concentration using a S220 Seven 
Compact™ pH/ion meter equipped with a perfectION™ comb Ca Combination 
Electrode (Mettler Toledo, USA). The electrode reference electrolyte (Ion 
Electrolyte A) was refreshed and a calibration curve for Ca2+ at 1000 mg/L, 
100 mg/L and 10 mg/L following the probe manufacturers guidelines was 
collected for conversion of mV reading to mg/L (Figure S3.2). Replenishment 
of the solution phase was undertaken appropriately after collection of each 
sample aliquot. This was considered a dilution factor and was accounted for in 
the final Ca2+ concentration calculation (Equation S3.1). Finally, concentration 
units were converted to mM. 
 
3.2.5 Measuring PO43- in gel phase 
NaCl 2 M gels of the standard system were investigated layered with 
20 mL PO43-solutions of 0 M, 0.25 M, 0.5 M, 1 M, 1.5 M, 2 M and 2.5 M (n=2 
per PO43- solution employed). After 15 minutes, the solution phase was tipped 
away and the gel surface rinsed briefly with distilled water. A corer (2 cm 
diameter) was used to retrieve a sample of gel that was cut to produce a 
cylindrical gel specimen of 65 mm length including gel surface. The gels were 
then submerged in 35 mL of distilled water, broken down and left overnight to 
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soak. It was assumed that any PO43- in the gel phase would leach out of the 
gel network and be diluted from the soaking solution. The dilution factor of the 
leaching volume of water was accounted for to give the measured PO43- in gel 
phase (Equation S3.2). A Phosphate assay (Sigma-Aldrich Phosphate 
Colourmetric kit, MAK030) was then used to find the concentration of PO43-. 
The calibration curve is provided (Figure S3.3), and was used to directly 
measure PO43- concentration.  
 
3.2.6 Scanning electron microscopy (SEM) 
SEM micrographs were collected for intact tube structures placed on 
double adhesive carbon tapes attached to aluminium stubs. All sample were 
gold sputter coated. Secondary electron images of the tubes were obtained 
using a Sigma SEM (Carl Zeiss AG, Germany) operating at 10 kV.   
 
3.2.7 X-ray diffraction (XRD)  
Powder XRD patterns were acquired using a Powder Diffractometer D8 
Autosampler (Bruker, USA) using the Cu Kα line. Pattern data was collected 
from between 2θ = 5 o to 60 o with a 0.02 o step-size and a step time of 0.5 
s/o. The background signal was removed and intensity normalised. Patterns 






3.2.8 Micro- X-ray fluorescence (µ-XRF) 
µ-XRF was performed using a M4 Tornado instrument (Bruker, USA) in 
mapping mode. The scan area measured 900 µm x 645 µm. The X-ray tube 
was operated at 50 kV voltage with anode current of 300 mA. The mapping 
scan was acquired over 20 frames with a time of 5 ms/pixel. The chamber 
was kept under a vacuum of 30 mbar. 
 
3.3 RESULTS AND DISCUSSION 
3.3.1 Initial observations and understanding CaPO4 chemical garden 
growth regimes  
Nodular and unstructured CaPO4 precipitate was observed at the 
gel/solution interface at PO43- solution concentrations between 0.25 and 0.5 M 
(Figure 3.1a,b). Generally, solutions between 0.5 and 1.5 M PO43- resulted in 
substantially faster rates of tube formation and in larger number (75-125 
tubules per 236 mm2) (Figure 3.1a). The macromorphology of these tubes is 
typically straight with kinks, suggesting a jetting and popping regime of 
growth. Different growth regimes occur as a consequence of variations in 
anionic solution density.  Low density Ca2+ solution entering the PO43- solution 
phase can either rise quickly producing a jet that catches to form a straight 
tube section or lead to oscillatory tube growth characterised by budding 
architectures and alterations in tube growth direction [15]. Tube length was 
observed to reach several centimeters within 15 minutes and within 2 hours it 
appeared some tubes had begun to agglomerate due to a lack of free growth 
space that resulted in wall bound features after several days (Figure 3.1c).  
117 
 
Figure 3.1 Influence of PO43- concentration on CaPO4 tube formation. 
Visualisation of tube growth after 15 minutes, and 1 hour in 0.25-2 M PO43- 
solutions (a), unstructured precipitate in 0.25 M PO43- solution after 4 days 
(b), tube agglomeration and wall bound growth in 1 M PO43- solution after 4 
days (c), thick budding tubes grown in 2 M PO43- solution after 4 days (d), 
sack-like morphologies grown in 2 M PO43- solution after 4 days (e).   
 
Initially, layering of 2 M PO43- solutions upon the gel phase produces 
no CaPO4 precipitate. On occasion, relatively thick tubes were observed in 2 
M PO43- solutions after a few days (Figure 3.1d). These tubes were evidently 
wider than those grown in 0.5-1.5 M PO43- solutions and synonymous with a 
budding regime of tube growth, forming from the release of less buoyant 
cationic solution providing a wider tube girth at the origin of growth [13-16]. 
Similarly thick tubes that formed in a chemical garden consisting of a calcium 
chloride (CaCl2) seed in 6 M silicate solution have been reported [15]. It is 
suggested that air bubbles developed in the concentrated (6 M) and viscous 
silicate solutions used, acting as templates for wide tubes at the origin of 
growth [15]. Although air bubbles were not observed to aid the formation of 
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CaPO4 structures, they provide an interesting means for controlling tube 
growth parameters that has been explored elsewhere [34, 35]. As well as 
thick tubes, CaPO4 sack-like morphologies arose in some 2 M PO43- solutions, 
which likely formed through inflation of the precipitate membrane with Ca2+ 
rich liquid without sufficient osmotic force to cause rupture (Figure 3.1e).  
The growth behaviour and resulting morphology of tubules between 
thin shoots of material, thicker tubules and inflated sacks is partially linked to 
the development of a semi-permeable precipitate membrane upon the 
gel/solution interface due to the reaction between metal ions and reactive 
anions in solution. For the analogous classical set-up, it is believed that 
concentrated anionic solutions produce a firmer colloidal membrane that is 
more difficult to rupture promoting membrane inflation, whilst relatively lower 
concentrations produce a comparably thinner membrane that can be more 
easily penetrated by metal-ion streams to go to form tubes [13-16]. 
Similar tube morphology and growth characteristics are observed for CaPO4 
tubes grown in low (0.25 M) and high (2 M) PO43- solution concentrations 
(Figure 3.1a).  The growth mechanism that results in CaPO4 morphologies is 
further discussed in this work alongside the fundamental experimental data.  
When PO43- solutions were layered upon the Ca2+ gel phase, a 
concentration dependent coverage of precipitation was observed. Between 
0.25 and 0.5 M PO43-, a membrane of precipitate formed that occupied 99.6 % 
and 63 % of the gel/solution interface respectively (Figure 3.2). At 0.25 M 
PO43-, membrane rupture results in jetting streams of CaPO4 material that fail 
to form tubes, consistent with the proposition of a weak rupture membrane 
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[13-16]. In relatively low concentrations of PO43- solutions (0.25-0.5 M), the 
CaPO4 membrane may take longer to form, as the initial precipitate 
membrane disappears within 2 hours and tubes are only visible after this time. 
For PO43- solutions in the concentration range between 0.75 and 1.25 M, 
localised spots of precipitate were visible upon the gel solution interface, 
which provided the origin of tubes that formed immediately. Despite the 
expectation of a precipitate membrane when solutions of 2 M PO43- were 
employed, no precipitate coverage was observed upon the gel/solution 
surface. It is possible that the required levels of Ca2+ and PO43- ions are 
insufficient to induce precipitation when 2 M PO43- is immediately layered 
upon gel. Alternatively, the ionic concentration of both species may well be 
sufficient for precipitation, however the increased concentration of non-
precipitate counter ions may decrease the effective concentration of Ca2+ and 
PO43- in solution through ionic shielding phenomena [36]. Ionic shielding 
involves counter ions surrounding reactant ions of opposite change in 
solution, preventing them from reacting even in concentrated solutions where 
products would be expected to form [36]. An extended induction time is 
evidently required for the precipitate reaction of Ca2+ and PO43- ions in these 
systems, eventually resulting in structures (Figure 3.1d,e). The inflated nature 
of constructs that are produced suggests that despite taking longer to 
develop, the resulting precipitate membrane can resist rupture to an extent 
beyond that formed in solutions >2 M. However, whilst optimum solution 
concentration ranges for inducing tubules have been explored in different 
chemical garden systems, the observation and quantification of a 
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concentration dependent precipitate coverage upon the cationic source, in this 
case the Ca2+ loaded gel, has not previously been reported for chemical 
garden systems. The colour similarity between the newly forming precipitate 
and that of the crystal seed make this differentiation difficult in the classical 
set-up. Hence the use of a gel/solution system may enable us to gather 
further mechanistic insights into spontaneous tube formation gardens.   
 
Figure 3.2 Top down view binary image of the typical CaPO4 precipitation 
coverage formed upon the gel/solution interface for PO43- solutions of 0.25 
and 0.5 M 1 minute after layering upon the gel surface.  
 
 
3.3.2 Response of the gel phase to varying solute potential  
Gel mass change experiments were conducted in solutions of 1 and 5 
M NaCl as opposed to PO43- in order to avoid initiating precipitation; selected 
solutions exhibit an equivalent solute potential to PO43- solutions of 0.5 and 
2.5 M respectively, calculated using the van’t Hoff equation (Equation S3.3 
and Table S3.1). Gel mass gain/loss profiles were dynamic in both 1 and 5 M 
NaCl solutions (Figure 3.3). As expected, a 1 M NaCl solution brought about 
an initial gradual gel mass increase in the first 3 minutes (+2.7±0.2 %), 
measured at its most substantial after 10 minutes (+3.2±1.6 %), due to the 
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potential gradient favouring the net movement of solution into the gel from 
solution phase. Gels in 5 M NaCl solutions decreased in mass by 0.7±0.3 % 
after 10 minutes due to the potential gradient favouring the net movement of 
Ca2+ rich solution out of the gel into the solution phase (Figure 3.3). At 30 
minutes, despite gaining some mass, the gels in 5 M PO43- solution remained 
in a net mass loss regime (-0.1±0.5 %) before further mass decrease at 2 
hours (-1.4±1.7 %). Statistical analysis performed using a two-way ANOVA 
revealed a significant difference in the gel mass gain/loss response from 
employment of low concentration (1 M NaCl) and high concentration (5 M 
NaCl) solution environments (F (1, 4) = 26.57, p = 0.0067) within the first 30 
minutes of gel exposure to solution. Post hoc t-tests revealed significance 
between the mass gain/loss gel response at 1 minute (p = 0.0067), 3 minutes 




Figure 3.3 Mass gain/loss profile of gels exposed to 1 and 5 M NaCl solutions 
between 0-120 minutes (error bars represent standard deviation for n = 3 
measurements of individual samples, * = significance as determined by post 
hoc t-test analysis, where p = < 0.05). 
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These results go some way to understanding the preferential formation 
of CaPO4 tubes in PO43- solutions between 0.5-2.5 M. Between these 
concentrations, osmotic driving forces appear to drive movement of solution 
across the semi-permeable precipitate barrier, the coverage taking the form of 
a sheet or localised spots upon the gel/solution interface, towards the gel. 
Consequently, the gel mass increase leads to a build-up in osmotic pressure. 
In order to counteract this, the pressure is relieved through rupturing the 
precipitate membrane, which releases streams of Ca2+ rich solution into the 
corresponding solution of PO43-. The jetting and occasional oscillatory nature 
of these Ca2+ streams provides a template for the growth of tubular constructs 
with straight and kinked macromorphology (Figure 3.1a). Solutions of PO43- 
either side of the 0.5-1.5 M concentration range as investigated through NaCl 
solutions with matching solute potentials, appear not to elicit a gel mass 
increase, but rather a decrease, indicating that solution is expelled. As such, 
the build up of osmotic pressure within the gel does not take place and tubes 
are not immediately formed from the employment of 0.25 and 2 M PO43- 
solutions.     
 
3.3.3 Ca2+ and PO43- ion transport  
Release of Ca2+ ions occurred in all NaCl solutions in the range 0.5-5 
M and progressed steadily with time (Figure 3.4a). Expectedly, elution rate 
increased gradually with increasing NaCl solution concentration as the 
potential for ionic Ca2+ movement from gel into solution phase proportionally 
intensifies in more concentrated solution environments.  
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Before layering with PO43-solutions, the PO43- concentration found in 
the gel existed at a comparatively low concentration of 0.11±0.00 mM (Figure 
3.4b). After 30 minutes, concentration of PO43- in the gel peaked at 
34.30±5.87 mM when PO43- concentration of the solution was 1 M, and 
decreased at higher PO43- concentrations of solution phase; ingression of 
PO43- into the gel as a function of initial PO43-concentration in solution was 
therefore not monotonic and did not follow the same trend as Ca2+ release 
into the anionic solution phase (Figure 3.4b). 
 
 
Figure 3.4 Ca2+ release into bulk solution dependent on NaCl solution 
concentration (error bars represent standard deviation for n = 3 
measurements of individual samples) (a) and PO43- ingress into the gel 
dependent on PO43- solution concentration (error bars represent standard 
deviation for n = 2 measurements of individual samples) (b). 
 
3.3.4 Observing pH change as an indicator of ionic movement  
A capillary tube was inserted just below the gel/solution interface 
allowing the collection of ejected calcium rich solution from the gel (Figure 
3.5a). Universal pH indicator revealed the acidic nature of the Ca2+ rich fluid in 
124 
contrast to the neutral-alkali nature of the PO43- solution that had also been 
collected on pull out (Figure 3.5b). The pH of the gel mixture before heating 
and setting was determined to be 4.5-5.5 and gels stained with universal pH 
indicator became orange due to the acidic cationic environment. PO43- 
solution pH was between 8 and 9.  
 
 
Figure 3.5 Ca2+ rich solution as collected in a capillary tube placed at the 
gel/solution interface (a), followed by removal of the capillary tube and 
staining of the collected contents with universal pH indicator (b) (PO43- 
solution was drawn up the capillary tube on pull out). 
 
CaPO4 tubes form preferentially in regions where the pH at the 
gel/solution interface experiences a substantial shift to alkalinity by turning 
blue or purple in the gel phase, suggestive of an environment at pH 8 to 10 
(Figure 3.6a and S3.4)(Movie S3.1). Regions that did not experience this shift 
resulted in little or poor CaPO4 tubular growth, but sometimes developed a 
red colouration band at the gel/solution interface (Figure 3.6a)(Movie S3.1). 
Similar experiments have shown that although shifts in pH are not a trigger for 
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tubule formation, but rather a by-product of precipitate development, 
measurements of pH can be utilised as an indicator of solution exchange and 
tubule formation [21]. 
Layering of 0.25 and 0.5 M PO43- solutions facilitated a red (acidic) 
band at the gel/solution interface (Figure 3.6b) that was more prominent in 
gels layered with 0.25 M solutions (Figure 3.6c). From Ca2+ release 
measurements (Figure 3.3a), release of Ca2+ ions was less extensive in 
equivalent 0.25 M PO43- solutions compared to 0.5 M PO43- solutions. 
Therefore, red colouration represents a build-up of unreleased acidic Ca2+ 
ions just below the gel/solution interface, which ultimately delays the onset of 
tubules (Figure 3.1a). Red (acidic) banding eventually turned blue in colour 
(increasingly alkaline) when both 0.25 and 0.5 M PO43- solutions were used, 
and coincided with the onset of CaPO4 nodular precipitate and tubular 
structure formation, respectively (Figure 3.1a and 3.6a). Colouration at the 
gel/solution interface for gels layered with 0.75 and 1 M PO43- solutions was 
blue (alkali) initially before appearing purple (stronger alkali). Gels layered 
with solutions between 1.25 and 2.5 M PO43- developed a purple band 
immediately.  
Depth of the alkaline colouration bands increased with increasing PO43- 
solution concentration in the range 0.75-2 M (Figure 3.6b,c), which correlates 
to the exodus of Ca2+ ions and ingress of PO43- anions into the gel by solution 
movement (Figure 3.3 and 3.4a,b). The resulting exchange of ions promotes 
the induction of tubule formation above the gel/solution interface in 0.75-1.5 M 
PO43- solutions (Figure 3.1a). This doesn’t necessarily correlate with the 
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formation of precipitate in 2 M PO43- solutions. Although a relatively high 
concentration of Ca2+ ions are released into a 4 M NaCl solution with a 
comparable osmotic potential to 2 M PO43- solution suggests that super 
saturation criteria for CaPO4 precipitation are met (Figure 3.4a), previously 
alluded to ionic shielding effects ultimately diminish the effective concentration 
of ions available to react [36].   
 
Figure 3.6 Universal pH indicator stained gel layered with 0.5 M PO43- 
solution changing colouration in response to CaPO4 tubular formation (a). 
Gels stained with universal pH indicator and layered with 0.25-5 M PO43- 
solutions at 30 mins (Field of view ~30 mm) (b) and quantification of the 
colouration band depth (error bars represent standard deviation for n = 3 
measurements of individual samples) (c).   
 
 
3.3.5 Microstructural and compositional evolution of CaPO4 tubes 
A tube widening phenomena was observed from micrographs of 
CaPO4 tubes grown in 0.5 M PO43- solutions over 24 hours. Tubes typically 
matured to a final diameter of 100-150 µm, and possessed a bilayer wall 
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consisting of a porous outer layer (~10 µm) and continuous inner layer (~10 
µm) that is consistent with the microstructure of chemical gardens [18] (Figure 
3.7a). This arrangement is comparable to the structuring of micron width 
dentinal tubules, although existing at length scales typical of Haversian canals 
which at maturity exhibit an average diameter between 50 and 200 µm in 
human bone [1, 4, 9, 37, 38].  
 
 
Figure 3.7 Micrographs of CaPO4 tubes grown in 0.5 M PO43- solutions 
extracted at 5 hours (a) and 24 hours (b), CaPO4 tubes grown in 1.25 M PO43- 
solutions (c), and CaPO4 tubes grown in 2 M PO43- solutions (d) extracted at 
10 days.  
 
At 24 hours, widened tubes possessed a diameter >300 µm and a gap 
space developed between the outer and inner tube layers suggesting 
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immiscible material phase separation (Figure 3.7b). Close inspection of the 
walls of typical and widened tubes revealed that both the inner and outer 
thickness remained ~10 µm per layer. Wall thickness may be maintained 
through a spontaneous self-healing mechanism that allows for total tube 
widening whilst maintaining the thickness of the tube walls in order to support 
structural integrity and microstructural evolution [14]. In response to increased 
periods of cationic fluid flow, that are dependent on solution potential 
differences between cationic and anionic phases, tubes may expand.   
The diameter of CaPO4 tubes from PO43- solutions between 0.75 - 1.5 
M ranged from 100 - 150 µm (Figure 3.7c). Tubes grown in 0.75 and 1 M 
PO43- solutions shared similar microstructure to those grown in 0.5 M PO43-, 
possessing a porous outer layer and continuous inner layer. In contrast, tubes 
grown in 1.25 and 1.5 M PO43- solutions possessed a single porous wall that 
was microstructurally similar to the outer wall of tubes that exhibited a bilayer 
structure (Figure 3.7c). Tubes grown in 2 M PO43- had a strikingly different 
microstructure that consisted of organized flowering flake clusters (Figure 
3.7d). The diameter of these tubes was also considerably wider (500-600 
µm).   
It is evident that the scale and microstructure of these tubes mimics 
intrinsic features of natural bone tissue at the length scale of Haversian canals 
that house vascular networks. As such, the fabrication of CaPO4 tubules may 
be of interest for replicating these structures through physical phenomena at 
gel/solution interfaces.  
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X-ray diffraction patterns were collected to study the evolution of 
crystallinity and crystalline phase during initial precipitate formation in 0.5 M 
PO43- solutions (Figure 3.8a). After 3 and 5 hours, the precipitate consisted of 
poorly crystalline apatite, as suggested by the broad peaks, which correlate 
well with the diffraction pattern of hydroxyapatite (HA - Ca10(PO4)6(OH)2 - 
ICDD – 01-074-9761). After 24 hours, peaks matching dicalcium phosphate 
dihydrate (DCPD - CaHPO4.2H2O - ICDD - 04-013-3344) were detected, 
which became noticeably more pronounced and sharper with increasing time.  
Crystalline composition of tubes grown in PO43- solutions of 0.25-1.5 M 
was also assessed after 30 days of ageing (Figure 3.8b). Peaks 
corresponding to both HA and DCPD were still present in the diffraction 
pattern of 0.5 M PO43- precipitate (Figure 3.8b). Patterns collected for all other 
solution concentrations also matched to HA and DCPD references (Figure 
3.8c). The phase composition of similarly prepared CaPO4 tubes was 
previously determined to consist of a mixture of HA and DCPD phases [20, 
22]. The resulting CaPO4 phase is highly dependent on solution environment, 
with prominent factors, including pH and solubility, influencing the formation of 
minerals. Both of these phases are of biological importance within mammalian 
systems. For instance, HA is the primary mineral component of hard tissue 
and provides a physiological stable phase that can support the growth and 






Figure 3.8 XRD diffraction patterns of the development of CaPO4 precipitate 
grown for up to 48 hours in PO43- 0.5 M solutions (a), and after 30 days for 
CaPO4 precipitates grown in 0.25-1.5 M PO43- solutions (b). ICDD reference 
patterns for CaHPO4.2H2O, Ca10(PO4)6(OH)2, NH4H2PO4 and NH4NO3 
matched to collected patterns (c).  
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The presence of highly soluble phases was also detected; 
biphosphammite (NH4H2PO4 - ICDD – 01-072-4581) in precipitates grown in 
0.75 and 1.5 M PO43- solutions, and nitrammite (NH4NO3 - ICDD – 00-047-
0867) found in precipitates grown in 1.5 M PO43- solutions (Figure 3.8b,c). 
The reagent salts employed in tube formation experiments provide ions 
required to produce such phases, which have not been fully washed away 
after precipitate extraction.   
CaPO4 tube structures are compositionally heterogeneous in nature 
during growth: a growing acidic Ca2+ rich core that evolves through an alkali 
PO43- solution phase. Bilayer tube wall formation, best observed in 
micrographs of CaPO4 tubes grown in 0.5 M PO43- solution after 5 hours and 
24 hours (Figure 3.7a,b), can therefore be explained. An amorphous outer 
wall of the CaPO4 tubes is likely to comprise of low crystallinity HA precipitate 
which is the first to develop, before formation of an inner wall composed of 
DCPD since XRD patterns show that amorphous HA phase development 
precedes that of DCPD whilst also being consistent with the fact that chemical 
garden tube wall thickness develops inwards via propagating reaction-
diffusion front and pH profile [18].  
Similar to synthesis of mineral phases in many organisms, self-
assembling CaPO4 tubes evidently exhibit exceptional thermodynamic and 
kinetic control of precipitating amorphous and crystalline mineral phases [39]. 
As such, employment of a gel/solution model for creating structured mineral 
far surpasses many synthetic mineral synthesis pathways associated with 
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combining ionic solutions that result in the precipitation of mineral crystals, 
being as the precipitate does not possess regulated macroscopic structuring.   
 Elemental analysis was undertaken on tubes grown in 0.5 M PO43- 
solutions to further understand tube wall composition using a µ-XRF mapping 
instrument. The scan area was selected in order to reveal the chemical 
composition along the tube length. The major elemental components of the 
tubes were calcium and phosphorus distinguished by Kα lines appearing in 
the expected vicinity of 3.69 keV and 2.01 keV, respectively and an additional 
line for Ca (Kβ at 4.01keV) was also observed (Figure S3.5). Mapping of the 
additional elements detected, namely Aluminum (Al), Silicon (Si), Sulphur (S), 
Chlorine (Cl), Potassium (K), Iron (Fe) and Copper (Cu) showed these 
elements to reside outside of the tube structure, originating from the 
background material upon which the tubule sample is supported. 
Elemental maps of calcium (Figure 3.9a) and phosphorus (Figure 3.9b) 
were combined and a line scan collected across the diameter of the tube 
(Figure 3.9c). This allowed the Ca and P signal intensity to be plotted along 
the selected line scan. The outer tube wall was found to be relatively P rich 
(Figure 3.9c), which supports the proposed compositional hierarchy of a HA 
outer layer that develops into a DCPD inner layer. This biphasic ordering of 
compositional phases is obtained through exposure of developing precipitate 
to an acidic Ca2+ rich core and an alkaline PO43- exterior, shedding light on 
how the creation of similar structures may be obtained from physical driving 
forces that are currently only possible in biological systems.  
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Figure 3.9 µ-XRF maps of a CaPO4 tube structure grown in 0.5 M PO43- 
solution. Elemental mapping of calcium (a) and phosphorous (b). Elemental 
maps of calcium and phosphorus were combined; calcium and phosphorus 
Kα signal intensity of both elements was plotted from a line scan (blue) taken 
along the tube circumference (c). 
 
Acquiring control of these structuring processes may allow for designer 
CaPO4 regenerative biomaterials. Desirable features include similar 
composition and architecture to naturally occurring dentinal tubules and 
Haversian canals capable of directing angiogenesis and tubulogenisis 
processes beyond synthetic systems through provision of high surface area, 
porosity and mass transport facilitation [28-32]. Promisingly, mineral tubular 
constructs can support the viability of cell cultures and further ways in which 
to incorporate biological cells during tube fabrication are active areas of 
research, bridging the gap between chemical gardens and tissue engineering 
applications [33, 40].   
 
3.4 CONCLUSIONS 
Long standing interest in chemical garden structures goes back as far 
as the 17th century, and stems from their resemblance to a number of 
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naturally occurring formations, such as hydrothermal vents upon the sea floor, 
and mineralised biological structures such as corals, shells and mammalian 
bone. Here we generate CaPO4 tubules that resemble dentinal tubules and 
Haversian canals found in human hard tissues. This supports the notion that 
not only biological processes, but also physical driving forces play a 
fundamental role in biotic structuring.  
Compiling results associated with the mechanism of CaPO4 
precipitation and tubular formation in a gel/solution set-up, it is evident there is 
a complex relationship between Ca2+ gel and PO43- solution phases that 
allows for the formation of chemical garden structures. CaPO4 tube 
morphology was only initiated by specific PO43- solutions in a range of 0.5-1.5 
M. A significant difference was found in gel response to either high or low 
solute environments of 1 and 5 M NaCl solutions, respectively within 30 
minutes. Conditions that facilitate self-assembly of CaPO4 tubular structures 
are an increase in gel mass followed by decrease, representative of an influx 
of solution into the gel driven by osmotic forces and subsequent release of 
Ca2+ rich fluid to relieve osmotic pressure, as supported by gel Ca2+ release 
and PO43- ingress measurements. Although gels layered with 2 M experience 
substantial exodus of Ca2+ as determined by direct measurement and 
observation of gel pH change, CaPO4 precipitate and tube formation are likely 
initially inhibited by ionic shielding.  
Presence of contrasting pH environments, namely acidic Ca2+ rich fluid 
travelling through CaPO4 tube structures and alkali PO43- ion solution external 
to CaPO4 tubes, drives the development of differing crystalline phases that 
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constitutes the observed hierarchical tube microstructure. Typical CaPO4 
tubes possessed a bilayer structure composed of outer layer of HA and an 
inner layer of DCPD. Mastering control over the generation of these structures 
may allow creation of regenerative biomaterials that are comparable to human 
tissue architecture and composition. 
 
3.5 ASSOCIATED CONTENT 
Supporting figures and equations are included in Appendix Part 2. Supporting 
movies are provided in Electronic Appendix Part 1.  
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A new bone augmenting material is reported which is formed from 
calcium-loaded hydrogel-based spheres. On immersion of these spheres in a 
physiological medium, they become surrounded with a sheath of precipitate, 
which ruptures due to a build-up in osmotic pressure, resulting in the 
formation of mineral tubes that protrude from the sphere surface. When 
brought into close contact with one another, these spheres become fused 
through the entanglement and subsequent interstitial mineralisation of the 
mineral tubules.  This is the first report of a bioceramic material that is formed 
in its entirety in situ and is therefore likely to provide a better proxy for 
biological mineral than other existing synthethic alternatives to bone grafts. 
 
4.1 INTRODUCTION 
A range of synthetic materials have been developed that are capable of 
filling hard tissue defects to overcome the issues that are often associated 
with autologous tissue harvesting, such as local tissue morbidity and lack of 
availability [1, 2]. In particular, there have been many ceramic-based materials 
used for hard tissue augmentation. Calcium phosphate and sulphate-based 
products are available commercially, but are yet to replace autograft as the 
so-called “gold-standard” [3, 4]. The ceramic materials used for the 
augmentation of hard tissues are often produced using high-temperature 
treatment processes, meaning that they are of high-crystallinity and relatively 
low specific surface area [5-7]. Consequently, synthetic ceramic bone 
replacements often bare little resemblance to native bone mineral, which is 
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predominantly nano-crystalline structured hydroxyapatite (HA, Ca5(PO4)3OH) 
that is compositionally poorly crystalline overall [8]. Even in the case of 
cements, which harden through reprecipitation in the body, much of the 
hardened structure is formed in the presence of excess micro crystalline 
reactant [9, 10]. Moreover, conventional regenerative materials do not feature 
channels to support the penetration of surrounding vascular and nervous 
networks [11, 12]. The level of structuring that is possible with synthetic 
alternatives to bone graft is limited to the production of biomimetic corals and 
sponge-like structures that provide an interporous network for bone 
regeneration, but replicate none of the microstructural organisation of hard 
tissue at the osteonal level [13-15]. Hard tissues exhibit precisely defined 
hierarchical architectures, with organisation from the molecular level through 
to the macroscale. It is this well preserved architecture that is critical to the 
extraordinary mechanical performance of bone – which is stronger and 
tougher per unit weight than steel [13]. One preserved feature of hard tissue is 
the presence of intricate tubular networks, such as canaliculi, Haversian and 
Volkman’s canals found in mature bone, as well as dentinal tubules within 
teeth, that are critical to the function of such tissues [16-18]. Tubular channels 
like these are essential for transporting chemicals, gases and nutrients in 
order to maintain the viability of cells cocooned within typically dense 
mineralised tissue. Mimicking the natural structural features of bone is a major 
challenge but one that is subject to substantial research effort. A prerequisite 
to facilitating the development of vascular networks throughout hard tissue 
scaffolds may be the provision of tubular structures similar in nature to those 
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found in mineralised tissues. It has been shown that mineralised tubular 
frameworks provide an ideal framework to mediate revascularisation of bone 
in vivo [19].  
Mineral tubes similar to those found in bone and teeth may be formed 
using a system that is analogous to a chemical garden, where hollow tubular 
precipitates form at the interface between a cationic seed crystal and an 
anionic solution [20, 21]. These structures have been likened to a range of 
tubular minerals found throughout nature [22, 23]. Surprisingly, there is 
relatively little work that examines the use of such systems for biotechnology 
applications despite the fact that they have been shown to support the 
entrapment and growth of cells  [24, 25]. With the exception of calcium 
silicates, phosphates and carbonates, the majority of salts traditionally 
generated in chemical gardens would not be compatible with implantation into 
the body, including but not limited to cobalt, copper, iron, manganese and 
nickel compounds [20-22, 24, 26]. There has recently been work that has 
shown it is possible to produce biologically relevant calcium phosphate 
structures at the interface between a cation loaded hydrogel and anionic 
solution [27-30]. Indeed, we recently reported on the formation of tubular 
calcium phosphate that resembles tubular architectures found in bone both 
structurally and compositionally [30]. 
This paper describes the production of a hardening material formed 
from hydrogel-based spheres that can be packed into defects similar to those 
encountered in vivo. On immersion in phosphate rich physiological media, a 
sheath of precipitate forms around the spheres, which ruptures due to an 
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increase in osmotic pressure. This release of pressure drives the formation of 
tubular mineral from the gel surface. The mineral tubules become 
intermeshed, which ultimately causes the spheres to fuse. Formation of the 
calcium loaded spheres and their capacity to fill an ex-vivo defect in retrieved 
human bone, in addition to the morphology, structure and composition of the 
precipitated mineral phase, are investigated. 
 
4.2 EXPERIMENTAL METHODS 
4.2.1 Calcium loaded hydrogel fabrication and mineral initiation  
Calcium loaded gels were made by adding 5 wt% agar powder (for 
microbiology, Sigma-Aldrich, UK) to 1 M calcium solutions prepared from 
calcium nitrate tetrahydrate crystals (99 %, ACS reagent, Sigma-Aldrich, UK) 
and distilled water before heating the mixture to 80-90 oC. For conventional 
set-up, a layer of gel was set in clear cylindrical containers and allowed to 
cool to room temperature. For calcium loaded spheres, warm gel was added 
drop-wise to an insulated chamber of liquid nitrogen. Spheres were collected 
after dissipation of the nitrogen. Self-mineralisation was initiated upon gel 
surfaces, calcium loaded sphere constructs, and within an ex vivo bone defect 
using phosphate solutions prepared by dissolving crystals of dibasic 
ammonium phosphate (≥ 98.0 %, reagent grade, Sigma-Aldrich, UK) at 





4.2.2 Human tissue model 
Bone tissue was collected from patients undergoing elective knee 
replacement surgery. The United Kingdom National Research Ethics Service 
(East of Scotland Research Ethics Service) provided ethical approval 
(11/ES/1044). Tissues were washed using phosphate buffered saline (PBS) 
(calcium and magnesium free, Sigma-Aldrich, UK) before defects 10 mm wide 
and a minimum of 10 mm deep were introduced using a surgical drill. Calcium 
loaded spheres were gently packed into defect spaces and self-mineralisation 
initiated as detailed above.      
 
4.2.3 Scanning electron microscopy (SEM)  
Samples were placed on an aluminum stub using double-sided sticky 
carbon discs. Gold sputter coating was performed prior to imaging using a 
K550X sputter coater (Quorum Technologies, U.K.). SEM images were then 
acquired using an EVO MA 10 scanning electron microscope operating at 10 
kV (Carl Zeiss AG, Germany).   
 
4.2.4 Micro- X-Ray Fluorescence (µ-XRF) 
Specimens were elementally mapped using an M4 Tornado instrument 
(Bruker, U.S.A.). Measurement settings of 20 ms/pixel over 25 frames in the 
case of Figure 1f, and 2 frames in the case of Figure 2b and 3c, were 
employed with the instrument operating at 50 kV with anode current of 300 
mA. During measurements, the chamber was maintained at 500 mbar in the 
case of Figure 1e.  
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4.2.5 Micro- computed tomography (µ-CT) scanning 
Samples were transferred to a sealed low X-ray attenuation tube. 
Structures were scanned using a Skyscan1172 microcomputed tomography 
(µ-CT) instrument (Bruker, U.S.A) with 60 kV maximum X-ray energy, 6 W 
beam power, 2000 ms exposure per projection, and 12.44 µm pixel size. Slice 
data was reconstructed using NRecon (Version 1.6.10, Bruker) and visualised 
using CTVox (Version 3.0, Bruker). For self-mineralising sphere pyramid 
constructs, greyscale images were artificially coloured by assigning blue, 
green, and red transfer functions to grey scale ranges matching the calcium 
loaded spheres (blue) and mineralised regions (green and red). For the 
mineralised human defect model, an opacity transfer function was applied to 
best segment the greyscale range corresponding to the tubules from the rest 
of the structure to render 3D images of deposited mineral within the defect.  
 
4.3 RESULTS AND DISCUSSION 
The generation of tubule structures results from the exposure of 
calcium loaded agarose layered with a phosphate rich solution, which 
ultimately produces a forest of hollow white precipitate tubes (Figure 4.1a). 
Initially, a precipitate is formed at the gel-liquid interface, which impedes 
dissolution and creates an osmotic pressure. When the osmotic pressure 
causes localised rupture of the precipitate layer, calcium ions are able to 
diffuse into the liquid phases where a tubular calcium phosphate based 
precipitate forms [30, 31]. Growth of these tubes is maintained through cyclic 
build-ups in osmotic pressure and release, which drives calcium ions through 
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the established tubule to the tip where it ruptures and a new section of tubule 
is formed [30, 31]. The mineral from which these tubules are formed is a 
poorly crystalline calcium phosphate, similar to that found in the body.  
The tubular precipitate did not only form on planar surfaces, but also 
formed when spheres of hydrogel loaded with a 1M calcium nitrate solution 
were placed into a 0.5 M phosphate solution. The spheres were produced 
through the drop-wise addition of hot (80 - 90oC) calcium-loaded agarose gel 
mixture through a 2 mm wide pipette aperture into a reservoir of liquid 
nitrogen (Figure 4.1b). Upon contact with the liquid nitrogen, the gel droplets 
quickly solidified through the inverse Leidenfrost effect [32]. The resulting 
spheres had an average diameter of 3.7 ± 0.4 mm (n = 10). The use of this 
method of manufacture meant that spherical agarose particles could be 
produced loaded with relatively high concentrations of calcium ions (>1 M), 
which would be very difficult to achieve using standard processing methods or 
soaking pre-formed spheres in a cation containing solutions [33]. Agarose 
was selected as the soft material of choice as a consequence of its neutral 
charge, meaning that it does not impeded diffusion of the calcium ions. 
Furthermore, others have reported the use of mineralised agarose for bone 
augmentation [34, 35]. 
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Figure 4.1 (a) Conventional experimental set-up (Reported in reference 30), 
which produces calcium phosphate tubules that are structurally and 
compositionally similar to bone, providing the starting point for the work 
reported herein. (b) Schematic of fabrication method of calcium-loaded 
spheres, involving drop-wise addition of calcium loaded agarose hydrogel into 
a reservoir of liquid nitrogen. (c) Calcium loaded spheres before and after 
mineralisation, showing the ejection of tubular calcium phosphate mineral. (d) 
SEM micrograph showing the tubule microstructure, consisting of a bilayer 
tubule wall surrounding a hollow core. (e) SEM micrograph of tube wall bilayer 
structuring. (f) µ-XRF elemental mapping of a calcium phosphate tubule 
150 
cross-section (Kα channels for calcium (red) and phosphorous (green) 
shown). 
 
When the calcium loaded spheres were immersed in phosphate 
solutions, tubules precipitated around the periphery of the particles but grow 
preferentially upward due to buoyancy effects (Figure 4.1c) [21]. Altering the 
concentration of the metal and reactive counter ions directly influences the 
kinetic driving forces of self-assembly of the tube like structures by changing 
osmotic, diffusion and pH gradients within the material. This influences the 
gross morphology of the tubes and can also be used to tailor the rate of 
formation. Increasing phosphate solution concentration from 500 mM to 1 M 
allows control over mineral tubular growth rate between 0.3 mm/min (18 
mm/h) to 0.5 mm/min (30 mm/h) (Figure S4.1).  
The tubules typically exhibit diameters between 100 and 150 µm, 
which is ideal for ingress of osteogenic cells (Figure 4.1d) [36]. They also 
exhibit a hierarchical bilayer wall structure comprised of low crystallinity HA 
(Ca5(PO4)3OH) and dicalcium phosphate dihydrate (DCPD, CaHPO4.2H2O) 
(Figures 4.1e and S4.2). This structure develops inwards as a consequence 
of the contrasting environments inside and outside of the tube resulting in a 
steep concentration gradient of reactive species across the tube wall. This 
ultimately results in a calcium rich inner wall, and phosphate rich outer wall 
(Figure 4.1f) [37]. 
In the presence of phosphate, calcium loaded spheres placed in close 
contact with one another fuse through the formation of mineral and the 
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development of interweaving tubes at their periphery (Figure 4.2a). The 
interactions formed between the spheres were of sufficient strength to allow 
for the fusion of multiple spheres to form a larger structure (Movie S4.1). 
	
Figure 4.2 (a) Fusion of two calcium loaded spheres in close proximity to one 
another during self-mineralisation. (b) µ-XRF elemental mapping of a calcium 
loaded sphere cross-section before and after inducing self-mineralisation (Kα 
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channels for calcium (red) and phosphorous (green) shown) (c) Calcium 
loaded sphere pyramid construct before and after triggering self-
mineralisation, leading to complete unification. (d) µ-CT of calcium loaded 
sphere pyramid after submersion in phosphate solution. Colour scales in-set 
represent an increase in relative density of material from blue (calcium loaded 
sphere) to green and red (mineral).  
 
Elemental mapping using micro X-ray fluorescence (µ-XRF) confirmed 
that the particles were united by a calcium phosphate phase (Figure 4.2b). It 
was possible to assemble the gel spheres into relatively complex geometries, 
such as the pyramid shown in Figure 4.2c. 3D micro-computed tomography 
(µ-CT) reconstructions of this structure show that mineral coverage (red and 
green) occurs extensively across the surfaces of hydrogel spheres (blue), and 
even in the centre of the structure (Figure 4.2d). 
To demonstrate that this approach could be used for the augmentation 
of a hard tissue defect, a cylindrical defect approximately 10 mm wide and 15 
mm deep was introduced into an ex vivo human tissue model which was 
packed with calcium loaded spheres (Figure 4.3a). The filled defect was then 
placed into a phosphate rich medium (1 M phosphate solution) and mineral 
was observed to form rapidly across the surface with the formation of tubes 
becoming apparent soon thereafter. 
After 24h this structure could be inverted and irrigated with water 
without a loss of mechanical integrity (Movie S4.2). µ-CT revealed the extent 
of mineral deposition within the defect (Figure 4.3b). Cross-sectional images 
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show mineral around the surface of spheres and tubular structures within the 
defect, filling the inter particulate spaces with a mineral phase. 
	
Figure 4.3 (a) Schematic of calcium loaded spheres augmenting an ex vivo 
human bone defect, showing an empty bone defect, the packing of spheres to 
augment the defect, and triggering of self-mineralisation with 1 M phosphate 
solution. (b) µ-CT of human hard tissue model containing mineralised calcium 
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loaded spheres that have deposited mineral and tubular structures within the 
defect. (c) µ-XRF elemental mapping of a cross-section of the human hard 
tissue defect (Kα channels for calcium (red) and phosphate (green) shown).   
 
From µ-CT examination, the interfaces between the spheres and the 
mineral deposited are extremely difficult to differentiate from the apposing 
bone. µ-XRF analysis demonstrates that the elemental composition of 
precipitated calcium phosphate mineral is similar to the surrounding tissue, 
also making it difficult to distinguish a clear interface between bone and the 
spheres (Figures 4.3c and S4.3). 
 
4.4 CONCLUSIONS 
Inspired by processes that are able to mimic natural tubular mineral 
structures, we have developed a device capable of augmenting a hard tissue 
defect through the production of tubular mineral. The material consists of 
calcium loaded spheres manufactured using a process that allows for the 
incorporation of high concentrations of calcium. Immersion of these spheres in 
physiologically relevant solutions rich in phosphate stimulates tube formation, 
which means that they could be ideal for use in biological environments. 
Compared with the majority of synthetic bone substitutes that are typically 
dense and highly crystalline, this system enables: (1) the formation of tubular 
calcium phosphate mineral that is structurally and compositionally akin to the 
tubular features found in bone and tooth, providing a structured osteogenic 
scaffold, (2) mineral formation occurs in situ in the absence of microcrystalline 
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reactant, facilitating a low-crystallinity product comparable to the surrounding 
hard tissue, and (3) mineral synthesis can be tuned by the adjustment of 
precipitation parameters, enabling physical properties such as fusion time of 
spheres to one another and to bone to be modified. The microscale structural 
features of the mineral phase may also enable better vascularisation of the 
implant [19].  
In summary, we present a strategy for directly delivering hierarchical 
tubular mineral into hard tissue defects using spheres of agarose hydrogel 
loaded with calcium. In phosphate solutions, these spherical structures fuse, 
forming a solid through the intermeshing of mineral tubules that are expelled 
from the surface of the soft material.  
 
4.5 ASSOCIATED CONTENT 
Supporting figures are included in Appendix Part 3. Supporting movies are 
provided in Electronic Appendix Part 2. 
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Novel hydroxyapatite (HA) loaded poly(ether ether ketone) (PEEK) 
composites are now used to manufacture commercially available spinal fusion 
devices. In this work, the interfacial interactions between HA and PEEK are 
improved beyond mechanical and physiochemical interlocking by creating 
covalent bonds between dissimilar phases. HA particulates were coated with 
(3-Mercaptopropyl) triethoxysilane (MPTES) introducing thiol moiety (-SH). 
PEEK ketone groups (C=O) were reduced to hydroxyl groups (-OH). HA-SH 
and PEEK-OH derivatives respectively were then coupled using a 
heterobifunctional linker. Compared to non-linked materials (HA_PEEK), 
covalently linked composites (HA_L_PEEK), loaded with 2.5 wt% HA, 
possessed an improved flexural modulus. No significant difference was 
between between the flexural modulus of PEEK and HA_L_PEEK  (p = 
0.127). However, HA_PEEK was significantly weakened (p = 0.026). 
Mechanical properties of composites are augmented by a reduction in HA 
debonding and micro crack development, in addition to enhanced load 
transfer between phases.  
 
5.1 INTRODUCTION 
Poly(ether ether ketone) (PEEK) is a high performance semi-crystalline 
engineering polymer that has been implemented across a range of industry 
sectors, including oil and gas, electronics, aerospace, automotive and medical 
[1-3]. One of the major uses of PEEK in the medical sector is in the fabrication 
of spinal fusion cages [2, 3]. Spinal cages have been in clinical use since the 
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1990’s and were first shown to be successful in the treatment of horses 
suffering from nerve root compression [2, 4].  
PEEK is an attractive material for this role as it is lightweight, strong 
and well suited for high load-bearing application [5-7]. It exhibits a modulus of 
3 GPa to 4 GPa which falls within the range of cancellous and cortical bone 
(0.05 GPa to 30 GPa) [2]. Metallic spinal cages, such as those fabricated from 
titanium alloy (Ti-6Al-4V), are considerably heavier and exhibit a higher 
modulus (approximately 110 GPa) compared with polymeric counterparts [8, 
9]. This modulus mismatch with hard tissue can lead to stress shielding, 
where bone does not experience mechanical stimuli due to the high modulus 
material bearing a considerable fraction of the applied load. Additionally, 
titanium based cages are associated with a high occurrence of subsidence for 
both lumbar and cervical devices, hard tissue weakening and porosity 
development [10-12].  
Improving the ability of PEEK to integrate with bone is recognised as 
essential for guaranteeing spinal fusion [10, 13, 14]. In a side-by-side study of 
stand-alone devices, 100 % of titanium cages facilitated fusion, whereas 
PEEK cages were only 76 % successful [10]. PEEK is both hydrophobic and 
chemically inert, limiting bone attachment and osseointegration compared to 
Ti-6Al-4V [13, 15].  
Researchers have extensively developed and characterized PEEK 
surface porosity and bulk porosity, coatings, surface modifications, and 
composite formulations [14-25]. It appears that PEEK composite structures 
are beginning to play a more prominent role as commercially available 
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medical implants as alternatives to metallic materials such as Ti-6Al-4V and 
stainless steel [2, 17]. These materials typically contain bioactive calcium 
phosphate particulates, including hydroxyapatite (HA, Ca5(PO4)3(OH)2) and 
beta tricalcium phosphate (β-TCP, Ca3(PO4)2), which have been shown to 
improve the osseointegration of PEEK with increasing loading level [14, 16-
20, 25]. Invibio® currently manufacture a medical grade HA and PEEK 
material, PEEK-OPTIMA™ HA Enhanced, which has FDA approval for 
orthopaedic devices and recently acquired the European CE mark of approval 
[26]. PEEK-OPTIMA™ HA Enhanced devices out-perform PEEK-OPTIMA™ 
Natural devices (HA free) in terms of bone on growth and fusion, 
demonstrated in a sheep model [27].   
Under loading, however, inclusions can act as stress initiators and 
risers that diminish the mechanical properties of these materials [28]. 
Moreover, dissimilarity between HA and PEEK leads to poor interfacial 
interactions between the phases, limiting the level of biologically beneficial 
inclusion. Failure can arise due to HA particulates becoming debonded from 
the polymeric matrix of PEEK [16, 20]. High inclusion levels of HA also 
increases the brittleness of composites as the ductile flow of the matrix is 
disrupted, decreasing the required energy to initiate fracture [19, 20, 29].  
Up until now, approaches to improve additive interactions with 
polymeric matrices have focused on improving physical or physiochemical 
interlocking [16, 30, 31]. Chemical interactions may facilitate more effective 
load transfer between composite components, allowing higher loadings of 
bioceramic to be added whilst avoiding shortfalls in mechanical properties that 
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lead to catastrophic failure during load bearing. Benefits of covalently linking 
composites have been demonstrated between modified PEEK and carbon 
nanotube fillers [32, 33]. In this paper, a covalently linked HA and PEEK 
composite is engineered by functionalizing HA with (3-Mercaptopropyl) 
triethoxysilane (MPTES) and modifying PEEK by a reduction reaction, 
producing HA-SH and PEEK-OH respectively. p-Maleimidophenyl isocyanate 
(PMPI) is then used to link HA-SH to PEEK-OH to produce a covalently linked 
HA_L_PEEK additive, before processing composite materials in a PEEK 
matrix. Extensive characterization of bioceramic and polymer starting 
materials and their respective derivatives is provided, as well as 
physiochemical analysis of PEEK, HA_PEEK and HA_L_PEEK composites. 
 
5.2 EXPERIMENTAL METHODS 
5.2.1 Materials 
Hydroxyapatite (20 µm agglomerations from SEM analysis, ≥97 %, 
synthetic), (3-Mercaptopropyl) triethoxysilane (MPTES) (≥ 95 %), Propan-2-ol 
(puriss, p.a., ACS reagent, ≥ 99.8 % (GC)), HCl (ACS reagent, 37 %), 
Potassium hydroxide (reagent grade, 90 %), Methanol (CHROMASOLV®, ≥ 
99.9 %), p-Maleimidophenyl isocyanate (purum, ≥ 97 %) and Sodium 
borohydride (99.99 % trace metals basis) were acquired from Sigma Aldrich 
Ltd (U.K.). Ethanol (absolute, analytical reagent grade), dimethyl sulfoxide 
(DMSO) (analytical reagent grade) and Ellman’s reagent (5,5'-Dithio-bis-(2-
nitrobenzoic acid)) were acquired from Fisher Scientific (U.K.). Acheson Silver 
DAG was acquired from Agar Scientific (U.K.). VICTREX® PEEK 450PF (25 
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µm, easy fine flow) was acquired from Victrex plc (U.K.). Kapton® polyimide 
film was acquired from DuPont™(U.S.A). Loctite® Frekote® 44-NC mold 
release agent was acquired from Henkel (Germany). Distilled water acquired 
from an arium® advance EDI pure water system by Sartorius (Germany). 
 
5.2.2 Synthesis and fabrication methods 
5.2.2.1 Synthesis of HA-SH derivative  
In order to yield a sufficient quantity of HA-SH, three identical synthesis 
reactions were undertaken simultaneously. Briefly, three vessels were 
individually filled with 200 mL 90/10 (vol %) propan-2-ol/water solution. 2 mL 
MPTES and 250 mg HA were added to each vessel under stirring (250 rpm) 
on a MR stirrer hotplate (Heidolph, Germany). At 40 minute intervals, a further 
2 mL MPTES and 250 mg HA were added. Upon addition of MPTES and 250 
mg HA, the reaction pH was adjusted to between 3 and 6, and after 20 
minutes adjusted to between 9 and 11. This process was repeated totalling 7 
40 minute cycles (4.67 h). pH profiles were manually tracked with a Mettler 
Toledo SevenCompact™ pH/ion meter equipped with InLab Expert Pro-ISM 
probe (Mettler Toledo, U.S.A). The resulting HA-SH products from each 
separate vessel were then combined and washed in 5 mL ethanol five times, 
and recovered by centrifugation with a CR4.22 centrifuge (Jouan SA, France) 
at 4000 rpm for 10 minutes. HA-SH was then dried at 60 oC for 30 minutes to 




5.2.2.2 Synthesis of PEEK-OH derivative  
5 g of PEEK 450PF was dispersed in 120 mL DMSO charged with 1.5 
g NaBH4 under inert argon (Ar) atmosphere. The suspension was heated to 
120 °C and allowed to react for 24 hours, after which the contents was cooled 
to room temperature. PEEK-OH product was filtered and washed with excess 
ethanol, distilled water and 0.1 M HCl (diluted from concentrate), then dried at 
80°C under vacuum. 
 
5.2.2.3 Synthesis of HA_L_ PEEK  
5 g HA-SH was dispersed in 10 mL DMSO charged with 50 mg of 
PMPI under constant agitation. After 15 min, 5 g of PEEK-OH was added to 
the reaction mixture, and the reaction allowed to proceed for a total of 3 h. 
The resulting product was then washed in methanol, water and methanol 
again.  
 
5.2.2.4 Composite fabrication and acquisition of test specimens  
PEEK, HA_PEEK and HA_L_PEEK powder batches were prepared at 
a total mass of 50 g. Regarding HA containing batches, the bioceramic 
content was 2.5 wt%, and the polymeric matrix was unmodified PEEK. Prior to 
processing, batches were kept at 140 oC overnight period in order to remove 
residual moisture. Plaques were fabricated in a Moore Hydraulic Press 
retrofitted with heating plates (JRD Bipel, U.K.) to attain temperatures of 400 
oC. A spacer placed between the plates acted as a frame for the plaque, 
providing a 27.9 cm3 volume. Powders were spread evenly within the press 
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volume and heated to 125 oC at minimal plate contact to remove air pockets. 
Contact pressure was then applied and the temperature increased to 400 oC. 
After 4 h, heating was turned off and the apparatus was allowed to cool to 
room temperature before retrieval of plaques with dimensions 180 x 150 x 1.2 
mm.  
 
5.2.3 Chemical and physical characterisation methods  
5.2.3.1 Raman spectroscopy 
Raman spectroscopy data were collected using an inVia Raman 
microscope (Renishaw, U.K.). The instrument was equipped with a 532 nm 
laser. Each spectrum was collected over 3 acquisitions between 100 cm-1 and 
4100 cm-1 and the data normalised between sets. 
 
5.2.3.2 Powder X-ray diffraction (XRD) 
Powder XRD patterns were acquired using a Powder Diffractometer D8 
Auto sampler (Bruker, U.S.A.) with Cu Kα line (0.154 nm). Pattern data was 
collected between 2θ values of 5 o and 60 o with a 0.02 o step-size and a step 
time of 0.5 s/o. Patterns were matched to patterns within The International 
Centre for Diffraction Data (ICDD) database.    
 
5.2.3.3 Thiol group (-SH) quantification 
Quantification of thiol groups was undertaken using an Ellman’s 
reagent (DTNB, 5,5'-Dithio-bis-(2-nitrobenzoic acid)) assay protocol [38]. 
Briefly, a buffer solution was prepared (distilled water, 100 mM Na3PO4 , 1 
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mM EDTA, pH 8). 0.05 mL of Ellman’s solution (4 mg DTNB in 1 mL buffer 
solution) was added to 2.5 mL of buffer solution to produce a reaction 
solution. 5 mg of HA-SH was dispersed in a 0.25 mL of buffer solution and 
added to the reaction solution. The solution was kept agitated for 15 minutes 
to develop an assay solution. Upon reacting with free thiol groups, DTNB is 
converted to 2-nitro-5-thiobenzoic acid (TNB). TNB has a molar absorption 
coefficient of 14150 M-1 cm-1 at 412 nm. 1 mL of this solution was then 
transferred to a cuvette and the absorbance read at 412 nm with a Cecil 
CE7500 spectrophotometer (Buck Scientific, U.S.). The absorbance reading 
for unmodified HA sample was used as a control, and was automatically taken 
away from the reading acquired from the HA-SH samples. Equation S5.3-S5.5 
were followed in order to determine the molar concentration of –SH groups 
present in the sample [38].  
 
5.2.3.4 Differential scanning calorimetry  (DSC) 
DSC analysis was undertaken using a DSC 6000 N520-0116 
instrument (Perkin Elmer, U.S.A). Approximately 10 mg of sample was held 
for two minutes at 20 oC for temperature stabilisation of the equipment. 
Samples were then heated to 400 oC at a ramp rate of 10 oC/min before 
cooling back down to 20 oC at the equivalent ramp rate. 
 
5.2.3.5 Thermal gravimetric analysis (TGA) 
TGA was carried out using a STA 449 F3 Jupiter instrument (Netzsch, 
Germany). Samples were heated to 700 oC at a ramp rate of 10 oC/min. 
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Further analysis was carried out directly on the data to calculate hydroxylation 
degree (HD) of the PEEK-OH derivative (Equation S5.6-S5.11).  
 
5.2.3.6 Scanning electron microscopy (SEM) 
For Figure 5.4a-c and S5.7a-c, specimens were placed upon double-
sided sticky carbon discs that had been secured onto aluminum stubs. 
Specimens were then gold sputter coated using a K550X sputter coater 
(Quorum Technologies, U.K.). SEM images were then acquired using an EVO 
MA 10 scanning electron microscope operating at 10 kV (Carl Zeiss AG, 
Germany). For Figure 5.7d-f, specimen test pieces were placed in liquid 
nitrogen to allow for cryogenic fracture and exposure of a clean internal 
surface. Upon the underside of each specimen, a small amount of silver 
Acheson Silver DAG was applied in order to reduce charging. Double-sided 
sticky carbon discs and adhesive were used to secure specimens firmly to 
aluminum stubs. Specimens were then gold sputter coated using a Polaron 
SC7640 sputter coater (Quorum Technologies, U.K.). SEM images were then 
acquired using a 6060 scanning electron microscope operating at 10 kV 
(JOEL, U.S.A.).  
 
5.2.3.7 Fourier transform infrared (FT-IR) spectroscopy  
FT-IR spectra were collected using a Nicolet 380 FT-IR spectrometer 
(Thermo-Scientific, U.S.A.), fitted with a Golden Gate ATR attachment 
(Specac, U.K.). Measurements were collected between 100 cm-1 and 4100 
cm-1 wavenumbers. A background scan was acquired before each scan and 
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subtracted in order to minimize the appearance of H2O and CO2 molecular 
modes contaminating each spectrum of interest.  
 
5.2.3.8 Micro- X-ray fluorescence spectroscopy (µ-XRF) 
Scans were performed in mapping mode on sections of PEEK 
composites materials with exposed areas of HA using a M4 Tornado 
instrument (Bruker, U.S.A.). Measurements settings of 20 ms/pixel were 
employed with the instrument operating at 50 kV with anode current of 300 
mA. The chamber was maintained at 20 mbar during measurements.  
 
5.2.3.9 Flexural 3-point bend testing  
A schematic of the mechanical testing set-up is provided (Figure S5.1). 
Specimens of 60 x 12 x 1.2 mm were cut out from plaques with a band saw. 
The span to depth ratio was calculated as outlined in ASTM D790/ISO 178 to 
ensure specimens failed through compression stress whilst minimising shear 
stress. Tests were performed on a 5566 testing rig (Instron, U.K.) at a 
crosshead speed of 1 mm/min. Flexural strength and flexural modulus were 
calculated using Equations S5.1-S5.2 included in Appendix Part 4. 
 
5.2.4 Statistical analysis  
One-way ANOVA and corresponding Holm-Sidak post-hoc tests were 
performed upon mechanical testing data. Values of p<0.05 were deemed 
statistically significant.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 Synthesis of HA-SH  
 
Figure 5.1 (a) Hydrolysis and (b) condensation reactions of MPTES. (c) pH 
profile of the reaction between HA and MPTES to produce HA-SH. (d) Raman 
spectra and (e) XRD patterns of as received HA and following the synthesis of 
HA-SH.  
 
MPTES attaches to substrates through hydrolysis and subsequent 
condensation reactions (Figure 5.1a, b). Adjustment of pH over several hours 
promoted favorable thermodynamic environments for both reactions (Figure 
5.1c) [34]. Acidic regions between pH values of 3 and 7 were used to promote 
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hydrolysis of siloxy groups (R-Si-(OCH3)3) to silanol groups (R-Si-(OH)3), and 
adjustment of the pH to above 9 promoted condensation upon HA.     
Vibrations of the tetrahedral HA PO4 anion, including symmetric 
stretching (PO4 v1), symmetric bending (PO4 v2), asymmetric stretching (PO4 
v3) and asymmetric bending (PO4 v4), are identified by peaks present at 435 
cm-1, 590 cm-1, 960 cm-1 and 1050 cm-1 respectively (Figure 5.1d). Carbonate 
substitution of the HA crystal lattice is suggested by peaks at approximately 
1070 cm-1 (CO2 v1).  
Peaks relating to MPTES upon HA are present in the HA-SH spectrum, 
evidencing silane attachment [35-39]. A Si-C stretching peak appears at 652 
cm-1. A peak at 864 cm-1 is present due to CH2 rocking. Peaks at 1262 cm-1, 
1301 cm-1, 1342 cm-1 and 1431 cm-1 are indicative of –CH2 twisting modes. 
Overlapping peaks at 2804 cm-1, 2891 cm-1 and 2918 cm-1 are due to –CH2 
vibrations. The –SH stretching peak at 2569 cm-1 confirms HA-SH thiol groups 
[38]. A Si-O-Si stretching peak located at 809 cm-1 indicates silane 
oligmerisation, suggesting a network of MPTES molecules bound to HA-SH.           
Subtle broadening of PO4 v1-4 peaks in the spectrum HA-SH indicates 
alterations of P-O bonding environments. Broader peaks indicate structural 
disorder, whilst sharper peaks arise from ordered environments [40]. 
Differences could be due to the dynamic reaction experienced by HA during 
modification with MPTES, which may be capable of promoting dissolution and 
re-precipitation of alternative calcium phosphate phases, as well as the 
bonding of MPTES to HA-SH.  
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XRD confirmed HA remained the sole crystalline phase following 
modification with MPTES (Figure 5.1e). HA and HA-SH were successfully 
matched to ICDD pattern number 01-076-0694 (synthetic HA, * quality, with 
formula Ca5(PO4)3OH). Additionally, crystalline regions of HA were minimally 
disrupted by the reaction with MPTES, as there was a non-substantial 
decrease in crystallinity from 77.0 % to 76.6 % as determined by analysis of 
XRD patterns, further evidencing that the widening of PO4 peaks in the 
Raman spectrum of HA-SH is likely due to grafting of MPTES to HA rather 
than a reduction or change in crystallinity. 
Quantification of thiol groups associated with the surface of HA-SH was 
approximated at 5.9 x 10-6 ± 8.2 x10-8 mol g-1 calculated using equations S5.3-
S5.5. 
 
5.3.2 Synthesis of PEEK-OH  
PEEK was converted to PEEK-OH by reduction (Figure 5.2a) [41, 42]. 
Crystal structures of PEEK and PEEK-OH were assessed by powder XRD 
(Figure 5.2b). Peaks of both patterns were located at 2θ values of 19 °, 21 °, 
23 ° and 29 °, representative of orthorhombic unit cell PEEK crystal planes of 
110, 111, 200 and 211 respectively, suggesting that the lattice parameters are 
preserved during hydroxylation [41]. Conversion of PEEK to PEEK-OH 
reduced crystallinity from 46.1 % to 38.4 %.  
The melting temperature (TM) of PEEK was found to be 347.8 oC, 
which was approximately 4 oC greater than the TM possessed by PEEK-OH of 
343.7 oC (Figure 5.2c). On cooling, PEEK-OH appears to undergo minimal 
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crystallization, possessing no clear peak to define crystallization temperature 
(TC), whilst PEEK possesses a TC of 306.47 °C. This indicates that PEEK-OH 
becomes fully amorphous due to thermal treatment. When PEEK undergoes 
reduction chirality is introduced, which may increase the amorphous nature of 
PEEK-OH compared to PEEK (Figure S5.2). The -OH moiety introduced 
along the polymer chain may also inhibit crystallization by creating irregularity 
in forming crystalline regions. Moreover, hydrogen bonding mediated by -OH 
groups may be extensive enough to suppress polymer chain mobility required 
for crystallization [41].   
PEEK undergoes a one step degradation beginning at approximately 
550 oC (Figure 5.2d). The steep drop off in mass with temperature is 
indicative of main chain degradation [43]. PEEK-OH undergoes an initial mass 
loss between 100 oC and 250 oC that is attributed to the loss of weakly bound 
H2O molecules.  Loss between 250 °C and 400 °C was used to calculate the 
hydroxylation degree (HD) of PEEK-OH of 37.6 %, consistent with previous 
work (Figure S5.3)(Equations S5.6-S5.11). Main chain degradation begins at 
approximately 500 °C, suggesting a lower thermal stability of PEEK-OH 
compared to PEEK. Promisingly, the polymer derivative remains intact with 
respect to processing temperatures for PEEK between 380 oC and 400 oC.   
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Figure 5.2 (a) Reduction reaction of PEEK to PEEK-OH. (b) XRD patterns, 
(c) DSC traces and (d) TGA traces of as received PEEK and following 
reduction to PEEK-OH.  
 
5.3.3 Synthesis of chemically linked HA_L_PEEK  
PMPI possesses maleimide and isocyanate termini. HA-SH thiol 
groups react with maleimide to produce a thioether bond (C-S-C) (Figure 
5.3a). Hydroxyls of PEEK-OH react with isocyanate to produce a carbamate 
bond (R-O-C(=O)-NH-R) (Figure 5.3b).  
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Newly formed chemical bonds were assessed by FT-IR spectroscopy 
(Figure 5.3c). PO4 modes associated with the structure of HA-SH are located 
at 470 cm-1, 608 cm-1, 962 cm-1 (as a shoulder), and 1033 cm-1. Peaks 
associated with C-H stretching that originate from MPTES on the HA-SH 
surface are observed at 2920 cm-1 [38, 39]. FT-IR confirms formation of C-S-
C bonds with PMPI by the symmetric and asymmetric peaks of which are 
detected at 677 cm-1 and 771 cm-1 [44]. The –SH stretching peak at 2546 cm-1 
suggests a portion of thiol groups remain unreacted [38].  
PEEK-OH peaks include out of plane aromatic hydrogen (O.A.H.) 
modes at 840 cm-1 and 860 cm-1, a diphenyl ketone band at 927 cm-1, 
asymmetric C-O-C bending at 1182 cm-1 and 1278 cm-1, C-C(=O)-C bending 
at 1307 cm-1, aromatic skeletal vibrations (A.S.V.) at 1412 cm-1 and 1493 cm-
1, and C=O stretching at 1650 cm-1. Identification of carbamate bonds was 
made, but was difficult due to peak overlapping [45-47]. Carbamate COO- and 
C=O stretching modes expected at 1600 cm-1 and 1650 cm-1 are overlapped 
by peaks relating to C=C and C=O stretching from PEEK-OH. Peaks for C-N 
stretching are found at 1220 cm-1 and 1703 cm-1. N-H stretching peaks are 
located at 1550 cm-1 and 3370 cm-1. Peaks at 1495 cm-1 and 2194 cm-1 are 
evidence of NH3+ modes. Unreacted N=C=O groups are identified by the peak 
at 2341 cm-1. Minimal evidence of –OH stretching bands in the region 
between 3200 cm-1 and 3550 cm-1 also indicates the formation of carbamate 
bonds, as hydroxyls are used up during formation.  
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Figure 5.3 (a) Reaction between HA-SH and PMPI chemical linker and (b) 
between PEEK-OH and PMPI. (c) FT-IR spectrum for HA_L_PEEK.  
 
SEM micrographs further evidenced the success of the linking 
procedure. Figure 5.4a shows that HA-SH particulates are in the approximate 
size range of between 25 µm and 50 µm in diameter and furthermore possess 
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textured surfaces and sharp interfaces. Particles of PEEK-OH were between 
10 µm and 30 µm in diameter, and possessed smooth surfaces (Figure 5.4b). 
HA-SH and PEEK-OH powder particulates do not appear to interact strongly 
when mixed (Figure 5.4c). Mixing alone therefore does not appear to facilitate 
interactions between the dissimilar phases. After chemical linking with PMPI 
however, the resulting HA_L_PEEK appears to consist of agglomerates of 
both powders (Figure 5.4d).  
 
Figure 5.4 SEM micrographs of (a) HA-SH, (b) PEEK-OH, (c) a 
mixture of HA-SH and PEEK-OH particulates, and (d) chemically linked HA-
SH and PEEK-OH (additive material for HA_L_PEEK composites).   
 
Larger HA-SH particles appear to act as a substrate for bonding 
interactions with PEEK-OH particles, made possible through the chemical 
linking procedure. This is also consistent with our experimental method, 
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whereby the maleimide groups of PMPI firstly react with the –SH groups of 
HA-SH, allowing the then presented isocyanate groups of the linker to react 
with the –OH groups of PEEK-OH following its addition to the reaction 
mixture.         
 
5.3.4 Composite characterisation  
Mechanical properties of the composites were determined from 3-point 
bend testing (Figure 5.5a and Figure S5.1). PEEK specimens underwent 
ductile failure without fracture, and demonstrated plastic deformation at 
extension beyond the elastic region (Figure 5.5b). PEEK specimens remained 
whole after testing. Both HA_PEEK (without chemical linking) and 
HA_L_PEEK (with chemical linking) specimens containing 2.5 wt% HA 
underwent brittle failure immediately following elastic deformation, resulting in 
fracture (Figure 5.5b).  
PEEK exhibited a flexural strength of 201.2±8.3 MPa, which was 
significantly greater that the flexural strength of HA_PEEK and HA_L_PEEK 
being 170.7±5.4 MPa (p<0.001) and 171.7±14.8 MPa (p<0.001) respectively 
(Figure 5.5c). Although covalent bonding slightly enhanced the flexural 
strength of HA_L_PEEK, it was not found to be significant (p = 0.851), 
presumably due to variation of results expected from brittle failure. The 
flexural modulus of PEEK was 5.3±0.3 GPa (Figure 5.5d). Interestingly, there 
was no statistical difference between PEEK and HA_L_PEEK materials in 
terms of flexural modulus, the former possessing a value of 5.0±0.3 GPa 
(p=0.127). However, the flexural modulus of HA_PEEK was significantly lower 
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in comparision to PEEK (p = 0.026). Therefore, HA_L_PEEK substantially 
improved upon HA_PEEK in terms of flexural modulus.  
 
Figure 5.5 (a) 3-point bend test set-up (LVDT = Linear Variable Displacement 
Transducer). (b) Load displacement curves for PEEK, HA_PEEK and 
HA_L_PEEK materials. (c) Flexural strength box-plots for all groups 
calculated from the load displacement curves in (b) (n = 7) (* = p < 0.05 for 
PEEK vs. HA_PEEK and for PEEK vs. HA_L_PEEK). (d) Flexural modulus 
box-plot for all groups calculated from the load displacement curves in (b) (n = 
7) (* = p < 0.05 for PEEK vs. HA_PEEK, ** = p > 0.05 for PEEK vs. 
HA_L_PEEK). 
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5.3.5 Mechanism of composite enhancement by covalent bonding  
Chemical linking remained intact following composite fabrication, as 
confirmed by elemental mapping µ-XRF spectroscopy and DSC analysis, the 
latter described in Appendix Part 4 (Figure 5.6 and S5.4). Analysis of the 
chemical linking chemistry after fabrication was undertaken by comparing 
elemental maps of HA inclusions within HA_PEEK and HA_L_PEEK 
composites acquired using a µ-XRF instrument. The main elemental 
constituents of the HA inclusions were expectedly calcium (Ca) and 
phosphorous (P) as indicated by Kα signals at 3.7 KeV and 2.0 KeV 
respectively (Figure 5.6a,b). Elemental silicon (Si) was also detected in 
HA_L_PEEK by a peak at 1.75 keV, but was absent in HA_PEEK (Figure 
5.6c). The silicon signal originates from the presence of the MPTES 
molecules grafted to HA as part of chemical linking formulation. Mapping of 
the Ca Kα and P Kα signals show that elemental Ca and P are localised to 
the HA particulates in both composites (Figure 5.6d).  
During processing, high temperatures and mobile PEEK chains during 
melt are most likely to disrupt and distribute components of the linking 
chemistry throughout the wider polymeric matrix. Given that the Si content of 
HA_L_ PEEK appears to remain localised to HA particulates (Figure 5.6e), it 
can be taken as evidence that the chemical linking chemistry remains intact 
during the processing of composites to provide enhanced interactions 
between HA and PEEK. 
The linking chemistry present in HA_L_PEEK may facilitate the 
observed improvement in both flexural strength and flexural modulus 
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compared to HA_PEEK through the provision of enhanced interfacial 
interactions between HA and PEEK components that is greater than 
mechanical interlocking alone.  
 
Fig 5.6 µ-XRF elemental mapping of HA particulates within HA_PEEK and 
HA_L_PEEK materials following composite fabrication. (a) µ-XRF spectrum 
central to the Ca Kα signal. (b) µ-XRF spectrum central to the P Kα signal. (c) 
µ-XRF spectrum central to the Si Kα signal. (d) Elemental map for a fracture 
surface of HA_L_PEEK with Ca and P Kα channels shown. (e) Elemental 




It is likely that this acts through two mechanisms as evidenced by SEM 
analysis of intact and fracture surfaces of HA_PEEK and HA_L_PEEK. Firstly, 
the established chemical interactions appear to lessen the development of HA 
debonding and micro-cracks (Figure 5.7a-c). Pre-existing microcracks can 
promote crack initiation, leading to premature failure of materials under load 
[48]. HA inclusions within HA_PEEK surfaces appear to promote micro cracks 
spanning 10’s of microns (Figure 5.7 a, b). HA on the surface of HA_L_PEEK 
was not associated with debonding from PEEK or crack development prior to 
mechanical testing (Figure 5.7c).  
Secondly, mechanical failure of these composites is partly dependent 
on flaws present within the brittle HA component, as well as HA particulates 
themselves. HA is a relatively stiff ceramic and can provide the resulting 
composite with an enhanced modulus [20, 49]. However, gains are dependent 
on loading level and the nature of the filler particulates [28, 49]. Lower levels 
of loading are generally favoured using both micro- and nano- scale 
particulates, as filler agglomeration that occurs at high loading levels reduces 
mechanical properties [25, 28, 49, 50]. This is because as particulate 
inclusions become smaller, they are less liable to contain flaws or act as flaws 
[48, 49, 51, 52]. Griffith’s law states that the stress concentration at the tip of a 
defect depends on the defects size [51, 52]. Thus, the combined stress 




Figure 5.7 As fabricated surface of (a) PEEK, (b) HA_PEEK and (c) 
HA_L_PEEK. Fracture surface of (d) PEEK, (e) HA_PEEK and (f) 
HA_L_PEEK.  
 
Particle shape and size distribution of covalently linked HA and PEEK 
is difficult to control due to the additive itself existing as an agglomeration of 
bioceramic and polymeric materials. The effect is exacerbated in the case of 
HA_L_PEEK composites (Figure 5.7d-f). Therefore, the particle size range of 
HA within HA_PEEK is between 60 µm to 220 µm, and between 125 µm to 
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1000 µm within HA_L_PEEK, as measured by SEM analysis. Evidently, 
covalent bonding maintains the mechanical properties of composite 
possessing larger inclusions, considering that there is no significant difference 
in flexural modulus between PEEK and HA_L_PEEK materials, whilst the 
properties of HA_PEEK are significantly lessened. Covalent interactions 
appear to improve load transfer between HA and PEEK phases by arresting 
crack growth and propagation at the interface, benefiting the ability of 
HA_L_PEEK to resist failure under load by increasing fracture energy [19, 20, 
29]. Mechanical locking interactions present in HA_PEEK likely promotes 
brittle failure at lower force loadings due to the high stiffness possessed by 
HA not as effectively being transferred to the surrounding polymeric matrix, 
reducing regions of ductile flow about bioceramic irregularities [19, 20, 29]. 
Further work will look to reduce inclusion particle size, lessen 
agglomeration, increase the range of HA loadings and assess in vitro 
cytotoxicity. Utilising nano HA particulates will increase interaction surface 
area, and make it easier to attain homogeneous distribution, allowing higher 
loadings of HA to be included for the enhancement of integration with bone.  
 
5.4 CONCLUSIONS 
The formulation of a covalently linked HA and PEEK composite was 
demonstrated. Covalent interactions significantly improve the flexural modulus 
of HA_L_PEEK over HA_PEEK at 2.5 wt% HA loading, despite the former 
possessing larger HA inclusions due to agglomeration effects. Chemical 
linking contributes to the flexural modulus gains by reducing HA particle 
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debonding, arresting the development of micro cracks, and facilitating 
enhanced load transfer between phases.  
Improvements to covalently linked composites may allow for the 
development of spinal fusion devices that potentially out perform metallic 
alternatives (i.e. Ti-6Al-4V) and plain PEEK in terms of fusion capacity, whilst 
avoiding additive debonding and diminishment of mechanical properties that 
currently hamper HA and PEEK composites. However, this will be challenging 
considering the good fusion capacity of titanium implants.  
 
5.5 ASSOCIATED CONTENT 
Supporting figures and equations are included in Appendix Part 4.   
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Chapter 6. Conclusions and future work 
6.0 GENERAL OVERVIEW 
Whilst many hard tissue biomaterials ably serve their purpose as 
regenerative scaffolds and fusion devices, advancements in the formulation 
and fabrication of biomaterials are continually being driven forward by the 
need to meet the demands of an ever increasing and ageing population. The 
requirements of future bone graft substitutes and spinal implants requires 
composite biomaterials that are able to restore and support the regeneration 
of bone cost-effectively, as well as their use ultimately eliminating the need for 
revision surgery.  
In order to deliver biomaterials of this nature, the aim of this thesis was 
to formulate calcium sulphate and phosphate based composites with 
enhanced properties that could be utilised in applications including bone 
regeneration and hard tissue fusion. This was achieved by identifying and 
formulating solutions to overcome the inherent limitations of current calcium 
based biomaterials. The formulation and characterisation strategies presented 
herein created, exploited and understood the interfacial interactions between 
organic/inorganic interfaces present between dissimilar phases. It was found 
that enhancing the organic/inorganic interfaces between dissimilar phases 
can result in significant improvements to the physiochemical attributes of the 





6.1 STUDY LIMITATIONS AND FUTURE PERSPECTIVES 
6.1.1 Characterisation of novel poly (ether ether ketone)/calcium 
sulphate composite for bone augmentation 
Chapter 2 is titled “Characterisation of novel poly (ether ether 
ketone)/calcium sulphate composite for bone augmentation” and focusd on 
the reinforcement of the biomedical cement, calcium sulphate (CS). Inorganic 
cements are used extensively in restoration of hard tissues such as bone, for 
instances where bone is unable to heal naturally. A reported limitation of CS is 
that it is very soluble when placed in physiological conditions and therefore 
may not provide a long-term scaffold for bone formation. Previously, it had 
been shown that polymer reinforcement of CS could slow resorption but 
lowered the mechanical properties. By reinforcing the ceramic with poly(ether 
ether ketone) (PEEK), a high performance engineering polymer, it was 
postulated that the properties of the ceramic content could be augmented, 
thus extending the period of time the osteogenic scaffold remains intact under 
physiological conditions. For the first time, both physical and chemical 
interfaces between the two materials were shown to develop as a result of a 
heat treatment process, which produced PEEK/CS composite materials. The 
treatment was found to be successful in reducing the rate of calcium sulphate 
degradation in a simulated physiological environment, as well as enhancing 
mechanical strength of the material.  
As direct implication of this study, PEEK reinforcement of other 
biomedical ceramics may extend their longevity as an osteogenic scaffold in 
vivo. A calcium phosphate phase such as brushite (CaHPO4.2H2O), which 
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undergoes rapid dissolution when placed in the body, may benefit from such a 
treatment. Although it will likely dehydrate to monetite (CaHPO4) at high 
temperature, which is more soluble, PEEK reinforcement may facilitate the 
hydration of the ceramic to brushite once the samples are placed in biological 
solutions.  
From this study, the fate of PEEK following resorption of the 
degradable ceramic component remains unclear. It is assumed that if 
PEEK/CS were to be implanted, CS would provide an osteogenic scaffold for 
bone formation, with new bone taking up the volume occupied by CS and 
encasing the remaining PEEK framework. Following a dynamic ageing 
process over a period of 21 days, specimens of PEEK/CS with PEEK loadings 
>20 wt% remained intact and the CS structure underwent limited dissolution, 
although hydration of CS was detected. Had the ageing protocol been 
extended, it may have been possible to detect the onset of CS dissolution, 
and furthermore obtain the PEEK framework following complete dissolution of 
the CS. Prolonging the period of ageing would allow for further understanding 
as to the fate of PEEK, and moreover enable further study of in vitro biological 
responses to PEEK (e.g. cell attachment) in the absence of CS.   
Further work should also investigate the loading of soluble 
therapeutics through liquid exchange with PEEK/CS materials, including 
antibiotics, as a preventative measure against infection, or growth factors to 
promote osteogenesis and bone healing. Additives may be incorporated by 
pre-soaking composites in solutions that contain the desired solute 
molecules prior to implantation. 
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Whilst PEEK was able to bring about significant gains in both the 
mechanical and degradation properties of CS, the compressive strength and 
modulus is short of the values acquired for other CS cements reported in the 
literature. Additionally therefore, compaction of CS and PEEK powders before 
hardening and heat-treatment, and increasing the P:L ratio whilst maintaining 
a workable formulation, may contribute to the reduction of pores that weaken 
hardened structures as has been previously demonstrated with other 
compositions of cement.  
 
6.1.2 Biologically analogous calcium phosphate tubes from a chemical 
garden 
Chapter 3 is titled “Biologically analogous calcium phosphate tubes 
from a chemical garden” showed that the interface between calcium loaded 
agar based hydrogel and phosphate solutions could be employed to produce 
tubular calcium phosphate structures. The structures produced were similar to 
chemical garden architectures. The micro scale architecture and composition 
of the resulting tubes makes them a prospective scaffold material for bone 
formation. However, in vitro studies need to be undertaken to determine the 
benefits of CaPO4 tubular microstructure to facilitate cellular attachment and 
ingress, proliferation, and differentiation over conventional microstructures 
(e.g. powder micro particulates). Tubes can provide a high surface area, 
narrow pore distribution, and mass transport opportunities, which may benefit 
the development of an osteogenic environment over non-tubular materials.   
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Problematically, the tubule structures are very delicate, making it 
difficult to remove them from the solution phase. This may be overcome by 
encasing the tubules in a secondary phase, such as a ceramic slurry or 
polymeric hydrogel phase, that would penetrate the volume between tubules 
before hardening around them. The resulting structure would house the 
tubules, preserving their structure and facilitating an easier route of recovery 
following formation. Development of these structures could foreseeably be 
utilised as scaffolds for in vitro cell work regarding cellular viability and 
ingress.  
 
6.1.3 Interfacial mineral fusion and tubule entanglement as a means to 
harden a bone augmentation material 
Directly following on from the work in the preceding chapter, Chapter 4, 
titled “Interfacial mineral fusion and tubule entanglement as a means to 
harden a bone augmentation material”, explored the development of a bone 
graft technology that can harden in situ through generating biologically 
analogous tubular calcium phosphate structures. Calcium-loaded agarose 
spheres, and not just planar surfaces, were found to be capable of generating 
mineral tubes. This enabled the delivery of calcium-loaded hydrogel to bone 
defects, which could deposit tubular structures. Clinical application of the 
system was shown to be feasible using a defect model representative of a 
typical bone cavity encountered in surgery. Spheres in the vicinity of one 
another were able to unite within the defect through mineral deposited on 
adjacent sphere surfaces and interactions of tubule extensions.  
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Further work regarding this system should attempt to reduce the 
current Ca2+ and PO43- concentrations required for tube growth to near 
physiologically relevant levels, as to limit the exposure of cells to harsh ionic 
concentrations that are potentially cytotoxic. Alterations in Ca2+ and PO43- 
concentrations should maintain the capacity to generate a volume of mineral 
that is able to replenish a model defect. An ex vivo tissue model such as that 
employed in this chapter would be suitable, as it allows simultaneous 
characterisation of both native bone and mineral deposited, thus composition 
can be directly compared.  
An alternative approach that would not require the adjustment of ionic 
concentrations would be to form a consolidated structure prior to implantation. 
This would require a mold of the defect site to be acquired and used as a 
template for which calcium loaded spheres can be packed into before 
stimulating mineralisation using concentrated phosphate solutions. Once 
unified, the construct could then be implanted in vivo providing an immediate 
scaffold for bone growth. 
A limitation of employing an agarose hydrogel as the primary delivery 
vehicle of calcium ions in this system is its ability to provide biomechanically 
stability during defect healing.  To overcome this, reinforcement of the 
spheres with ceramic particulates may increase the load bearing capability of 
the spheres whilst hardening within a bone defect. These particulates may 
also act as seeds of further nucleation throughout the hydrogel spheres. This 
would advantageously encourage mineralisation throughout the soft 
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component, in addition to the extensive mineral deposition upon the exterior 
of spheres and regions of porosity between spheres. 
 
6.1.4 Development of a covalently bonded hydroxyapatite and poly(ether 
ether ketone) composite 
Chapter 5, titled “Development of a covalently bonded hydroxyapatite 
and poly(ether ether ketone) composite”, explored the development of a 
covalently linked PEEK and hydroxyapatite (HA) composite material for spinal 
fusion devices. Currently, the addition of bioactive particulates into polymer 
matrices such as PEEK results in a trade-off in mechanical properties. Given 
that the interface between polymer and bioceramic particulates is crucial to 
mechanical performance, a method of covalently linking the two phases that 
assists in the transference of mechanical loading between brittle and ductile 
components was developed.  
Chemically linking HA and PEEK significantly improves the flexural 
modulus of composites intended for the fabrication of spinal implants.  The 
study demonstrates that the interfacial interactions between composite 
components can be improved beyond mechanical interlocking and 
physiochemical interactions by obtaining a direct chemical link between 
polymer and additive phases. Between HA and PEEK, the chemical linking 
procedure lessened particulate debonding, reduced the development of 
microcracks, and facilitated enhanced load transfer between the polymer 
matrix and filler particulates compared to HA_PEEK composites without 
linking. Consequently, the loading of HA within PEEK could be increased 
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without a loss of mechanical properties, which would be of benefit to the 
fusion capacity of a spinal fusion device fabricated from HA_L_PEEK.  
Whilst this approach may potentially allow greater loadings of HA to be 
included in a PEEK matrix resulting in an increase in its fusion capacity and 
integration with hard tissue, further expansion of the of HA loadings are 
required. Production of the HA_L_PEEK additive was limited by a low yield 
synthesis method. Improvement in the yield of additive may be improved by 
alterations in reaction time and pH adjustment, ultimately requiring a 
systematic study into these effects.  
Further work in this area should look to reducing inclusion particle size 
and increase the range of additive loadings mechanically tested. Ideally, 
smooth nano-scale spherical particulates should be introduced to increase the 
surface area of interaction with the matrix. Such particulates will also ensure 
more homogeneous distribution of the additive phase, reducing the variation 
between localized areas of composition and ultimately allow higher loadings 
of HA to be included for the purpose of enhancing bone/implant interface and 
attaining greater levels of bone growth.  
In vitro biological analysis of the composites should additionally be 
undertaken to ensure osteoblast like cells attach and can proliferate upon 
chemically linked composites. It is currently unknown as to whether the 
chemistries present within the chemically linked HA_L_PEEK are cytotoxic 
under physiological conditions. Cytotoxicity may result from the chemistries 
not being compatible in the processed composite, or as a result of the 
hydrolytic or cell mediated break down and release of dissolution products 
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originating from the linking chemistry. Supernatant that has contained 
chemically linked HA_L_PEEK material may be analysed further to determine 
release of potentially cytotoxic products.  
Thereafter, in vitro studies should then explore the detection of 
osteogenic differentiation and mineralisation markers produced by osteoblast 
precursor cells seeded upon chemically linked composites. The results may 
be used to indicate the most appropriate formulation for spinal fusion 
application. With regards to spinal fusion application, a composite that 
induces osteoblastic differentiation and mineralisation may accelerate fusion 
time. 
 
6.2 CONCLUSIVE SUMMARY 
In summary, the work presented in this thesis covers the development 
of several biomaterials and their subsequent characterisation, providing a 
valuable contribution to the literature, knowledge and industry. This was 
achieved by following the logical progression of the stated objectives. The 
research findings show that improving the organic/inorganic interactions 
between differing phases of a composite system significantly enhances the 
physiochemical nature and performance of the resulting novel biomaterials.  
Given that prevention strategies to reduce hard tissue injury will never 
eliminate the evident need to restore and regenerate bone tissue in an ever 
increasing and ageing population, the systematic approaches taken in this 
thesis allow for the creation of new, improved and relevant composite 
formulations. Limitations of the novel composite systems conceived may be 
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overcome through future study and systematic method alteration. Overall, the 
methods herein address the requirement for the formulation biomaterials with 
augmented application parameters.  
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Appendix Part 1 
Characterisation of a novel poly (ether ether 






Figure S2.1 Averaged stress vs. strain curves for n=10 PEEK/CS specimens 
tested (a) after heat treatment prior to ageing (0 Days) and (b) after 7 Days,  
(c) 14 Days and (d) 21 Days of ageing. 
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Figure S2.2 Top down view of PEEK/CS specimens during dynamic ageing 
study at 1 day, 7 days, 14 days and 21 days, bar above individual images is 
the colouration of an aliquot of PBS ageing media after addition of universal 
pH indicator before replenishment (PBS media was green) (orange = pH 5 – 
5.5, yellow = pH 6 – 6.5, green = pH 7 - 7.5). 
 
Equations  
% volumetric shrinkage = ((V1 – V2) / V1) x 100    (Equation S2.1)  
Where,  
V1 = Volume of specimen prior to heat treatment (mm3) 




ρrel =  ρapp  / ρtrue        (Equation S2.2)  
Where,  
ρrel = Relative density of specimen (g/cm3) 
ρapp = Apparent density of specimen (g/cm3) 
ρtrue = True density of specimen (g/cm3) 
 
Porosity = (1 - ρrelative) x 100      (Equation S2.3)   
Where,  
ρrelative = Relative density of specimen  
 
σ = F / A          (Equation S2.4)  
Where,  
σcomp = Compressive stress (MPa) 
F = Loading force (N) 
A = Specimen contact area (mm2) 
 
ε = lchange / loriginal         (Equation S2.5) 
Where,  
ε = Strain  
lchange = Change in specimen height (mm) 





Ecomp = (σ / ε) / 1000       (Equation S2.6)  
Where, 
Ecomp = Compressive modulus (GPa) 
σ = Stress (MPa) 
ε = Strain 
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Appendix Part 2 
Biologically analogous calcium phosphate tubes from a 
chemical garden 
Supporting information:  
Figures  
 
Figure S3.1 A 12 mm x 6 mm gel specimen employed in gel mass gain/loss 
studies (a) and gels soaking in various NaCl solutions (b).  
 
 
Figure S3.2 Ca2+ calibration curve of mV against Log Ca2+ concentration of 




Figure S3.3 PO43- calibration curve of absorbance @650 nm against PO43- 
concentration of known standards (equation of trend line and r2 value shown, 
each data point is average of n=2, error bars represent standard deviation). 
 
 
Figure S3.4 Universal pH indicator solution colour change corresponding to 
values of pH between 4 and 11. 
 
 





Table S3.1 Concentrations of PO43- and NaCl salts with equivalent solute 
potentials used in experiments.  
PO43- [M] NaCl [M] Equivalent solute 
potential (bar)  
0.25 0.5 -24.8 
0.5 1 -49.5 
1 2 -99.1 
1.5 3 -148.6 
2 4 -198.1 







      (Equation S3.1) 
 
Where, [Ca$%]'	= Final Ca2+ concentration eluted, [Ca$%]*  = Measured Ca2+ 





M@=4	AB4 = 		M@=4	x	0.98      (Equation S3.2) 
 
Where, M@=4	AB4  = Mass of gel specimem solution phase content (assuming 
98% water content), M@=4	= Mass of gel specimen. 
 
ψI = -iCRT        (Equation S3.3) 
Where, ψI =  Solute potential, i =	 Ionisation constant, C =	 Solution 
concentration, R = Gas constant, T = Temperature (Conversion from bar to 






Appendix Part 3  
Interfacial mineral fusion and tubule entanglement as 




Figure S4.1 Calcium phosphate tubule growth after 2 mins, 15 mins, and 30 
mins from calcium loaded spheres placed in phosphate solutions at 




Figure S4.2 Raman spectrum (red) and powder XRD pattern (blue) of tubule 
precipitate harvested at 3 h. The presence of both HA and DCPD is confirmed 
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by Raman spectroscopy through the identification of stretching and bending 
modes associated with PO43- ions (found in HA) and HPO42- ions, present in 
the structure of HA and DCPD respectively. The predominant crystalline 
phase constituting tubule precipitate was found to be HA. Inability to identify 
DCPD peaks suggests the phase exists in an amorphous form. Peak 
broadening a high noise to signal ratio suggests the mineral is of low 




Figure S4.3 (a) µ-XRF elemental mapping of a cross-section of the human 
hard tissue defect (Kα channels for calcium (red) and phosphate (green) 
shown), as presented in Figure 3c. µ-XRF spectra were acquired for the total 
scan points within the referenced square areas placed upon areas of mineral. 
The areas selected account for two areas of bone (Areas 1 and 2), a mineral 
fusion interface between a calcium loaded sphere and bone (Area 3), and 
likewise between two calcium loaded spheres within the defect (Area 4). (b) 
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Spectra of highlighted areas for the P Kα signal. (c) Spectra of highlighted 
areas for the Ca Kα signal. Both (b) and (c) show slight variation in Kα signal 
strength, however, there exists a distinct elemental similarity between mineral 




Appendix Part 4 
 
Development of a covalently bonded hydroxyapatite 






Figure S5.1 Schematic of mechanical 3-point bend testing set-up, where b = 
specimen width, d = specimen thickness, l = separation length between 
supports, lt = total specimen length, and LVDT = linear variable displacement 
transducer. Specimen dimensions and support separation distance comply 




Figure S5.2 PEEK reduction to PEEK-OH by entioselective and non-specific 
reducing agents resulting in chiral or non-chiral forms of PEEK-OH 
respectively. 
 
Chirality is introduced when PEEK is chemically modified by reducing 
agents facilitating the conversion of =O groups to –OH groups. An 
enantioselective reducing agent may produce only one enantiomer of PEEK-
OH, whereby the –OH groups are configured in one direction. Because 
NaBH4 is non-selective, a mixture of PEEK-OH enantiomers is expected. The 
mixture of resulting –OH group configurations may disrupt forming crystallites 
of the material leading to an increase in the amorphous nature of PEEK-OH 







Figure S5.3 PEEK-OH hydroxylation degree (HD) resulting from the reaction 
of PEEK with NaBH4 at various reaction times. Shown in red is the value for 
HD acquired in this work, whilst values shown in blue are those reported by 











Figure S5.4 Dynamic scanning colorimitry (DSC) traces for HA_PEEK and 
HA_L_PEEK materials. Heating runs for (a) HA_PEEK materials and (b) 
HA_L_PEEK. Cooling runs for (c) HA_PEEK materials and (d) HA_L_PEEK 
(solid lines are those of run 1, dashed lines are those of run 2) 
 
Regarding the HA_PEEK and HA_L_PEEK materials, run 1 heating 
traces appear to contain some noise contamination indicative of polymer 
movement in the melt (Figure S5.4a,b). This is not apparent in the second 
heating run, suggesting that the samples settled within the DSC sample pan. 
Interestingly, a pronounced drop off in the DSC trace is observed for 
HA_L_PEEK material containing > 25 wt % HA content (Figure 5.4b). We 
attribute this to loss of excess solvent present in the HA_L_PEEK that was not 
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removed during our purification steps, as during the second heating run, the 
traces conform to a regular pattern.   
The cooling curves are noteworthy in that as the HA content increases, 
the crystallisation of PEEK appears to be hindered, given that exotherm shift 
to reduced temperatures with increasing HA content (Figure S5.4c-d). Re-
crystallisation may be affected more extensively within HA_L_PEEK as the re-
crystallisation temperatures are consistently lower than those observed for 
HA_PEEK.  This may be due to the improved interaction between HA 
chemically linked to PEEK in this system.  
These preliminary data appear to suggest the interfacial interactions 
present in HA_L_PEEK affect the re-crystallisation of the material more 
extensively than the interactions present between non-linked phases 
comprising HA_PEEK. Furthermore, processing considerations for these 
materials may need to take into account the effects of solvent release during 






          (Equation S5.1) 
 
Where: σ'= Flexural strength (MPa), F= Max force before yielding or fracture 
(N), l= Test specimen support separation length (mm), b= Test specimen 







          (Equation S5.2) 
 
Where: E'= Flexural modulus (MPa), F= Force (N), l= Test specimen support 
separation length (mm), b= Test specimen width (mm), d= Test specimen 




          (Equation S5.3) 
 
M = 2.80	mL	x	 C	x	 `	+
`)))	*+







     (Equation S5.5) 
 
Where: C =	 -SH concentration as measured (mol L-1), E =  TNB molar 
absorption coefficient, 14150 (M-1 cm-1), b =path length of cuvette (1 cm), M = 
-SH concentration as measured (mol), and CA/*>4= = -SH concentration of the 
sampled volume 0.25 mL containing HA-SH (mol L-1). 
 
The concentration of –SH groups was converted from units of mol L-1 to 
mol g-1 by calculating the equivalent mass in grams of HA-SH sample in 1 L 









	x	%	MX))c.       (Equation S5.7) 
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             (Equation S5.9) 




x	100                                  (Equation S5.11) 
 
Where: MA = TGA sample mass (g), M$b)c. = TGA sample mass at 250 oC 
(g), %	M$b)c. = % TGA sample mass remaining at 250 oC (%), MX))c. = TGA 
sample mass at 400 oC (g), %	MX))c. = % TGA sample mass remaining at 
400 oC (%), Mfg = Mass of OH groups lost from PEEK-OH between 250 oC 
and 400 oC (g), molfg = Moles of OH groups lost from PEEK-OH between 
250 oC - 400 oC (g), Mrfg = Molar mass of OH group (g mol-1), Mk\\l-fg = 
Mass of PEEK-OH in sample (g), Mrk\\l-fg = Molar mass of PEEK-OH group 
(g mol-1), and HD = PEEK-OH hydroxylation degree (%).  
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